BACKGROUND
Cancer refers to a group of more than 100 diseases characterized by uncontrolled cellular growth, proliferation, and spread. This group of diseases has an enormous impact on health in the US. As the second leading cause of death, cancer was responsible for an estimated 569,490 deaths among adults and children in 2010. Measuring the quality of care for the many patients diagnosed with any of these diseases is important to ensure safe, cost-effective care consistent with the current evidence. The recommended measures include those endorsed prior to 2009 that are undergoing maintenance. The majority of measures considered in Phase 1 focus on melanoma, hematology, general oncology, prostate, lung, and palliative and end-of-life care.

A 21-member Steering Committee representing a range of stakeholder perspectives was appointed to review a total of 26 candidate and endorsement maintenance standards for quality performance in melanoma, hematology, general oncology, prostate, lung, and palliative and end-of-life care in this phase. The Steering Committee is recommending 22 measures, 2 of which are being recommended for time-limited endorsement.

Comments and Revised Voting Report
NQF received 109 comments from 14 member organizations, representing a variety of stakeholders.

A table of complete comments submitted during the comment period, with the responses to each comment and the actions taken by the Steering Committee and measure developers, is posted to the Cancer Endorsement Maintenance project page under the Public and Member Comment – Phase 1 section.

The revised draft document, National Voluntary Consensus Standards: Cancer Endorsement Maintenance, is posted on the Cancer Endorsement Maintenance project page on the NQF website along with the following additional information:

- Measure submission forms
- Meeting and call transcripts and recordings from the Steering Committee’s discussions.

Revisions to the draft report and the accompanying measure specifications are identified as red-lined changes. (Note: Typographical errors and grammatical changes have not been red-lined to assist in reading).
COMMENTS AND THEIR DISPOSITION

The Steering Committee reviewed the comments and focused its discussion on specific measures or topic areas with the most significant and recurring issues that arose from the comments. Comments about specific measure specifications were forwarded to the measure developers, who were invited to respond.

During the review of all comments, the Steering Committee had the benefit of developer responses, and focused their discussion on recurring concerns, specific measures and topic areas that were most controversial or that questioned positions the Committee had taken. The Committee made no changes to its measure recommendations.

Many of the comments were supportive of the work by NQF and the Steering Committee around the Cancer Endorsement Maintenance measures. Several themes emerged in the comments including:

- Concern regarding the clarity and burden of measures 0383 and 0384
- Request for reconsideration of measure 0562
- Concern regarding the understandability and usability of the Palliative Measures (0210-0216)
- Request for reconsideration of measure 0212

**Concern regarding the clarity and burden of measures 0383 and 0384**

Commenters stated that measure 0383: Oncology: Plan of Care for Pain – Medical Oncology and Radiation Oncology (paired with 0384) and measure 0384: Oncology: Pain Intensity Quantified – Medical Oncology and Radiation Oncology (paired with 0383) need to be harmonized with other pain measures that do not require an intervention for reports of mild pain. Commenters noted that by focusing on interventions and care plans for mild pain, the providers may be burdened and the impact of this measure for patients experiencing severe pain may be diluted.

*Steering Committee Response:* The Steering Committee agreed with the commenter that patients with mild pain likely do not require documented care plans for addressing the pain. The Steering Committee stated that documentation of a care plan for patients with mild pain in this patient population may very well present a substantial burden to the provider, as many patients being actively treated with chemotherapy or radiation therapy for cancer have mild pain. The Steering Committee questioned whether there are other measures that address pain for this patient population in the NQF portfolio. NQF staff stated that there are measures that may overlap with patients in this population that address moderate to severe pain; however, there are no measures that target the entirety of the patient population (patients with cancer being treated at an outpatient facility) addressed by this measure. Consequently, the Steering Committee determined that they would like to move this measure forward with a recommendation for endorsement; however, the Steering Committee made several recommendations for future iterations of the measure. Those recommendations are as follows:
• Remove specifications for documenting a care plan for patients with mild pain, in order to focus on patients who most need an intervention (patients with moderate to severe pain).
• Further define what constitutes a plan of care, to remove ambiguity about what “counts” for the measure. This will move the measure away from being a “check the box” measure and further assist in defining the measure as we move toward integration into electronic health records.

Request for reconsideration of Measure 0562: Overutilization of Imaging Studies in Melanoma (AMA-PCPI)

The Steering Committee did not recommend measure 0562 for endorsement. The American Academy of Dermatology (AAD), the American Medical Association (AMA) convened Physician Consortium for Performance Improvement® (PCPI™), and the National Committee for Quality Assurance (NCQA) requested reconsideration of the measure. As the measure was voted down on the evidence criteria, the developers provided additional evidence demonstrating that the measure was based on evidence-based guidelines from the National Comprehensive Cancer Network (NCCN) and the AAD.

Information on the Scientific Acceptability of the measure testing results was also provided, including the agreement on exceptions to the measure.

Lastly, with respect to Steering Committee concerns that patients with recurrent disease would not be restaged at the time of recurrence and thus may not receive appropriate care, including potential imaging, the developers noted that this measure focuses on localized melanoma patients only. The measure is specified to capture patients “without signs or symptoms suggesting systemic spread.”

Steering Committee Response: Steering Committee members stated that there is limited evidence of overuse of imaging in this patient population, as no study has been undertaken. The developers noted that the measure is supported by evidence-based guidelines (AAD and NCCN) that recommend that both newly diagnosed patients with stage 0-IIC melanoma without signs or symptoms suggesting systemic spread and patients with a history of melanoma at any stage without signs or symptoms suggesting systemic spread, should not receive unnecessary imaging. The developers emphasized that patients with signs or symptoms suggesting systemic spread would not be counted in the denominator and thus would be eligible for imaging, allowing providers to exercise clinical judgment when signs or symptoms are present.

Steering Committee members raised concerns that the measure would restrict imaging of patients with recurrence of melanoma, not taking into account patients who are seen many years out for follow up who present with symptoms or signs of illness. Steering Committee members noted that these patients receive imaging, in accordance with NCCN guidelines. The developers noted that the measure provides explicit denominator exceptions for patients with signs or symptoms of systemic spread to be evaluated using imaging (see denominator exclusion details, section 2a1.9 of the measure submission form). Patients with a history of melanoma who present with signs or
symptoms of systemic spread would not be included in the denominator and would be eligible for imaging.

Steering Committee members questioned whether providers might be able to manipulate the measure and create exceptions in order to justify ordering imaging. The developers noted that there have been several studies on exception methodology, with very high concordance between what is documented and what are considered acceptable exceptions as defined by a group of experts. With respect to this measure, for patients with newly diagnosed melanoma, the exception agreement was 100%. For patients with existing diagnoses of melanoma, the exception agreement was 74.59%. The developer cautioned that this was calculated using a small sample size.

Steering Committee members agreed to reconsider the measure in light of the information presented by the developers. The Steering Committee voted to recommend measure 0562 for endorsement. Full voting results and the details of the Steering Committee discussion can be found in the measure evaluation of measure 0562.

Concern regarding the understandability and usability of the Palliative Care Measures (0210-0216)

Commenters noted that while overtreatment of terminally ill patients is an important area for study and measurement, there are concerns that the measures imply that patients receiving such treatments as chemotherapy in the last 14 days of life, or patients with more than one ER visit in the last days of life, are receiving poor care. The commenters expressed concern that by grouping all patient populations together in these measures, patients appropriately receiving the indicated treatments would be counted in the numerator, and the reporting facility penalized. Further, commenters indicated that prognostication of death is limited, and in addition to being unable to determine accurately in advance a patient’s expected death, the measures do not distinguish between patients who were terminally ill and those who died suddenly.

Steering Committee Response: These issues were discussed extensively during the Cancer Steering Committee in-person meeting. In that discussion, the measure developer noted that at times the interventions can and should occur for many patients. The measures are intended to compare similar providers who have similar patient mixes and identify outlying patterns of care. Consequently, relative incidence of the situations should be similar. For example, grouping patients receiving palliative chemotherapies at the end of life with those receiving curative chemotherapies should not result in markedly different measure score performance between two facilities with a similar case mix. This reasoning may also be applied to grouping patients who are terminally ill and those who died suddenly.

Further, the Steering Committee respectfully disagreed with the statement that prognostication of death is limited, and believed that taking this stance would severely limit measures of this type, which are very important quality indicators for patient preference and the availability of resources at the end of life.
The Steering Committee also noted that though there are a limited number of studies, it has been demonstrated that patients who receive palliative care earlier have lower rates of chemotherapy at the end of life, lending credence to the importance of palliative interventions in reducing overtreatment.

**Request for reconsideration of Measure 0212: Proportion with more than one hospitalization in the last 30 days of life (American Society of Clinical Oncology), to be paired with Measures 0211 and 0213**

The Steering Committee did not recommend measure 0212 for endorsement. Commenters urged endorsement of the measure as complementary to measures 0211 and 0213. Commenters indicated that given the variation in the use of emergency department or direct hospital admissions for patients in advanced stages of illness, as well as variation in the intensity of care provided in diverse health care settings, it would not be possible to understand variations in emergency department and intensive care unit (ICU) use at the end of life without including the hospital admissions piece represented by measure 0212. Commenters suggested excluding patients in inpatient hospice and palliative care units to strengthen the measure.

**Steering Committee Response:** Steering Committee members noted that emergency department and ICU utilization varies regionally and often by facility, with some facilities utilizing ICUs in circumstances where other facilities would simply admit a patient to the hospital. However, the Committee members stated concerns that without a way to distinguish palliative care units, many patients who were receiving appropriate and necessary care via hospitalization would be counted in this measure. The data source for the measure is Medicare claims data, which does not currently distinguish between palliative care units and other hospitalizations. Because of this, the Steering Committee agreed the measure would not present a valid depiction of the quality of care provided within a facility. Consequently, the Committee did not move to re-vote on measure 0212 and maintains its recommendation that the measure not be endorsed.

**NQF MEMBER VOTING**

Information for electronic voting has been sent to NQF Member organization primary contacts. Accompanying comments must be submitted via the online voting tool.

Please note that voting concludes on Tuesday, June 26, 2012 at 6:00pm ET – no exceptions.
NATIONAL QUALITY FORUM

CANCER ENDORSEMENT MAINTENANCE PHASE 1, 2011

DRAFT TECHNICAL REPORT FOR VOTING

June 12, 2012

NQF VOTING DRAFT—DO NOT CITE OR QUOTE
NQF MEMBER votes are due June 26, 2012 by 6:00 PM ET
# Table of Contents

Introduction ............................................................................................................................................... 3  
Measure Evaluation .................................................................................................................................. 3  
  Overarching Issues ............................................................................................................................ 4  
Recommendations for Future Measure Development .............................................................................. 6  
Measure Evaluation Tables ....................................................................................................................... 9  
Measures Recommended ......................................................................................................................... 9  
Measures Not Recommended .................................................................................................................. 51  
Notes ....................................................................................................................................................... 57  
Appendix A - MEASURE SPECIFICATIONS ................................................................................... A-1  
Appendix B - STEERING COMMITTEE ........................................................................................... B-1  
Appendix C - RELATED MEASURE COMPARISON TABLE ........................................................ C-1
INTRODUCTION
Cancer refers to a group of more than 100 diseases characterized by uncontrolled cellular growth, proliferation, and spread. This group of diseases has an enormous impact on health in the US. As the second leading cause of death, cancer was responsible for an estimated 569,490 deaths among adults and children in 2010. The National Cancer Institute estimates that half of all men and one-third of all women in the US will develop cancer during their lifetimes. Diagnosis and treatment of cancer also has great economic impact as well. In 2010, the estimated total annual costs of cancer reached $263.8 billion: $102.8 billion in direct medical costs; $20.9 billion in loss of productivity from illness; and $140.1 billion in lost productivity from premature death. Despite enormous focus on prevention and treatment of disease, inconsistencies in cancer care exist, with many patients not receiving care that follows clinical practice guidelines. Studies demonstrate persistent socioeconomic disparities in treatment and survival for many different types of cancer, including gastric, breast, prostate, and lung cancers.

Cancer care is complicated for many reasons: treatment regimens are complex, often involving multiple providers, settings of care, and levels of treatment; patients with cancer often require individualized therapies; an evolving evidence base for treatment exists; and care can be hampered by a sometimes limited supply of highly specialized personnel or technologies. There is a need for measures that address the quality of cancer care, taking into account the nuances mentioned.

The Cancer Endorsement Maintenance Project seeks to evaluate for endorsement measures for accountability and quality improvement that address breast, colorectal, lung, prostate, hematologic and skin cancers, as well as symptom management and end of life care. Cancer care consensus standards that have been endorsed by NQF before 2009 are evaluated under the maintenance process. Endorsement maintenance ensures the currency of NQF’s portfolio of voluntary consensus standards, provides the opportunity to harmonize specifications, and ensures that endorsed measures represent the best in class. Measures that address specific aspects of the National Quality Strategy (NQS)—particularly those focused on person and family engagement, communication, coordination and safety are a priority.

MEASURE EVALUATION
To facilitate the evaluation the project is divided into two phases. For this first phase the Cancer Endorsement Maintenance Steering Committee reviewed candidate standards relating to hematologic, lung, esophageal, skin, prostate, and colon cancer as well as palliative care. Committee members were divided into four workgroups. The workgroups conducted a preliminary review of measures against the evaluation sub-criteria prior to consideration by the entire Steering Committee. At its in-person meeting on March 13-14, 2012 the Committee evaluated four new measures and 22 measures undergoing maintenance review against NQF’s measure evaluation criteria. The Committee’s discussion and rating of the criteria are summarized in the evaluation tables beginning on page 8.
TABLE 1: CANCER ENDORSEMENT MAINTENANCE SUMMARY

<table>
<thead>
<tr>
<th></th>
<th>MAINTENANCE</th>
<th>NEW</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measures under consideration</td>
<td>23</td>
<td>4*</td>
<td>27</td>
</tr>
<tr>
<td>Withdrawn from consideration</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Recommended</td>
<td>17</td>
<td>4</td>
<td>21</td>
</tr>
<tr>
<td>Not recommended</td>
<td>54</td>
<td>0</td>
<td>54</td>
</tr>
</tbody>
</table>

*Includes two untested measures eligible for time-limited endorsement.

Overarching Issues

During the Steering Committee’s discussion of the measures, several overarching issues emerged that were factored into their ratings and recommendations. These issues are discussed in detail in the following sections.

Palliative Measures

The Steering Committee noted that several of the events covered by the palliative care measures including receipt of chemotherapy (#0210), having more than one emergency room visit (#0211) and admission to the ICU in the last days of life (#0213) can and should happen in some cases. The Committee agreed that the measures would be useful for detecting patterns in practice, variation in performance and identifying outliers when comparing similar practices with similar patient populations; addressing patient preference and overtreatment at the end of life; and, reflecting disparities in access to care and the capacity of the local healthcare system to treat patients appropriately at the end of life. The Committee also noted that two measures related to admission to hospice and hospice length of stay were important as they could indicate a need for more hospice facilities or a need for greater physician and patient education around using this resource, leading to improved patient-centered quality of care. The Committee also noted that the area of palliative care and the concept of hospice and the settings in which hospice care is given are evolving and that future measures should consider that palliative care may be provided in the home, special facility, or in a hospital.
NATIONAL QUALITY FORUM

Harmonization of Related Measures

The Steering Committee recommended that the developer harmonize measures #0384 with currently endorsed measures #1628 and #1634, which are also related to pain assessment and pain treatment. The measures differ in the following ways:

<table>
<thead>
<tr>
<th>Measure</th>
<th>Data Source</th>
<th>Level of Analysis</th>
<th>Patient Population</th>
<th>Exclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1628</td>
<td>Registry, paper records.</td>
<td>Facility, health plan, integrated delivery system</td>
<td>Adult patients with Stage IV cancer who are alive 30 days or more after diagnosis and who have had at least 1 primary care visit or cancer-related/specialty outpatient visit.</td>
<td>None, other than patients who did not survive at least 30 days after cancer diagnosis.</td>
</tr>
<tr>
<td>#1634</td>
<td>EHR, structured medical record abstraction tool.</td>
<td>Group practice, facility</td>
<td>Patients enrolled in hospice for 7 or more days OR patients receiving hospital-based palliative care for 1 or more days. The Pain Screening quality measure is intended for patients with serious illness who are enrolled in hospice care OR receive palliative care in an acute hospital setting. Conditions may include, but are not limited to: cancer, heart disease, pulmonary disease, dementia and other progressive neurodegenerative diseases, stroke, HIV/AIDS, and advanced renal or hepatic failure.</td>
<td>Patients with length of stay &lt; 7 days in hospice, or &lt; 1 day in palliative care. Calculation of length of stay; discharge date - date of initial encounter.</td>
</tr>
<tr>
<td>#0384</td>
<td>Administrative claims, EHR, registry paper records.</td>
<td>Group practice, facility, individual clinician, team</td>
<td>All visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy, within a 12 month period.</td>
<td>None</td>
</tr>
</tbody>
</table>

The Committee noted the burden on providers but agreed that there is a preference for a standardized quantitative pain tool that could be used across measures. It was also suggested that in the future, the developers of measures #0383 and #0383 eliminate specifications for documenting a care plan for patients with mild pain, in order to focus on patients who most need an intervention (patients with moderate to severe pain), and further define what constitutes a plan of care to clarify the measures. The Committee suggested that care plans for pain should be broadly specified to include all patients regardless of the type of modality of treatment but also be more precise as to what may be included as an acceptable plan of care as additional data collection methods become more common, including registry reporting and EHR reporting. The related measure comparison table is in Appendix D.
NATIONAL QUALITY FORUM

Electronic Health Record Specifications

One measure recommended for endorsement in this phase was submitted with additional electronic specifications: #0389 Prostate Cancer: Avoidance of Overuse Measure - Bone Scan for Staging Low Risk Patients (AMA-PCPI). This was one of the measures retooled in 2010 and updated in 2011. The submitted e-specifications were reviewed by NQF Health IT staff for accuracy.

RECOMMENDATIONS FOR FUTURE MEASURE DEVELOPMENT

During the measure evaluation process, including the discussions of relating/competing measures, the Steering Committee identified several areas where additional measure development is needed.

Disease Specific Gaps
- PSA screenings for patients diagnosed with prostate cancer
- Measures addressing hematological malignancies, particularly first line therapies
- Measures addressing targeted therapies for kidney and lung cancer, as well as other solid tumor cancers
- Measures capturing deviations in care for the CMS priority areas of prostate, lung, breast, and colon cancers
- Measures addressing management of complications such as febrile neutropenia (FN)
- Measures for pediatric patients, including measures in cross cutting areas such as pain assessment and palliative care

Pathology and Treatment Reports
- Measures ensuring that reporting details in pathology reports are standardized across all tumor types
- Measures ensuring that treatment summaries are standardized across medical and radiation oncologists

Appropriateness of Care
- Measures capturing enrollment of patients in clinical trials at appropriate times
- Measures addressing whether appropriate patients are offered enrollment in clinical trials
- Measures capturing access of patients to high quality hospice care facilities
- Measures addressing readmissions and value-based care
- Measures of care coordination

Patient Outcomes
- Measures capturing Patient Reported Outcomes
  - Measures capturing cancer survival rate curve measures that can be reported by stage, identified as both overall survival (OS) and disease free survival (DFS). Measures applicable to patients with:
    - lung, pancreas, liver, esophagus and colon cancer: 5-year survival rates
    - breast cancer: 10 year survival rates
    - thyroid cancer: 20-25 year survival rates
NATIONAL QUALITY FORUM

Surgical Care
- Measures capturing operating room procedures or processes that need to take place in the surgical theater

Other Measures
- Measures submitted by patient advocacy groups or other multidisciplinary stakeholders
- Prevention measures
- Screening measures
- Combined measures to be used in “toolkits” to ensure a process is associated with an improved outcome
MEASURES RECOMMENDED

0377 Myelodysplastic Syndrome (MDS) and Acute Leukemias – Baseline Cytogenetic Testing Performed on Bone Marrow ................................................................. 9
0378 Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy ........................................... 11
0379 Chronic Lymphocytic Leukemia (CLL) – Baseline Flow Cytometry ............................................................ 13
0380 Multiple Myeloma – Treatment with Bisphosphonates ......................................................................... 14
0562 Overutilization of Imaging Studies in Melanoma ... .............................. 16
0650 Melanoma Continuity of Care – Recall System .......................................................... 19
0381 Oncology: Treatment Summary Communication – Radiation Oncology ........................................ 21
0382 Oncology: Radiation Dose Limits to Normal Tissues ................................................................. 23
0383 Oncology: Plan of Care for Pain – Medical Oncology and Radiation Oncology (paired with 0384) ... 25
0384 Oncology: Pain Intensity Quantified – Medical Oncology and Radiation Oncology (paired with 0383) ................................................................. 27
0386 Oncology: Cancer Stage Documented ......................................................................................... 29
1854 Barrett’s Esophagus (Eligible for Time-Limited Endorsement) .......................................................... 31
0389 Prostate Cancer: Avoidance of Overuse Measure – Bone Scan for Staging Low-Risk Patients ...... 32
0390 Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Patients ............................................. 35
1790 Risk-Adjusted Morbidity and Mortality for Lung Resection for Lung Cancer .................................... 37
1853 Radical Prostatectomy Pathology Reporting (Eligible for Time-Limited Endorsement) .................... 38
0210 Proportion receiving chemotherapy in the last 14 days of life .......................................................... 40
0211 Proportion with more than one emergency room visit in the last days of life .................................... 42
0213 Proportion admitted to the ICU in the last 30 days of life .............................................................. 45
0215 Proportion not admitted to hospice ................................................................................................. 47
0216 Proportion admitted to hospice for less than 3 days ......................................................................... 49
1822 External Beam Radiotherapy for Bone Metastases ........................................................................ 50

MEASURES NOT RECOMMENDED

0561 Melanoma Coordination of Care ................................................................................................. 52
0625 History of Prostate Cancer - Cancer Surveillance ............................................................................. 54
0625 History of Prostate Cancer - Cancer Surveillance ............................................................................. 54
0212 Proportion with more than one hospitalization in the last 30 days of life ........................................ 55
0214 Proportion dying from Cancer in an acute care setting .................................................................. 57
### MEASURE EVALUATION SUMMARY TABLES

**MEASURES RECOMMENDED**

**Hematology and Melanoma Measures**

<table>
<thead>
<tr>
<th>Measure</th>
<th>Description</th>
<th>Numerator Statement</th>
<th>Denominator Statement</th>
<th>Exclusions</th>
<th>Adjustment/Stratification</th>
<th>Level of Analysis</th>
<th>Type of Measure</th>
<th>Data Source</th>
<th>Measure Steward</th>
<th>Other Organizations</th>
</tr>
</thead>
<tbody>
<tr>
<td>0377 Myelodysplastic Syndrome (MDS) and Acute Leukemias – Baseline Cytogenetic Testing Performed on Bone Marrow</td>
<td>Percentage of patients aged 18 years and older with a diagnosis of MDS or an acute leukemia who had baseline cytogenetic testing performed on bone marrow.</td>
<td>Patients who had baseline cytogenetic testing* performed on bone marrow</td>
<td>All patients aged 18 years and older with a diagnosis of MDS or an acute leukemia</td>
<td>Documentation of medical reason(s) for not performing baseline cytogenetic testing, Documentation of patient reason(s) for not performing baseline cytogenetic testing, Denominator Exclusions: Documentation of system reason(s) for not performing baseline cytogenetic testing</td>
<td>No risk adjustment or risk stratification</td>
<td>Clinician: Group/Practice, Clinician: Individual, Clinician: Team</td>
<td>Process</td>
<td>Administrative claims, Electronic Clinical Data: Laboratory</td>
<td>American Medical Association - Physician Consortium for Performance Improvement</td>
<td>The American Society of Hematology</td>
</tr>
</tbody>
</table>

1. Importance to Measure and Report: The measure meets the Importance criteria. (1a. High Impact; 1b. Performance Gap; 1c. Evidence)

1a. Impact: H-9; M-8; L-0; I-0
1b. Performance Gap: H-11; M-6; L-0; I-0
1c. Evidence: Y-13, N-1, I-3

Rationale:

- Myelodysplastic Syndrome (MDS) is increasingly common in an aging population and associated with high morbidity and mortality; baseline cytogenetic testing performed on bone marrow is important to measure and report due to its role in evaluating and managing this patient population.
- There is a striking performance gap: 48% non-compliance was demonstrated in the CMS 2008 Physician Quality Reporting System (PQRS).
- Measurement of cytogenetics at the time of diagnosis or prior to treatment has become the standard of care since therapies are stratified based on the cytogenetic profile.
- There was concern that the literature cited and rationale provided by measure authors focuses mainly on the use of cytogenetics in MDS and its evolution to acute myelogenous leukemia (AML) and does not include much information on de novo AML. Although much of the literature presented in the application is based on retrospective reviews, there is some prospective randomized literature in AML that is stratified based on prognostic factors (including...
Myelodysplastic Syndrome (MDS) and Acute Leukemias – Baseline Cytogenetic Testing Performed on Bone Marrow

cytogenetics) to indicate that cytogenetic abnormalities predict outcome. However, this measure is based mainly on a consensus guideline from the National Comprehensive Cancer Network (NCCN). The authors grade the literature as 2A based on lower level evidence.

2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.  
(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)  
2a. Reliability: H-7; M-9; L-1; I-0; 2b. Validity: H-8; M-9; L-0; I-0

Rationale:
- The PCPI Testing Project shows interobserver variability is minimal.
- Face validity is well demonstrated.
- The measure directs that the data be gathered in the ambulatory setting. For acute leukemia, much of the care is in the hospital setting. The Steering Committee recommended reporting the measure with a CPT procedure code or CPT-2 code in order to capture the inpatient setting.
- Extraction of data from separate EHRs was not addressed. The number of patients analyzed for these measures was small, and the sample needed to be extended beyond the scope of the measure to achieve an adequate sample for analysis.

3. Usability: H-10; M-6; L-1; I-0
(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

Rationale:
- The measure has been in use in the CMS Physician Quality Reporting System (PQRS) since 2007
- The data presented demonstrate a high failure rate to meet the measure, and since treatment is stratified based on the presence of cytogenetic information prior to initiating therapy this measure represents a highly useful measure for quality improvement.

4. Feasibility: H-5; M-11; L-1; I-0
(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/unintended consequences identified 4d. Data collection strategy can be implemented)

Rationale:
- Collection of this data is a routine part of care.
- Data can be extracted, but may exist in different EHRs.

Steering Committee Recommendation for Endorsement: Y-17; N-0

Rationale:
- The measure represents standard of care measure that is useful to stratify treatments, possibly decrease toxicities and costs and assure appropriate therapies. The measure appears to be reliable, valid, useful and feasible.

RECOMMENDATIONS:
- This measure is becoming outdated, as diagnostic panels for MDS and acute leukemias rely heavily upon molecular panels and FISH in addition to standard cytogenetics. The responsibility for these assays is also divided between pathologists (who have no ongoing relationship with patients) and hematologists, who provide ongoing care. The Steering Committee recommended that the measure developer consider specifying this measure in the future to capture FISH and other tests.
- The Steering Committee recommended the measure developer consider specifying the measure to capture patients with MDS, acute myelogenous leukemia and acute lymphoblastic leukemia. The Committee believed that karyotypic data, stratified appropriately, might provide a way to make major therapeutic decisions with respect to the patient.
0377 Myelodysplastic Syndrome (MDS) and Acute Leukemias – Baseline Cytogenetic Testing Performed on Bone Marrow population.

Public and Member Comment

Comments included:
- Commenters suggested the time window be further defined to specify the look back period for the measure.
- Commenters suggested that in the future, the developer specify measure to capture FISH and other tests.

Developer Response:
- The developer will look to address these concerns in future iterations of the measure.

0378 Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy

Maintenance Measure

Measure Evaluation and Specifications

Description: Percentage of patients aged 18 years and older with a diagnosis of MDS who are receiving erythropoietin therapy with documentation of iron stores within 60 days prior to initiating erythropoietin therapy

Numerator Statement: Patients with documentation* of iron stores within 60 days prior to initiating erythropoietin therapy

*Definition: documentation of iron stores which includes either: 1) bone marrow examination including iron stain OR 2) serum iron measurement including ferritin, serum iron and TIBC

Denominator Statement: All patients aged 18 years and older with a diagnosis of MDS who are receiving erythropoietin therapy

Exclusions: Documentation of system reason(s) for not documenting iron stores prior to initiating erythropoietin therapy

Adjustment/Stratification: No risk adjustment or risk stratification. We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

Level of Analysis: Clinician: Group/Practice, Clinician: Individual, Clinician: Team

Type of Measure: Process

Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Laboratory

Measure Steward: American Medical Association - Physician Consortium for Performance Improvement Other organizations: American Society of Hematology

Steering Committee In-Person March 13-14, 2012

1. Importance to Measure and Report: The measure meets the importance criteria.

(1a. High Impact; 1b. Performance Gap; 1c. Evidence)

1a. Impact: H-3 ; M-11 ; L-1 ; I-0; 1b. Performance Gap: H-5 ; M-7 ; L-3 ; I-0 ; 1c. Evidence: Y-15 , N-0 , I-0

Rationale:
- This is an increasingly common condition, with diagnosis rising as the population continues to age.
- There is a significant performance gap; 58% of patients did not meet the measure as demonstrated in the PQRS testing information.
- The measure is based on a National Comprehensive Cancer Network (NCCN) consensus guideline.
- The measure only requires that iron stores be checked, not that an intervention as a result of the iron level occur (it would be far more important to document and supplement iron in patients receiving erythropoietin therapy). This is an area for future measure development.
NATIONAL QUALITY FORUM

0378 Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy

- This patient population falls outside of FDA regulations for testing of iron stores; this may make this measure more important.

2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.
(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)
2a. Reliability: H-4 ; M-10 ; L-0 ; I-1 ; 2b. Validity: H-5 ; M-9 ; L-0 ; I-1

Rationale:
- Numerator and denominator are precisely specified; clarification of the definition of “iron stores” in the numerator statement and specification of a 60-day time window the denominator allow for the measure to be precisely captured.
- Reliability data supports that the measure is reliable.
- Face validity has been demonstrated.

3. Usability: H-5; M-8; L-2; I-0
(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

Rationale:
- The measure has been in use in PQRS since 2007.
- The measure should be moderately understandable for public reporting.

4. Feasibility: H-7; M-8; L-0; I-0
(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

Rationale:
- Collection of this data is a routine part of care.
- Data can be extracted but may exist in different EHRs.

Steering Committee Recommendation for Endorsement:
Rationale: Y-14; N-1
- The Committee’s initial evaluation supported endorsement with clarification of iron measurements, which were addressed by the developer. The Committee noted that erythropoietin works sub optimally without adequate iron stores, and that the measure reflects FDA recommendations.
- The measure was improved with the addition of a testing time window, as the diagnosis of MDS may precede decision to use erythropoietin by many months if not years.
- This measure does not carry a high risk of unintended consequences.

RECOMMENDATIONS: The measure was not voted on at the in-person meeting due to ambiguity in the measure specifications. The Steering Committee asked the developer to clarify the definition of “iron stores” in the numerator statement and to specify time window the denominator. On a follow up call, the Steering Committee reviewed the measure with the clarified numerator and the addition of a 60-day time window to the denominator for the documentation of iron stores prior to the initiation of erythropoietin therapy. The Committee agreed with the changes and recommended the measure for endorsement.

Public & Member Comment
- Commenters indicated support for the measure.
### 0379 Chronic Lymphocytic Leukemia (CLL) – Baseline Flow Cytometry

**Maintenance Measure**

**Measure Evaluation and Specifications**

**Description:** Percentage of patients aged 18 years and older with a diagnosis of CLL who had baseline flow cytometry studies performed.

**Numerator Statement:** Patients who had baseline flow cytometry* studies performed.

**Definition:** *Baseline flow cytometry studies: Refer to testing that is performed at time of diagnosis or prior to initiating treatment for that diagnosis. Treatment may include antineoplastic therapy.

**Denominator Statement:** All patients aged 18 years and older seen within a 12 month reporting period, with a diagnosis of chronic lymphocytic leukemia (CLL) made at any time during or prior to the reporting period.

**Exclusions:**
- Documentation of medical reason(s) for not performing baseline flow cytometry
- Documentation of patient reason(s) for not performing baseline flow cytometry
- Documentation of system reason(s) for not performing baseline flow cytometry

**Adjustment/Stratification:** No risk adjustment or risk stratification. We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

**Level of Analysis:** Clinician: Group/Practice, Clinician: Individual, Clinician: Team

**Type of Measure:** Process

**Data Source:** Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Laboratory

**Measure Steward:** American Medical Association - Physician Consortium for Performance Improvement Other organizations: American Society of Hematology

**Steering Committee In-Person March 13-14, 2012**

1. **Importance to Measure and Report:** The measure meets the Importance criteria.
   (1a. High Impact; 1b. Performance Gap; 1c. Evidence)
   **1a. Impact:** H-7; M-5; L-3; I-0; 1b. Performance Gap: H-2; M-10; L-2; I-1; 1c. Evidence: Y-14, N-0, I-1

**Rationale:**
- This is the most common leukemia and involves high resource use.
- There is a performance gap: a 38% failure to perform shown in PQRS testing.
- Flow cytometry is important in diagnosis and treatment planning, but the data provided do not provide adequate rationale for measure. They discuss delays in diagnosis but measure is for flow cytometry following diagnosis or before treatment. So it is unclear how this would shorten time to diagnosis.

2. **Scientific Acceptability of Measure Properties:** The measure meets the Scientific Acceptability criteria.
   (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)
   **2a. Reliability:** H-5; M-9; L-0; I-1; 2b. Validity: H-5; M-9; L-0; I-1

**Rationale:**
- The measure is confusing. It specifies a 12-month reporting period in which all patients with CLL are captured in the denominator. However, flow cytometry may have been performed years prior to the initiation of treatment and reporting event. The numerator therefore may not correspond to the same reporting period as the denominator. The measure may be relying upon interventions done many years earlier. Per the Steering Committee’s recommendation, the developer will clarify the time window for flow cytometry studies to be performed.
- The Steering Committee noted that the clarification that flow cytometry baseline studies should take place at the time of diagnosis or prior to initiating treatment, and not necessarily within the time window for the measure, adds the necessary clarity to the measure specifications to make it easily captured.
### 0379 Chronic Lymphocytic Leukemia (CLL) – Baseline Flow Cytometry

#### 3. Usability: H-5; M-7; L-2; I-0

*(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)*

**Rationale:**
- The measure has been in use in PQRS since 2007.
- The measure should be moderately understandable for public reporting.

#### 4. Feasibility: H-3; M-11; L-1; I-0

*(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/unintended consequences identified 4d. Data collection strategy can be implemented)*

**Rationale:**
- Collection of this data is a routine part of care.
- Data can be extracted but may exist in different EHRs.

**Steering Committee Recommendation for Endorsement**

**Rationale:** Y-13; N-2
- The measure is improved with clarification of numerator/denominator.
- There is some concern about use as a quality measure as diagnosis is made based on flow cytometry results.
- Flow cytometry is sensitive and specific for diagnosis, impacts prognosis and decisions regarding follow-up; questions about time frames have been addressed.
- Even with the caveats discussed, the measure provides a reasonable assessment of quality care.
- Important to measure, and developer clarified numerator and denominator for more reliable measurement.

**RECOMMENDATIONS:** The Steering Committee did not recommend the measure at the in-person meeting; voting ended at 2.a Reliability. The Committee noted that the numerator should be clarified to identify patients who had documentation of the study having been performed, and that the denominator should be clarified regarding the time window. On a follow up call, the developer provided clarifications to the numerator and denominator for review and consideration by the Committee. The Committee agreed with the changes presented and recommended the measure for endorsement.

**Public and Member Comment**

**Comments included:**
- Commenters were concerned that because the diagnosis of CLL is based on the results of flow cytometry, nearly all patients with the diagnosis will be expected to have had flow cytometry.
- Commenters suggested that the measurement time period should be clarified.

**Developer Response:**
- We have received comments regarding clarifying the time period as well as the possibility that the flow cytometry would have taken place previously. We have incorporated these updates and comments into the measure language.

**Steering Committee Response:**
- The Steering Committee agrees with the developer’s response, which is in line with discussions that occurred at the in-person meeting and on related conference calls.

### 0380 Multiple Myeloma – Treatment with Bisphosphonates
<table>
<thead>
<tr>
<th>Measure Evaluation and Specifications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Description:</strong> Percentage of patients aged 18 years and older with a diagnosis of multiple myeloma, not in remission, who were prescribed or received intravenous bisphosphonates within the 12 month reporting period.</td>
</tr>
<tr>
<td><strong>Numerator Statement:</strong> Patients who were prescribed or received intravenous bisphosphonate therapy within the 12 month reporting period.</td>
</tr>
<tr>
<td><strong>Definition:</strong> Bisphosphonate Therapy: Includes the following medications: pamidronate and zoledronate</td>
</tr>
<tr>
<td><strong>Denominator Statement:</strong> All patients aged 18 years and older with a diagnosis of multiple myeloma, not in remission.</td>
</tr>
<tr>
<td><strong>Exclusions:</strong> Documentation of medical reason(s) for not prescribing bisphosphonates (eg, patients who do not have bone disease, patients with dental disease, patients with renal insufficiency).</td>
</tr>
<tr>
<td><strong>Adjustment/Stratification:</strong> No risk adjustment or risk stratification. We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.</td>
</tr>
<tr>
<td><strong>Level of Analysis:</strong> Clinician: Group/Practice, Clinician: Individual, Clinician: Team</td>
</tr>
<tr>
<td><strong>Type of Measure:</strong> Process</td>
</tr>
<tr>
<td><strong>Data Source:</strong> Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Paper Records</td>
</tr>
<tr>
<td><strong>Measure Steward:</strong> American Medical Association - Physician Consortium for Performance Improvement Other organizations: American Society of Hematology</td>
</tr>
</tbody>
</table>

1. **Importance to Measure and Report:** The measure meets the Importance criteria. (1a. High Impact; 1b. Performance Gap; 1c. Evidence) 
   - 1a. Impact: H-9; M-8; L-0; I-0; 1b. Performance Gap: H-11; M-6; L-0; I-0; 1c. Evidence: Y-13, N-1, I-3

   **Rationale:**
   - The measure developer cites an American Cancer Society publication to show that this is an issue of high impact that affects large numbers of patients (approximately 20,000 patients diagnosed annually).
   - The gap in care for prescribing bisphosphonates for patients in the measure was striking, with 47.4% of patients reported on not meeting the measure.
   - Supporting literature is of moderate to high quality and quantity.
   - Use of bisphosphonates increases quality of life, though it does not decrease mortality.
   - Intervention should occur more often; however, reporting annually on the measure is acceptable.

2. **Scientific Acceptability of Measure Properties:** The measure meets the Scientific Acceptability criteria. (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity) 
   - 2a. Reliability: H-7; M-9; L-1; I-0; 2b. Validity: H-8; M-9; L-0; I-0

   **Rationale:**
   - Previously endorsed measure; interval study data demonstrated a high degree of reliability (100%).
   - Face validity of the measure was well demonstrated.
   - The measure is well specified and will be easy to extract.

3. **Usability:** H-7; M-10; L-0; I-0
   (Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement) 

   **Rationale:**
   - The measure will be useful for QI, particularly given the performance gap.
0380 Multiple Myeloma – Treatment with Bisphosphonates

- The measure should be moderately understandable for public reporting.

4. Feasibility: H-5; M-12; L-0; I-0

(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

Rationale:
- Data easily extracted from EHR or paper chart

Steering Committee Recommendation for Endorsement: Y-17; N-0

Rationale: The Steering Committee found the intervention addressed by this measure affects a large patient population and is important in improving patient quality of life. There is a significant performance gap in meeting the measure, allowing room for improvement in patient care.

Public & Member Comment
- Commenters indicated support for the measure.

0562 Overutilization of Imaging Studies in Melanoma

Maintenance Measure

Measure Evaluation and Specifications

Description: Percentage of patients, regardless of age, with a current diagnosis of stage 0 through IIC melanoma or a history of melanoma of any stage, without signs or symptoms suggesting systemic spread, seen for an office visit during the one-year measurement period, for whom no diagnostic imaging studies were ordered

Numerator Statement: Patients for whom no diagnostic imaging studies* were ordered

Denominator Statement: All patients, regardless of age, with a current diagnosis of stage 0 through IIC melanoma or a history of melanoma of any stage, without signs or symptoms suggesting systemic spread, seen for an office visit during the one-year measurement period

Exclusions: Documentation of medical reason(s) for ordering diagnostic imaging studies (e.g., patient has comorbid condition that warrants imaging, other medical reasons); Documentation of system reason(s) for ordering diagnostic imaging studies (e.g., requirement for clinical trial enrollment, ordered by another provider, other system reasons)

Adjustment/Stratification: No risk adjustment or risk stratification. We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

Level of Analysis: Clinician: Group/Practice, Clinician: Individual, Clinician: Team

Type of Measure: Process

Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Imaging/Diagnostic Study, Electronic Clinical Data: Registry, Paper Records

Measure Steward: American Medical Association - Physician Consortium for Performance Improvement Other organizations: American Academy of Dermatology and National Committee for Quality Assurance

Steering Committee In-Person March 13-14, 2012

1. Importance to Measure and Report:


1a. Impact: H-9; M-4; L-2; I-0. 1b. Performance Gap: H-7; M-7; L-1; I-0. 1c. Evidence: Y-8, N-4, I-3

Rationale:
- The Steering Committee agreed that there is no question that imaging use and cost are rising; however, it is less

NQF VOTING DRAFT—DO NOT CITE OR QUOTE
NQF MEMBER votes are due June 26, 2012 by 6:00 PM ET

16
**0562 Overutilization of Imaging Studies in Melanoma**

- Clear to what extent that is true for this population.
- The measure is based mainly on consensus guidelines with a high volume of studies cited and limited data presented to specifically support measure. Literature is graded according NCCN guidelines and recommendations are not based solely on literature support.
- The body of evidence as noted above is larger for the general group of all patients when looking at hospital to outpatient settings. If this is restricted to melanoma patients and if it involves outpatient to outpatient settings, the body of evidence is low. However, there is no evidence for harm.
- The Steering Committee discussed that the measure assumes that treatment for metastatic melanoma is futile therapy, but two new agents have been FDA-approved for melanoma since this measure was adopted and future studies may indicate a new role for surveillance in the future.

**2. Scientific Acceptability of Measure Properties:** The measure does not meet the Scientific Acceptability Criteria

2a. Reliability – precise specifications, testing: 2b. Validity – testing, threats to validity

- 2a. Reliability: H-2; M-4; L-6; I-2
- 2b. Validity: H-1; M-4; L-5; I-2

**3. Usability: N/A**

(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

**4. Feasibility: N/A**

(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/unintended consequences identified 4d. Data collection strategy can be implemented)

**Steering Committee Recommendation for Endorsement:** The measure failed the Scientific Acceptability criteria and will not be recommended for endorsement.

- The Steering Committee expressed concerns regarding the reliability of the measure: the measure does not adequately address the distinction between initial stage and recurrence, and the definitions of these in data sources
- The measure reflects updated NCCN guidelines, impacts large numbers, and is important to address overuse.
- The topic is too narrow; one could argue for this type of measure for every type of primary cancer.
- The Committee disagreed with inclusion of downstream patients in the measure, as they felt it confounds reliability; data presented by the developers appears to show this.

**RATIONALE:** The Steering Committee did not recommend the measure at the in-person meeting; voting ended at 1.c Evidence. The Committee noted that the denominator should be limited to patients with a new diagnosis and asked the developer for analysis of the data on newly diagnosed patients versus patients with a history of melanoma. The developer presented reliability testing analysis showing an approximately 10% difference in reliability, but the SC noted that the testing was done on a relatively small sample size of 148. On a follow up call, the Committee reviewed the analysis presented by the developer again and discussed the measure. The Committee noted that cancer staging follows patients from the point of diagnosis; the stage should not migrate as the patient's disease changes. Instead the stage carries with notations denoting clinical or pathological observations. Because of this, the testing analysis demonstrating reliability of the measure was not persuasive, as the stage is from diagnosis and thus cannot be easily extracted for measurement. The Committee found that the information provided by developer did not allay concerns about ambiguities in the measure and did not recommend the measure for endorsement.

**Public and Member Comment Importance**
0562 Overutilization of Imaging Studies in Melanoma

- The Steering Committee members stated that there is limited evidence of overuse of imaging in this patient population, as no study has ever been undertaken.
  - The measure developers presented evidence that the measure was based on both the AAD and NCCN guidelines (please reference attached letter, section 1).
  - The developers noted that the measure is supported by evidence based guidelines (AAD and NCCN) that recommend that both newly diagnosed patients with stage 0-IIC melanoma without signs or symptoms suggesting systemic spread and patients with a history of melanoma at any stage without signs or symptoms suggesting systemic spread not receive unnecessary imaging. The developers emphasized that patients with signs or symptoms suggesting systemic spread would not be counted in the denominator and thus would be eligible for imaging, allowing providers to exercise clinical judgment when signs or symptoms are present.

Scientific Acceptability

- Steering Committee members raised concerns that the measure would restrict imaging of patients with recurrence of melanoma, not taking into account patients who are seen many years out for follow up who present with symptoms or signs of illness. Steering Committee members noted that these patients should be followed up with utilizing imaging, in accordance with NCCN guidelines.
  - The measure developers noted that the measure provides explicit denominator exceptions for patients with signs or symptoms of systemic spread to be evaluated using imaging (see denominator exclusion details, section 2a.1.9 of the measure submission form and also section 3 of the attached letter). These patients who have a history of melanoma who present with signs or symptoms of systemic spread would not be included in the denominator and would be eligible for imaging.
  - Signs are defined as: “Signs-For the purposes of this measure, signs include tenderness, jaundice, localized neurologic signs such as weakness, or any other sign”
  - Symptoms are defined as: “Symptoms-For the purposes of this measure, symptoms include cough, dyspnea, pain, paresthesia, or any other symptom”

- Steering Committee members questioned whether providers would game the system and create exceptions in order to justify ordering imaging.
  - The developers noted that there have been several studies on exception methodology, with very high concordance between what is documented and what is considered an acceptable exception as defined by a group of experts.
  - With respect to this measure, for patients with newly diagnosed melanoma, the exception agreement was 100%. For patients with existing diagnoses of melanoma, the exception agreement was 74.59%. The developer cautioned that this was calculated using a small sample size (please reference attached letter, section 2).

In light of the information presented on the follow up conference call, Steering Committee members motioned to formally vote on the measure. A SurveyMonkey link was sent to the Steering Committee members along with a summary of the discussion on the conference call. The voting results are presented below:

1. Importance to Measure and Report: The measure meets the Importance criteria.
   (1a. High Impact; 1b. Performance Gap; 1c. Evidence)
   1a. Impact: H-4; M-9; L-1; I-0; 1b. Performance Gap: H-1; M-11; L-1; I-1; 1c. Evidence: Y-11; N-2; I-1

2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.
   (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)
   2a. Reliability: H-2; M-10; L-2; I-0; 2b. Validity: H-2; M-10; L-2; I-0

3. Usability: H-1; M-11; L-2; I-0
0562 Overutilization of Imaging Studies in Melanoma

(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

4. Feasibility: H-1; M-13; L-0; I-0

(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/unintended consequences identified; 4d. Data collection strategy can be implemented)

Steering Committee Recommendation for Endorsement: Y-9; N-5

Rationale:

• Steering Committee members voted to recommend measure 0562 for endorsement, noting that the evidence presented by the measure developer alleviated concerns regarding the evidence base for overuse of imaging in patients with asymptomatic localized melanoma.

• Steering Committee member concerns that the measure specifications would limit the ability of providers to use clinical judgment when ordering imaging were addressed by the clarifying language regarding signs or symptoms of melanoma.

• Steering Committee member concerns that the reliability of the measure was different for patients with a new diagnosis versus patients with a history of melanoma were addressed by the additional stratified reliability testing provided demonstrating that the measure is reliable in both patient populations and that the exception rate is not markedly different between the two patient groups.

0650 Melanoma Continuity of Care – Recall System

Measure Evaluation and Specifications

Description: Percentage of patients, regardless of age, with a current diagnosis of melanoma or a history of melanoma whose information was entered, at least once within a 12 month reporting period into a recall system that includes:

• A target date for the next complete physical skin exam, AND
• A process to follow up with patients who either did not make an appointment within the specified timeframe or who missed a scheduled appointment

Numerator Statement: Patients whose information is entered, at least once within a 12 month period, into a recall system* that includes:

• A target date for the next complete physical skin exam, AND
• A process to follow up with patients who either did not make an appointment within the specified timeframe or who missed a scheduled appointment

Denominator Statement: All patients, regardless of age, with a current diagnosis of melanoma or a history of melanoma.

Exclusions: Documentation of system reason(s) for not entering patients into a recall system (eg, melanoma being monitored by another physician provider)

Adjustment/Stratification: No risk adjustment or risk stratification Not applicable We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

Level of Analysis: Clinician: Group/Practice, Clinician: Individual, Clinician: Team

Type of Measure: Structure

Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Registry, Other, Paper Records
<table>
<thead>
<tr>
<th>Measure Steward: American Medical Association - Physician Consortium for Performance Improvement Other organizations: American Academy of Dermatology and National Committee for Quality Assurance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>0650 Melanoma Continuity of Care – Recall System</strong></td>
</tr>
<tr>
<td><strong>Steering Committee In-Person March 13-14, 2012</strong></td>
</tr>
<tr>
<td><strong>1. Importance to Measure and Report: The measure meets the Importance criteria.</strong></td>
</tr>
<tr>
<td>(1a. High Impact; 1b. Performance Gap; 1c. Evidence)</td>
</tr>
<tr>
<td>1a. Impact: H-9; M-8; L-0; I-0; 1b. Performance Gap: H-4; M-11; L-1; I-1; 1c. Evidence: Y-7, N-1, I-9; Evidence Exception: Y-16, N-1</td>
</tr>
<tr>
<td><strong>Rationale:</strong></td>
</tr>
<tr>
<td>• Studies presented do not specifically address the melanoma recall system.</td>
</tr>
<tr>
<td>• Measure is likely an opportunity for improvement but data is unclear about performance gap with regard to a recall system. Authors cite that 9% did not meet measure; however, the Steering Committee views this as a “never event.”</td>
</tr>
<tr>
<td>• The body of evidence as noted above is larger for the general group of all patients when looking at hospital to outpatient settings. If this is restricted to melanoma patients and if it involves outpatient to outpatient settings, the body of evidence is low. However, there is no evidence for harm.</td>
</tr>
<tr>
<td>• Steering Committee members stated that the link between the process of utilizing a recall system and increased screening/examination of patients can be inferred.</td>
</tr>
<tr>
<td>• Steering Committee members stated that this is a valuable intervention because of the prevalence of the diagnosis, the increasing incidence of melanoma and the opportunity for impacting the outcome of patients by early diagnosis of a new primary melanoma, and chose to invoke the exception to empirical evidence rule because of this.</td>
</tr>
<tr>
<td><strong>2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.</strong></td>
</tr>
<tr>
<td>(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)</td>
</tr>
<tr>
<td>2a. Reliability: H-7; M-9; L-0; I-1; 2b. Validity: H-4; M-12; L-0; I-1</td>
</tr>
<tr>
<td><strong>Rationale:</strong></td>
</tr>
<tr>
<td>• The measure developer reports moderate reliability regarding a diagnosis of melanoma but high reliability for all other data elements including documentation of enrollment in a recall system.</td>
</tr>
<tr>
<td>• Measure specifications are reasonably precise.</td>
</tr>
<tr>
<td>• Face validity was demonstrated.</td>
</tr>
<tr>
<td><strong>3. Usability: H-4; M-12; L-1; I-0</strong></td>
</tr>
<tr>
<td>(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)</td>
</tr>
<tr>
<td><strong>Rationale:</strong></td>
</tr>
<tr>
<td>• Measure is currently in use for PQRS.</td>
</tr>
<tr>
<td>• Measure is easily understood.</td>
</tr>
<tr>
<td><strong>4. Feasibility: H-6; M-11; L-0; I-0</strong></td>
</tr>
<tr>
<td>(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/unintended consequences identified 4d. Data collection strategy can be implemented)</td>
</tr>
<tr>
<td><strong>Rationale:</strong></td>
</tr>
<tr>
<td>• Data elements relate to office procedures, not directly to care.</td>
</tr>
<tr>
<td>• Recall procedure may not be in EHR, may be in practice management software, other tracking software, or non-electronic.</td>
</tr>
<tr>
<td>• All criteria should be feasible within an EHR, but extracting information may be difficult.</td>
</tr>
<tr>
<td><strong>Steering Committee Recommendation for Endorsement: Y-15; N-2</strong></td>
</tr>
<tr>
<td><strong>Rationale:</strong> The Steering Committee found that the intervention addressed by this measure affects a large patient population and is important in ensuring continuity of care.</td>
</tr>
</tbody>
</table>

NQF VOTING DRAFT—DO NOT CITE OR QUOTE
NQF MEMBER votes are due June 26, 2012 by 6:00 PM ET
## Melanoma Continuity of Care – Recall System

### Public and Member Comment

Comments included:

- Commenters suggested the measure be expanded to capture data regarding multiple types of skin cancers so that continuity of care can be achieved.
- It was suggested that the measure capture how many patients had a follow-up appointment rather than how many patients were entered into a recall system.

### Developer Response:

- The Work Group will consider expanding the measure population, when the measure undergoes formal review and maintenance, according to the AMA-PCPI measure development/maintenance methodology, in the future.

### Steering Committee Response:

- The Steering Committee agrees with the developer's response, which is in line with discussions that occurred at the in-person meeting and on related conference calls.

### Oncology Measures

#### 0381 Oncology: Treatment Summary Communication – Radiation Oncology

**Maintenance Measure**

**Measure Evaluation and Specifications**

**Description:** Percentage of patients, regardless of age, with a diagnosis of cancer who have undergone brachytherapy or external beam radiation therapy who have a treatment summary report in the chart that was communicated to the physician(s) providing continuing care and to the patient within one month of completing treatment.

**Numerator Statement:** Patients who have a treatment summary* report in the chart that was communicated to the physician(s) providing continuing care and to the patient within one month of completing treatment.

**Definition:** *Treatment Summary: a report that includes mention of all of the following components: 1) dose delivered; 2) relevant assessment of tolerance to and progress towards the treatment goals; and 3) subsequent care plans.*

**Numerator Instructions:** This measure should be reported once per course of radiation treatment – less than or equal to 30 days from the end of treatment.

**Denominator Statement:** All patients, regardless of age, with a diagnosis of cancer who have undergone brachytherapy or external beam radiation therapy.

**Exclusions:** Documentation of a patient reason(s) for not communicating the treatment summary report to the physician(s) providing continuing care (e.g., patient requests that report not be sent) and to the patient within one month of completing treatment.

Documentation of a system reason(s) for not communicating the treatment summary report to the physician(s) providing continuing care (e.g., patient does not have any physician responsible for providing continuing care) and to the patient within one month of completing treatment.

**Adjustment/Stratification:** None. Risk adjustment or risk stratification is not applied. None.

**Level of Analysis:** Clinician: Group/Practice, Clinician: Individual, Clinician: Team

**Type of Measure:** Process

0381 Oncology: Treatment Summary Communication – Radiation Oncology

Clinical Data: Registry, Paper Records

Measure Steward: American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)

Other organizations: The measure set was developed in collaboration with the American Society of Clinical Oncology and the American Society for Radiation Oncology.

Steering Committee In-Person March 13-14, 2012

1. Importance to Measure and Report: The measure meets the Importance criteria.
(1a. High Impact; 1b. Performance Gap; 1c. Evidence)
1a. Impact: H-7; M-10; L-0; I-0; 1b. Performance Gap: H-4; M-10; L-1; I-2; 1c. Evidence: Y-9, N-1, I-7

Rationale:
- Radiation therapy treatment summaries have been a routine practice for years and are a requirement for payment.
- Many radiation therapy treatment summaries currently lack critical information, such as the site of radiation.
- Summary of evidence of impact is not specific to the focus of the measure. Most evidence is related to incidence, cancer-related death rates, and cancer costs. The most closely related statistic is that two-thirds of all cancer patients will receive radiation. However, there is no data on outcomes associated with the lack of a treatment summary.
- Steering Committee members noted that the information from a treatment summary is very important to disseminate amongst providers caring for the patient receiving radiation therapy.
- The measure affects a large number of patients, and there is demonstrated evidence of a performance gap.

2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.
(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)
2a. Reliability: H-7; M-10; L-0; I-0; 2b. Validity: H-1; M-14; L-1; I-1

Rationale:
- Inter-rater reliability is described as 100% accurate.
- Measure addresses an important priority area: coordination of care. The proximal relationship between performance on the measure and desired outcome is not addressed by available data, however, face validity was demonstrated.

3. Usability: H-6; M-10; L-1; I-0
(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

Rationale:
- The measure is being used in a QI program with plans for use in PQRS.

4. Feasibility: H-5; M-10; L-2; I-0
(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

Rationale:
- Data elements are available in an EHR and generated during the provision of care.

Steering Committee Recommendation for Endorsement: Y-14; N-3

Rationale: The intervention addressed by this measure affects a large patient population and is important in ensuring continuity of care.

RECOMMENDATIONS:
The Steering Committee recommended the measure developer consider including the site and stage in the measure in the future.

Public and Member Comment
Comments included;
**0381 Oncology: Treatment Summary Communication – Radiation Oncology**

**Developer Response:**
- Commenters were concerned that the measure only assesses standard practice that should be occurring routinely.

  
  The radiation oncology treatment summary should include many details regarding the treatment course and follow-up plan, which is critical to ensuring proper coordination of care among patient's current and future physicians, including oncologists and primary care physicians. This is especially important for radiation oncology given that cancer patients treated with radiation typically receive multimodality treatment and many patients receive care that is fragmented among several facilities. Unfortunately, as indicated by performance rates for this measure and medical literature on the topic, adherence remains suboptimal demonstrating a significant opportunity to improve the care provided to cancer patients. Specifically, results of the National Initiative for Cancer Care Quality indicated that across five metropolitan statistical areas, only 50% of radiation therapy medical records for patients with breast cancer included information regarding the total dose of radiation, dose per fraction, number of fractions, and the site treated. While this data does not speak to the existence of the report itself, it does speak to the completeness of the report which is a secondary component to the measure. Additionally, among physicians participating in ASTRO’s Performance Assessment for the Advancement of Radiation Oncology Treatment (PAAROT) program, an average performance rate of 92% was reported for this measure with variation among physicians ranging from 0-100%. PAAROT is a practice improvement program that enables a physician to analyze their practice and evaluate their strengths and areas for improvement.

**Steering Committee Response:**
- The Steering Committee agrees with the developer's response, which is in line with discussions that occurred at the in-person meeting and on related conference calls.

---

**0382 Oncology: Radiation Dose Limits to Normal Tissues**

**Maintenance Measure**

**Measure Evaluation and Specifications**

**Description:** Percentage of patients, regardless of age, with a diagnosis of pancreatic or lung cancer who receive 3D conformal radiation therapy with documentation in medical record that radiation dose limits to normal tissues were established prior to the initiation of a course of 3D conformal radiation for a minimum of two tissues.

**Numerator Statement:** Patients who had documentation in medical record that radiation dose limits to normal tissues were established prior to the initiation of a course of 3D conformal radiation for a minimum of two tissues.

**Denominator Statement:** All patients, regardless of age, with a diagnosis of pancreatic or lung cancer who receive 3D conformal radiation therapy.

**Exclusions:** None

**Adjustment/Stratification:** None.

**Level of Analysis:** Clinician: Group/Practice, Clinician: Individual, Clinician: Team.

**Type of Measure:** Process

**Data Source:** Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Registry, Paper Records.

**Measure Steward:** American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI). Other organizations: This measure set was developed in collaboration with the American Society of Clinical Oncology and the American Society for Radiation Oncology.
0382 Oncology:  Radiation Dose Limits to Normal Tissues
Steering Committee In-Person March 13-14, 2012

1. Importance to Measure and Report: The measure meets the Importance criteria.
   (1a. High Impact; 1b. Performance Gap; 1c. Evidence)
1a. Impact: H-12; M-4; L-0; I-0; 1b. Performance Gap: H-2; M-12; L-2; I-0; 1c. Evidence: Y-14, N-2, I-0

Rationale:
- The measure applies to lung and pancreatic cancer, with lung especially being a prevalent cancer with high morbidity and mortality. Radiation is a commonly used treatment.
- There was evidence cited showing 89% compliance with the PQRS measure, which highlights some, but not much room for improvement. The Steering Committee considered this a “never event” and felt compliance should be 100%.
- The Steering Committee stated the importance of calculating dose limits when giving radiation to a patient and noted that there is evidence to support this practice.

2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.
   (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)
2a. Reliability: H-11; M-5; L-0; I-0; 2b. Validity: H-7; M-9; L-0; I-0

Rationale:
- The measure contains specifications that allow for reliable ascertainment and data on reliability.
- The measure includes data on face validity from an expert panel.

3. Usability: H-10; M-6; L-0; I-0
   (Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

Rationale:
- The measure has been successfully implemented in PQRS.
- The measure should be easily understood for public reporting.

4. Feasibility: H-11; M-5; L-0; I-0
   (4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

Rationale:
- The data elements are all feasibly extracted from an EHR and generated during routine care delivery.

Steering Committee Recommendation for Endorsement: Y-16; N-0

Rationale: The Steering Committee noted that there is near universal concordance from an expert panel, excellent reliability, usability, and feasibility, and the target population comprises large numbers. There is no contradictory evidence for the measure.

Public and Member Comment
Comments included:
- Commenters were concerned that the measure only assesses standard practice that should be occurring routinely.

Developer Response:
- Identifying normal tissue dose constraints is an important step in the process of care for patients receiving radiation therapy treatments with significant impact on outcomes including reducing the toxic effects of radiation to normal tissues and subsequently reducing the long term potential for late carcinogenesis and a second malignancy, while delivering the desired dose distribution of radiation to target tissue. Unfortunately, as indicated by performance rates for this measure noted in the submission form, adherence remains suboptimal demonstrating a significant opportunity.
### 0382 Oncology: Radiation Dose Limits to Normal Tissues

**Steering Committee Response:**
- The Steering Committee agrees with the developer’s response, which is in line with discussions that occurred at the in-person meeting and on related conference calls.

### 0383 Oncology: Plan of Care for Pain – Medical Oncology and Radiation Oncology (paired with 0384)

**Maintenance Measure**

**Measure Evaluation and Specifications**

**Description:** Percentage of visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy who report having pain with a documented plan of care to address pain.

**Numerator Statement:** Patient visits that included a documented plan of care* to address pain.

**Numerator Instructions:** *A documented plan of care may include: use of opioids, nonopioid analgesics, psychological support, patient and/or family education, referral to a pain clinic, or reassessment of pain at an appropriate time interval.

**Denominator Statement:** All visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy who report having pain.

**Exclusions:** None

**Adjustment/Stratification:** None

**Level of Analysis:** Clinician: Group/Practice, Clinician: Individual, Clinician: Team

**Type of Measure:** Process

**Data Source:** Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Registry, Other, Paper Records

**Measure Steward:** American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)

**Other organizations:** This measure set was developed in collaboration with the American Society of Clinical Oncology and the American Society for Radiation Oncology.

**Steering Committee In-Person March 13-14, 2012**

1. **Importance to Measure and Report:** The measure meets the Importance criteria.
   1a. Impact: H-15; M-2; L-0; I-0; 1b. Performance Gap: H-12; M-5; L-0; I-0; 1c. Evidence: Y-15, N-0, I-2

**Rationale:**
- It is well documented that many cancer patients will experience pain during the course of treatment. The measure affects a large patient population.
- A performance gap was demonstrated, with performance in the ASCO QOPI study achieving the measure at 78.29% and in PQRS for 2009 at 91.24%.
- Concern that including any report of pain, even mild, may dilute the impact of this measure. However, the Steering Committee stated that simply noting that the patient was experiencing mild pain and the need to follow up on it would be sufficient to meet this measure, alleviating concerns.

2. **Scientific Acceptability of Measure Properties:** The measure meets the Scientific Acceptability criteria.
   2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity
   2a. Reliability: H-4; M-12; L-1; I-0; 2b. Validity: H-3; M-12; L-1; I-1

**Rationale:**
### 0383 Oncology: Plan of Care for Pain – Medical Oncology and Radiation Oncology (paired with 0384)

- Reliability was adequately demonstrated, albeit with a small sample size.
- Face validity was demonstrated.

#### 3. Usability: H-6; M-9; L-2; I-0

*(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)*

**Rationale:**
- The measure is currently being used in PQRS 2012; also used from 2009-2011.
- The measure is currently in use in ASCO's Quality Oncology Practice Initiative (QOPI ®) program and ASTRO's Performance Assessment for the Advancement of Radiation Oncology Treatment (PAAROT) program.

#### 4. Feasibility: H-4; M-13; L-0; I-0

*(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)*

**Rationale:**
- Data elements are available in an EHR and generated during the provision of care.

### Steering Committee Recommendation for Endorsement: Y-16; N-1

**Rationale:** The Steering Committee found that the intervention addressed by this measure affects a large patient population. There is room for improvement in performance of this measure.

### Public and Member Comment

**Comments included:**
- Commenters recommended the measure be harmonized with other measures of pain management, including QOPI and ASSIST which specify that a plan of care be required for moderate to severe pain.
- Commenters were concerned about the burden on providers to provide a documented plan of care for pain that is insignificant, and were concerned about potential problems differentiating quality of care for moderate to severe pain patients.
- Commenters were concerned that the measure only assesses standard practice that should be occurring routinely.

### Developer Response:

- The NCCN guideline recommendations for the management of cancer related pain in adults, upon which this measure is based, are categorized according to three levels of pain intensity - mild pain (1-3); moderate pain (4-6); and severe pain (7-10). Therefore, the plan of care for pain should be initiated at the lowest level of pain intensity. It is also important to recognize that the scope of the plan is broad and may include use of opioids, nonopioid analgesics, psychological support, patient and/or family education, referral to a pain clinic, or reassessment of pain at an appropriate time interval. Consistent with NCCN guidelines, the specific plan of care for an individual patient’s pain required by the measure is at the discretion of the individual clinician based on the needs and preferences of that specific patient.

- Pain is one of the most common symptoms associated with cancer. Pain occurs in approximately one quarter of patients with newly diagnosed malignancies, one third of patients undergoing treatment, and three quarters of patients with advanced disease. Proper pain management is critical to achieving pain control. This measure aims to improve attention to pain management and requires a plan of care for cancer patients who report having pain to allow for individualized treatment based on clinical circumstances and patient wishes. Unfortunately, as indicated by performance rates for this measure noted in the submission form and medical literature on the topic, adherence remains suboptimal demonstrating a significant opportunity to improve the care provided to cancer patients.
0383 Oncology: Plan of Care for Pain – Medical Oncology and Radiation Oncology (paired with 0384)

Steering Committee Response:

- The Steering Committee agreed with the commenter that patients with mild pain likely do not require documented care plans for addressing the pain. The Steering Committee stated that documentation of a care plan for patients with mild pain in this patient population may very well present a substantial burden to the provider, as many patients being actively treated with chemotherapy or radiation therapy for cancer have mild pain.
- The Steering Committee questioned whether there are other measures that address pain for this patient population in the NQF portfolio. NQF staff stated that there are measures that may overlap with patients in this population that address moderate to severe pain; however, there are no measures that target the entirety of the patient population (patients with cancer being treated at an outpatient facility) addressed by this measure. Consequently, the Steering Committee determined that they would like to move this measure forward with a recommendation for endorsement; however, the Steering Committee made several recommendations for future iterations of the measure. Those recommendations are as follows:
  - Remove specifications for documenting a care plan for patients with mild pain, in order to focus on patients who most need an intervention (patients with moderate to severe pain).
  - Further define what constitutes a plan of care, to remove ambiguity about what “counts” for the measure. This will move the measure away from being a “check the box” measure and further assist in defining the measure as we move toward integration into electronic health records.

0384 Oncology: Pain Intensity Quantified – Medical Oncology and Radiation Oncology (paired with 0383)

Maintenance Measure

Measure Evaluation and Specifications

Description: Percentage of visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified

Numerator Statement: Patient visits in which pain intensity is quantified*

* Pain intensity should be quantified using a standard instrument, such as a 0-10 numerical rating scale, a categorical scale, or the pictorial scale

Denominator Statement: All visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy

Exclusions: None

Adjustment/Stratification: None We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

Level of Analysis: Clinician : Group/Practice, Clinician : Individual, Clinician : Team

Type of Measure: Process

Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Registry, Other, Paper Records

Measure Steward: American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI) Other organizations: This measure set was developed in collaboration with the American Society of Clinical Oncology and the American Society for Radiation Oncology.

Steering Committee In-Person March 13-14, 2012

1. Importance to Measure and Report: The measure meets the Importance criteria.
   (1a. High Impact; 1b. Performance Gap; 1c. Evidence)

1a. Impact: H-16; M-1; L-0; I-0; 1b. Performance Gap: H-11; M-6; L-0; I-0; 1c. Evidence: Y-16, N-1, I-0

NQF VOTING DRAFT—DO NOT CITE OR QUOTE
NQF MEMBER votes are due June 26, 2012 by 6:00 PM ET
### 0384 Oncology: Pain Intensity Quantified – Medical Oncology and Radiation Oncology (paired with 0383)

#### Rationale:
- Measure developer presented good evidence showing the prevalence of pain; the measure will impact a large number of patients.
- Performance was documented at 89.49% in the ASCO QOPI study, 57% in ASTRO’s PAAROT program, and 66.83% in PQRS. There is an opportunity for improvement.

#### 2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.

(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)
- 2a. Reliability: H-7; M-10; L-0; I-0
- 2b. Validity: H-6; M-11; L-0; I-0

#### Rationale:
- The measure is precisely specified.
- Reliability testing demonstrates almost perfect reliability.
- Face validity is demonstrated.

#### 3. Usability: H-10; M-7; L-0; I-0

(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

#### Rationale:
- The measure is currently in use in PQRS.

#### 4. Feasibility: H-9; M-8; L-0; I-0

(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/unintended consequences identified 4d. Data collection strategy can be implemented)

#### Rationale:
- Data elements are available in an EHR and generated during the provision of care.

#### Steering Committee Recommendation for Endorsement: Y-17; N-0

#### Rationale:
The Steering Committee found that the intervention addressed by this measure affects a large patient population. There is room for improvement in performance of this measure.

#### RECOMMENDATIONS:
The Steering Committee recommended that the developer harmonize the definition of a standardized quantitative pain tool with that used in measure 1628: Patients with Advanced Cancer Screened for Pain at Outpatient Visits and measure 1634: Hospice and Palliative Care – Pain Screening. The definition used by those measures is as follows: Pain screening with a standardized quantitative tool during the primary care or cancer-related/specialty outpatient visit(s). Screening may be completed using verbal, numeric, visual analog, rating scales designed for use with nonverbal patients, or other standardized tools.

#### Public and Member Comment

Comments included:
- With regard to harmonizing pain measures, a commenter noted that pain measures are appropriate for all populations, noting that measure 1628 is specific to adult patients, while measures 1634 and 0384 appear to apply to all ages. The commenter noted that the discussion on harmonization under measure 0384 notes that the PICU pain assessment measures “do not require use of a standardized instrument,” and stated that the PICU pain measure calls for use of a nationally recognized pain assessment scale that is age and developmentally appropriate. The commenter was supportive of the inclusion of a pictorial in the measure.
- A commenter was concerned that the measure only assesses standard practice that should be occurring routinely.

#### Developer Response:
- As the commenter noted, there are a number of NQF-endorsed measures focusing on the assessment of pain in a...
variety of unique settings and circumstances. With the clarification regarding measures 0341 and 0342 in the PICU setting, it appears that all of these measures refer to conducting the assessment using a standardized tool. Similarly, measure 0384 suggests that pain should be quantified using a standard instrument, such as a 0-10 numerical rating scale, a categorical scale, or the pictorial scale.

• Initial and ongoing pain assessments, the focus of the measure, are essential to ensure proper pain management among patients with cancer. As noted in the NCCN cancer pain guidelines, failure to adequately assess pain frequently leads to poor control. Unrelieved pain denies patients comfort and greatly affects their activities, motivation, interactions with family and friends, and overall quality of life. Unfortunately, as indicated by performance rates for this measure and medical literature on the topic, adherence remains suboptimal demonstrating a significant opportunity to improve the care provided to cancer patients.

Steering Committee Response:
• The Steering Committee agrees with the developer’s response, which is in line with discussions that occurred at the in-person meeting and on related conference calls.

0386 Oncology: Cancer Stage Documented
Maintenance Measure
Measure Evaluation and Specifications
Description: Percentage of patients, regardless of age, with a diagnosis of breast, colon, or rectal cancer who are seen in the ambulatory setting who have a baseline AJCC cancer stage or documentation that the cancer is metastatic in the medical record at least once during the 12 month reporting period
Numerator Statement: Patients who have a baseline AJCC cancer stage* or documentation that the cancer is metastatic in the medical record at least once during the 12 month reporting period
Numerator Instructions: *Cancer stage refers to stage at diagnosis
Denominator Statement: All patients, regardless of age, with a diagnosis of breast, colon, or rectal cancer who are seen in the ambulatory setting
Exclusions: None
Adjustment/Stratification: No risk adjustment or risk stratification None We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.
Level of Analysis: Clinician : Group/Practice, Clinician : Individual, Clinician : Team
Type of Measure: Process
Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Pharmacy, Paper Records
Measure Steward: American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI) Other organizations: This measure is jointly copyrighted by the AMA-PCPI and American Society of Clinical Oncology. The measure set was also developed in collaboration with the American Society for Radiation Oncology.

Steering Committee In-Person March 13-14, 2012
1. Importance to Measure and Report: The measure meets the Importance criteria.
(1a. High Impact; 1b. Performance Gap; 1c. Evidence)
1a. Impact: H-14; M-2; L-1; I-0; 1b. Performance Gap: H-13; M-4; L-0; I-0; 1c. Evidence: Y-12, N-2, I-3
Rationale:
• Breast and colorectal cancer affect large numbers of patients and are leading causes of morbidity/mortality.

NATIONAL QUALITY FORUM

NQF VOTING DRAFT—DO NOT CITE OR QUOTE
NQF MEMBER votes are due June 26, 2012 by 6:00 PM ET
### 0386 Oncology: Cancer Stage Documented

- Information presented related to the impact of the measure is specific to the general topic area (breast and colorectal cancer) rather than specific to importance of documenting stage of disease or to the consequences of poor quality in this area. Steering Committee agreed that documentation of stage is essential for any treatment planning in oncology, representing a “floor” for improvement, however.
- The developer provided data from the QOPI measure showing an average performance rate of 83%, with a range of 35% to 100%. Data was also presented from ASTRO’s PAAROT program, which has an average performance rate of 87% with a range of 10% to 100%.
- Evidence for the measure is exclusively based on clinical practice guidelines; however, there is uniform NCCN consensus that the intervention is appropriate.

#### 2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.
(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)

<table>
<thead>
<tr>
<th>2a. Reliability</th>
<th>2b. Validity</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-5; M-9; L-1; I-2</td>
<td>H-2; M-13; L-1; I-1</td>
</tr>
</tbody>
</table>

**Rationale:**
- Staging is critical for any cancer diagnosis; the measure specifications should be broadened to include all patients with a cancer diagnosis.
- The Steering Committee was concerned that while it is important to know the stage of cancer at diagnosis, it is also important to know the stage over the course of treatment.
- The Steering Committee agreed that it is important to include clinical and pathological stage wherever possible.
- The measure is clearly specified.
- Reliability testing was adequate.
- Face validity was demonstrated.

#### 3. Usability: H-10; M-7; L-0; I-0
(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

**Rationale:**
- The measure developer has collected performance data; however, the measure has not been publicly reported.
- The measure is currently only being used in QI initiatives.
- The Steering Committee was concerned that patients do not always understand the concept of staging, which could limit use of the measure for public reporting.

#### 4. Feasibility: H-7; M-9; L-1; I-0
(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

**Rationale:**
- Data is generated during the provision of care and all data elements are found in an EHR.

**Steering Committee Recommendation for Endorsement:** Y-17; N-0

**Rationale:** The Steering Committee found that the intervention addressed by this measure affects a large patient population and is important in ensuring that patients are treated appropriately based on diagnosis. This measure is important for treatment planning.

**RECOMMENDATIONS:**
- The Steering Committee recommended the developer consider broadening measure specifications to include all patients with a cancer diagnosis. Additional experience with the measure should begin to show stronger evidence related to important outcomes.
### 0386 Oncology: Cancer Stage Documented

**Public and Member Comment**

Comments included:
- A commenter was concerned that the measure only assesses standard practice that should be occurring routinely.

**Developer Response:**
- Cancer stage is key to the implementation of therapeutic interventions demonstrated to improve survival and decrease the risk of recurrence. The documentation of cancer stage is therefore critical as it provides a means by which this information can readily be communicated to others, to assist in therapeutic decisions, and to help estimate prognosis. Unfortunately, as indicated by performance rates for this measure and medical literature on the topic, adherence remains suboptimal demonstrating a significant opportunity to improve the care provided to cancer patients.

**Steering Committee Response:**
- The Steering Committee agrees with the developer's response, which is in line with discussions that occurred at the in-person meeting and on related conference calls.

### 1854 Barrett’s Esophagus (Eligible for Time-Limited Endorsement)

**New Measure**

**Measure Evaluation and Specifications**

**Description:** Percentage of patients with esophageal biopsy reports for Barrett's esophagus that contain a statement about dysplasia.

**Numerator Statement:** Numerator: Esophageal biopsy reports with the histologic finding of Barrett’s mucosa that contain a statement about dysplasia (present, absent, or indefinite; and if present, contains appropriate grading.)

**Denominator Statement:** Denominator (Eligible Population): All esophageal biopsy reports that document the presence of Barrett's mucosa.

**CPT codes:**
- 88305 Level IV – Surgical pathology, gross and microscopic examination

**ICD-9 codes:**
- 530.85 Barrett’s esophagus

**Exclusions:** Documentation of medical reason for not reporting the histologic finding of Barrett's mucosa (eg, malignant neoplasm or absence of intestinal metaplasia).

**Adjustment/Stratification:** No risk adjustment or risk stratification Not applicable Not applicable

**Level of Analysis:** Clinician : Group/Practice, Clinician : Individual

**Type of Measure:** Process

**Data Source:** Administrative claims, Other, Paper Records

**Measure Steward:** College of American Pathologists

**Steering Committee In-Person March 13-14, 2012**

1. Importance to Measure and Report: The measure meets the importance criteria. 
   (1a. High Impact; 1b. Performance Gap; 1c. Evidence)
   1a. Impact: H-6; M-10; L-1; I-0; 1b. Performance Gap: H-2; M-12; L-1; I-2; 1c. Evidence: Y-11, N-2, I-4

**Rationale:**
- A clear link between Barrett's Esophagus and esophageal adenocarcinoma was demonstrated. Identifying those at
NATIONAL QUALITY FORUM

1854 Barrett’s Esophagus (Eligible for Time-Limited Endorsement)

- This measure will have a substantial impact for a smaller patient population (those diagnosed with Barrett’s Esophagus).

2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability requirement for untested measures.
   (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)
   **Precise Specifications: Y-16; N-1**
   **Rationale:**
   - The measure is well specified; however, the Steering Committee noted the importance of reporting not only the presence or absence of dysplasia, but also the grade of dysplasia. The measure developer addressed this recommendation and modified the numerator.
   - Plans for reliability and validity testing are in process.

3. Usability: **H-3; M-14; L-0; I-0**
   (Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)
   **Rationale:**
   - The measure has been included in the 2012 PQRS program with plans to publicly report performance results.

4. Feasibility: **H-8; M-9; L-0; I-0**
   (4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/unintended consequences identified 4d. Data collection strategy can be implemented)
   **Rationale:**
   - The data elements are generated during patient care; the measure should be feasible to implement.

Steering Committee Recommendation for Time-Limited Endorsement: **Y-15; N-2**
**Rationale:** The Steering Committee found that the intervention addressed by this measure will greatly impact the target patient population, albeit a smaller population. The link between dysplasia in Barrett’s Esophagus patients and incidence of esophageal adenocarcinoma is well substantiated.

**RECOMMENDATIONS:** The Steering Committee asked the developer to require reporting of the grade of dysplasia (high or low) as part of the numerator. The measure developer addressed this recommendation and provided updated the numerator to capture this information. The Steering Committee agreed with the changes and recommended the measure for time limited endorsement.

The measure has not yet been tested for reliability and validity and is being considered for time limited endorsement. The measure developer will have 12 months to provide testing data if time limited endorsement is granted.

Public & Member Comment
- Commenters indicated support for the measure.

Prostate and Lung Measures

0389 Prostate Cancer: Avoidance of Overuse Measure – Bone Scan for Staging Low-Risk Patients

Maintenance Measure
Prostate Cancer: Avoidance of Overuse Measure – Bone Scan for Staging Low-Risk Patients

**Measure Evaluation and Specifications**

**Description:** Percentage of patients, regardless of age, with a diagnosis of prostate cancer, at low risk of recurrence, receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer.

**Numerator Statement:** Patients who did not have a bone scan performed at any time since diagnosis of prostate cancer.

**Denominator Statement:** All patients, regardless of age, with a diagnosis of prostate cancer, at low risk* of recurrence, receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy.

**Exclusions:** Documentation of medical reason(s) for having a bone scan performed (including documented pain, salvage therapy, other medical reasons). Documentation of system reason(s) for having a bone scan performed (including bone scan ordered by someone other than reporting physician).

**Adjustment/Stratification:** No risk adjustment or risk stratification. Not applicable. We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

**Level of Analysis:** Clinician: Group/Practice, Clinician: Individual, Clinician: Team

**Type of Measure:** Process

**Data Source:** Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Registry, Paper Records

**Measure Steward:** American Medical Association - Physician Consortium for Performance Improvement Other organizations: American Urological Association and American Society for Therapeutic Radiology & Oncology

---

0389 Prostate Cancer: Avoidance of Overuse Measure – Bone Scan for Staging Low-Risk Patients

**Steering Committee In-Person March 13-14, 2012**

---

1. **Importance to Measure and Report:** The measure meets the Importance criteria. (1a. High Impact; 1b. Performance Gap; 1c. Evidence)

1a. **Impact:** H-8; M-8; L-0; I-0. 1b. **Performance Gap:** H-7; M-9; L-0; I-0. 1c. **Evidence:** Y-14, N-2, I-0

**Rationale:**
- The measure affects a high number of patients: those with low-risk prostate cancer, and the evidence presented shows the intervention is unnecessary for these patients.
- Data submitted demonstrates significant overuse of bone scans (84.31% of patients from 2008 PQRS did not meet this measure). There is an opportunity for improvement.

2. **Scientific Acceptability of Measure Properties:** The measure meets the Scientific Acceptability criteria. (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)

2a. **Reliability:** H-9; M-6; L-1; I-0. 2b. **Validity:** H-7; M-8; L-1; I-0

**Rationale:**
- The measure is specified with ICD-9 and CPT codes that can be ascertained consistently.
- Reliability testing presented was appropriate and demonstrated reliability of the measure.
- Validity was shown using results from an expert panel, and demonstrated strong face validity.

3. **Usability:** H-6; M-8; L-2; I-0

(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

**Rationale:**
- This measure has been included in the CMS Physician Quality Reporting System (PQRS) from 2008 through 2011. The measure is also included in PQRS 2012.
- A plan for public reporting has been outlined by the measure developer.
0389 Prostate Cancer: Avoidance of Overuse Measure – Bone Scan for Staging Low-Risk Patients

4. Feasibility: H-6; M-8; L-2; I-0

(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

Rationale:
- Data is generated during the provision of care and all data elements are found in an EHR.

Rationale: The Steering Committee found that the measure addresses an intervention that is currently overused for the target patient population; improved performance on this measure will likely reduce the use of unnecessary bone scans and decrease overall costs.

Public & Member Comment
Comments included:
- Commenters indicated that the Steering Committee should consider clarifying 'low risk' status for the measure population and that classification for measurement purposes should be based on staging information available at the time of decision making regarding whether or not to order a bone scan.
- Commenters believed that the measure should clearly articulate that even those patients with a positive bone scan remain in the denominator of this measure, even though the bone scan ultimately demonstrates that they are not actually low risk.
- Comments reflected questions on the measure specifications, specifically:
  - It is unclear how treatment interplays with this measure.
  - The numerator captures patients who did not have a bone scan performed prior to initiation of treatment nor at any time since diagnosis.
  - Patient eligibility for the denominator should be based on criteria known before the decision to deliver the service (the bone scan) is considered.
  - Exclusion criteria (i.e. treatment planned for future, patient preference, vulnerable health status, and poor access to care).
- Several commenters supported this measure.

Developer Response:
- The AUA/AMA-PCPI Prostate Cancer Work Group appreciates your comment. The Work Group will consider your feedback about the risk stratification, when the measure undergoes formal review and maintenance, according to the AMA-PCPI measure development/maintenance methodology, in the future. Additionally, the measure contains a medical exception, which allows physicians to use clinical judgment in order to have a bone scan performed on those low-risk prostate cancer patients who have a medical reason documented.
- The denominator was constructed so any patient that has already been stratified as a low risk patient and is being treated according to the low risk strata would be captured in the measure. The measure is aiming to reduce the use of bone scans that are clinically unnecessary, in low risk patients who generally have no indication for imaging studies. Additionally, the measure contains a medical exception, which allows physicians to use clinical judgment in order to have a bone scan performed on those low-risk prostate cancer patients who have a medical reason documented.

Steering Committee Response:
- The Steering Committee agrees with the measure developer's response. The response is in line with discussions that occurred.
0389 Prostate Cancer: Avoidance of Overuse Measure – Bone Scan for Staging Low-Risk Patients

at the in-person meeting and on related conference calls.

0390 Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Patients

Maintenance Measure

Measure Evaluation and Specifications

Description: Percentage of patients, regardless of age, with a diagnosis of prostate cancer, at high risk of recurrence, receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH agonist or antagonist)

Numerator Statement: Patients who were prescribed adjuvant hormonal therapy (GnRH [gonadotropin-releasing hormone] agonist or antagonist)

Denominator Statement: All patients, regardless of age, with a diagnosis of prostate cancer, at high risk of recurrence, receiving external beam radiotherapy to the prostate

Note: Only patients with prostate cancer with high risk of recurrence will be counted in the denominator of this measure

Exclusions: Documentation of medical reason(s) for not prescribing adjuvant hormonal therapy (eg, salvage therapy)

Documentation of patient reason(s) for not prescribing adjuvant hormonal therapy

Adjustment/Stratification: No risk adjustment or risk stratification. Not applicable. We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

Level of Analysis: Clinician: Group/Practice, Clinician: Individual, Clinician: Team

Type of Measure: Process

Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Registry, Paper Records

Measure Steward: American Medical Association - Physician Consortium for Performance Improvement Other organizations: American Urological Association and American Society for Therapeutic Radiology & Oncology

0390 Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Patients

Steering Committee In-Person March 13-14, 2012

1. Importance to Measure and Report: The measure meets the Importance criteria.
(1a. High Impact; 1b. Performance Gap; 1c. Evidence)

1a. Impact: H-12; M-4; L-0; I-0; 1b. Performance Gap: H-9; M-7; L-0; I-0; 1c. Evidence: Y-16, N-0, I-0

Rationale:
- The measure addresses appropriateness of care for patients with high-risk prostate cancer, a prevalent condition affecting a large number of patients.
- The evidence provided is high level and supportive of the measure focus.
- The Steering Committee noted that the survival benefit has been better documented than the evidence submitted suggests.
- Adherence is low: 83.41% of patients from 2008 PQRS did not meet this measure; there is an opportunity for improvement.

2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.
(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)

2a. Reliability: H-7; M-8; L-1; I-0; 2b. Validity: H-4; M-11; L-1; I-0

Rationale:
- The specifications are clear. The time window for reporting the measure is at each time adjuvant hormonal therapy occurs.
# National Quality Forum

## 0390 Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Patients

- The Steering Committee agreed it is important that proton beam therapy is included in the denominator for this measure.
- The reliability testing presented was appropriate and demonstrated the reliability of the measure.
- Face validity was confirmed with near universal agreement from an expert panel.

### 3. Usability: H-11; M-4; L-1; I-0

(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

#### Rationale:
- This measure has been included in the PQRS from 2008 through 2011. The measure is also included in PQRS 2012.
- A plan for public reporting has been outlined by the measure developer.

### 4. Feasibility: H-6; M-9; L-1; I-0

(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

#### Rationale:
- Steering Committee was concerned that the low number of patients meeting the measure in 2008 PQRS may be a result of difficulties reporting the measure rather than low performance of the measure intervention. The developer agreed that as the denominator requires both ICD codes and CPT category 2 codes, it likely complicated reporting for some providers reporting on the measure. The developer expects reporting to improve as providers become more familiar with the reporting requirements.
- The information in the measure can be abstracted from EHRs.

## Steering Committee Recommendation for Endorsement: Y-15; N-1

#### Rationale:
The Steering Committee found that this is a prevalent condition with a level of mortality that renders it a public health priority. The measure is supported by two randomized controlled trials, bolstered by expert opinion. The measure should be able to be reliably ascertained with EHR inputs.

## Public & Member Comment

### Comments included:
- For quality improvement purposes, commenters felt that the measure population should be defined more specifically in order to avoid use of resources to identify the denominator population; as specified it may include cases that are exceedingly rare or non-occurring for hospitals that care for children.
- Commenters referenced NCCN guidelines that suggest hormonal therapy for patients with advanced prostate cancer. They noted that the evidence for this measure is supported by a variety of articles that range from complete support to lack of efficacy of hormonal therapy and felt that developers need to reconsider this measure based on the variation in clinical evidence in support of hormonal therapy.

## Developer Response:
- The AUA/AMA-PCPI Prostate Cancer Work Group appreciates your comment. The Work Group will reconsider the measure population, when the measure undergoes formal review and maintenance, according to the AMA-PCPI measure development/maintenance methodology, in the future.
- The PQRS data included in the measure submission and the medical literature clearly indicate a remaining performance gap, with respect to adjuvant hormonal therapy in high risk prostate cancer patients. Therefore, the measure is still being put forth for accountability and quality improvement. Additionally, both the AUA and NCCN guidelines recommend adjuvant hormonal therapy with radiotherapy for high risk prostate cancer patients, for prolonged survival.
Steering Committee Response:

- The Steering Committee agrees with the measure developer’s response. The response is in line with discussions that occurred at the in-person meeting and on related conference calls.

1790 Risk-Adjusted Morbidity and Mortality for Lung Resection for Lung Cancer

New Measure

Measure Evaluation and Specifications

Description: Percentage of patients > 18 years of age undergoing elective lung resection (Open or VATS wedge resection, segmentectomy, lobectomy, bilobectomy, sleeve lobectomy, pneumonectomy) for lung cancer who developed any of the following postoperative complications: reintubation, need for tracheostomy, initial ventilator support > 48 hours, ARDS, pneumonia, pulmonary embolus, bronchopleural fistula, bleeding requiring reoperation, myocardial infarction or operative mortality.

Numerator Statement: Number of patients > 18 years of age undergoing elective lung resection for lung cancer who developed any of the following postoperative complications: reintubation, need for tracheostomy, initial ventilator support > 48 hours, ARDS, pneumonia, pulmonary embolus, bronchopleural fistula, bleeding requiring reoperation, myocardial infarction or operative mortality.

Denominator Statement: Number of patients > 18 years of age undergoing elective lung resection for lung cancer.

Exclusions: Emergency procedures

Adjustment/Stratification: Statistical risk model. Bayesian hierarchical modeling was used to assess the statistical reliability of hospital-specific standardized incidence ratio (SIR) estimates derived from the January 1, 2008 – December 31, 2010 STS data. All hospitals regardless of sample size were included in the estimation of model parameters. Reliability measures were initially calculated including all the hospitals and were subsequently calculated in subsets of hospitals having at least 10, 20, 30, 50, 100, or 200 eligible cases.

Three separate multivariable risk models were constructed (mortality, major morbidity, and composite mortality or major morbidity). The risk-adjustment models created for this measure and study have excellent performance characteristics and identify important predictors of mortality and major morbidity for lung cancer resections. These models may be used to inform clinical decisions and to compare risk-adjusted outcomes for quality improvement purposes. For additional information see the attachment:


Level of Analysis: Clinician : Group/Practice, Clinician : Team, Facility

Type of Measure: Outcome

Data Source: Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Registry, Paper Records

Measure Steward: Society of Thoracic Surgeons

1790 Risk-Adjusted Morbidity and Mortality for Lung Resection for Lung Cancer

Steering Committee In-Person March 13-14, 2012

1. Importance to Measure and Report: The measure meets the Importance criteria.

   (1a. High Impact; 1b. Performance Gap; 1c. Evidence)

   1a. Impact: H-17; M-0; L-0; I-0; 1b. Performance Gap: H-11; M-6; L-0; I-0; 1c. Evidence: Y-17, N-0, I-0

Rationale:

- Developer presented solid evidence for importance of the measure.
- The measure provides a good look at the spectrum of procedures done across a spectrum of hospitals, and a wide
NATIONAL QUALITY FORUM

1790 Risk-Adjusted Morbidity and Mortality for Lung Resection for Lung Cancer

- range of morbidities/mortalities.
  - Evidence was submitted demonstrating substantial variation in morbidity and mortality after lung cancer surgery.
  - The measure is a first step in developing a measure capturing long term survival rates.

2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.
(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)
2a. Reliability: H-8; M-9; L-0; I-0
2b. Validity: H-9; M-8; L-0; I-0

Rationale:
- The measure is clearly defined and well specified.
- Reliability of the measure was well demonstrated with a signal to noise ratio.
- Validity was demonstrated through testing, as well as having face validity assessed by an expert panel.
- The Steering Committee noted that many of these surgeries are performed by non-thoracic surgeons, a population this measure may not capture.

3. Usability: H-15; M-1; L-0; I-1
(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

Rationale:
- The developer has provided a detailed plan for representation of measure results, usability for QI, and public reporting of the measure within the next 2-3 years.

4. Feasibility: H-10; M-7; L-0; I-0
(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

Rationale:
- The Steering Committee noted that this is somewhat arduous to capture, but the data add significant value

Steering Committee Recommendation for Endorsement: Y-17; N-0
Rationale: The Steering Committee found that the measure will capture the spectrum of procedures done in a spectrum of hospitals-wide range of morbidities/mortalities. The evidence for the measure is high level, and capturing the measure will allow for development of an outcome measure in the future.

Public & Member Comment
- Commenters indicated support for the measure.

1853 Radical Prostatectomy Pathology Reporting (Eligible for Time-Limited Endorsement)

New Measure
Measure Evaluation and Specifications
Description: Percentage of radical prostatectomy pathology reports that include the pT category, the pN category, the Gleason score and a statement about margin status.

Numerator Statement: Numerator: Radical prostatectomy pathology reports that include the pT category, the pN category, Gleason score and a statement about margin status
Report the following CPT Category II code to confirm the inclusion of the designated elements in a radical prostatectomy pathology report: 3267F – pathology report

Denominator Statement: All radical prostatectomy pathology reports

Exclusions: Documentation of medical reason for exclusion (e.g. specimen originated from other malignant neoplasms, secondary site prostatic carcinomas, and transurethral resections of the prostate (TURP)

Adjustment/Stratification: No risk adjustment or risk stratification Not applicable Not applicable
### 1853 Radical Prostatectomy Pathology Reporting (Eligible for Time-Limited Endorsement)

**Level of Analysis:** Clinician: Group/Practice, Clinician: Individual  
**Type of Measure:** Process  
**Data Source:** Administrative claims, Other, Paper Records  
**Measure Steward:** College of American Pathologists

#### 1. Importance to Measure and Report: The measure meets the importance criteria.

(1a. High Impact; 1b. Performance Gap; 1c. Evidence)

1a. Impact: H-9; M-7; L-0; I-0;  
1b. Performance Gap: H-3; M-12; L-1; I-0;  
1c. Evidence: Y-15, N-1, I-0

**Rationale:**
- The Steering Committee agreed the measure would have a high impact as a large number of men are affected by this disease; this is a major health issue with significant mortality.  
- The measure developer presented two studies that showed a performance gap of 11.6% noncompliance. The Steering Committee agreed compliance should be 100% on the measure, and so there is an opportunity for improvement.  
- The measure developer presented consistent evidence that a variation exists in pathological reporting that impacts the quality of care provided to patients.

#### 2. Scientific Acceptability of Measure Properties: The measure meets the scientific acceptability requirement for untested measures.

(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)

**Precise Specifications:** Y-16; N-0

**Rationale:**
- The measure is precisely specified.  
- The Steering Committee agreed that it is highly likely that testing of the measure will demonstrate a high rate of reliability and validity.

#### 3. Usability: H-9; M-7; L-0; I-0

(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

**Rationale:**
- Usability has not yet been demonstrated; however, the Steering Committee believes that the measure will be useful for QI.  
- The measure is useful for public reporting: there is high interest, and there is ongoing active surveillance.

#### 4. Feasibility: H-12; M-4; L-0; I-0

(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

**Rationale:**
- The data elements are all available and may be implemented using an EHR.  
- Steering Committee members agreed that the measure will be feasible due to the availability of this information in tumor registries and pathology reports.

**Steering Committee Recommendation for Time-Limited Endorsement: Y-16; N-0**

**Rationale:** Steering Committee noted that staging information and a Gleason score are very important for patients with prostate cancer. There is a strong evidence base for this measure. There is a performance gap in meeting the measure and a need for improvement.
1853 Radical Prostatectomy Pathology Reporting (Eligible for Time-Limited Endorsement)

RECOMMENDATIONS: The measure has not yet been tested for reliability and validity and is being considered for time limited endorsement. The measure developer will have 12 months to provide testing data if time limited endorsement is granted.

Public & Member Comment
- Commenters indicated support for the measure.

Palliative Measures

0210 Proportion receiving chemotherapy in the last 14 days of life

Maintenance Measure

Measure Evaluation and Specifications

Description: Percentage of patients who died from cancer receiving chemotherapy in the last 14 days of life

Numerator Statement: Patients who died from cancer and received chemotherapy in the last 14 days of life

Denominator Statement: Patients who died from cancer.

Exclusions: None

Adjustment/Stratification: No risk adjustment or risk stratification. No risk adjustment or risk stratification is necessary because a) the measure is intended to be used for comparison among similar providers; unless there is a reason to believe that one providers' patients have significantly different risks than others, it will not affect relative comparisons, and b) comorbidity risks will if anything decrease the likelihood of experiencing this process of care. None


Type of Measure: Process

Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Pharmacy, Electronic Clinical Data: Registry, Management Data, Paper Records

Measure Steward: American Society of Clinical Oncology

Steering Committee In-Person March 13-14, 2012

1. Importance to Measure and Report: The measure meets the Importance criteria. (1a. High Impact; 1b. Performance Gap; 1c. Evidence)

1a. Impact: H-12; M-4; L-0; I-1 1b. Performance Gap: H-9; M-8; L-0; I-0 1c. Evidence: Y-13, N-3, I-1

Rationale:
- The measure affects a large number of patients and will have a high impact.
- The Steering Committee noted that in some cases it is appropriate for a patient to receive chemotherapy in the last 14 days of life. The measure is useful for detecting variation in performance and identifying outliers when comparing similar practices with similar patient populations.
- The measure is important because it addresses patient preferences and over-treatment at the end of life.
- The struggle between aggressive care and futile care often plays out in the amount of chemotherapy delivered to patients with advanced disease and poor performance status.
- The measure also reflects disparities in access to care and the capacity of a local healthcare system to treat patients appropriately at the end of life.

2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria. (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)

2a. Reliability: H-9; M-6; L-2; I-0 2b. Validity: H-4; M-9; L-3; I-1

Rationale:

NQF VOTING DRAFT—DO NOT CITE OR QUOTE
NQF MEMBER votes are due June 26, 2012 by 6:00 PM ET
### 0210 Proportion receiving chemotherapy in the last 14 days of life

- Steering Committee members agreed that the measure was well specified.
- The Steering Committee members raised concerns about how case mix would be accounted for in the measure. They also questioned whether facilities with a high number of patients enrolled in clinical trials would skew the measure results, so that those facilities would appear not to do as well on the measure. It was explained that the measure is intended for use in comparing like facilities, such as major cancer centers to other major cancer centers, where the case mix would be expected to be very similar.
- The reliability testing presented for the measure is appropriate and demonstrates the reliability of the measure.
- Face validity of the measure was demonstrated.

#### 3. Usability: H-6; M-7; L-2; I-2

*Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement*

**Rationale:**
- The Steering Committee agreed the measure is useful for QI, particularly when comparing facilities with similar patient populations to see if there are irregularities in achieving the measure.
- The measure is easily understandable for public reporting.
- The measure is currently in use in ASCO's QOPI program.

#### 4. Feasibility: H-7; M-6; L-2; I-2

*(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/unintended consequences identified 4d. Data collection strategy can be implemented)*

**Rationale:**
- The measure is reported using claims data and is feasible to implement.

### Steering Committee Recommendation for Endorsement: Y-15; N-2

**Rationale:** The Steering Committee found that the measure is important because it addresses patient preferences and overtreatment at the end of life.

### Public & Member Comment

**Comments included:**
- Commenters noted that while overtreatment of terminally ill patients is an important area for study and measurement, there are concerns that the measures imply that patients receiving such treatments as chemotherapy in the last 14 days of life, or patients with more than one ER visit in the last days of life, are receiving poor care.
- The commenters expressed concern that grouping all patient populations together in these measures results in patients who are appropriately receiving said treatments being counted in the numerator against the reporting facility.
- Further, commenters indicated that prognostication of death is limited; in addition to being unable to determine accurately in advance a patient’s expected death, the measures do not distinguish between patients who were terminally ill and those who died suddenly.
- Commenters also indicated that it was unclear by the description provided how the measure of chemotherapy received in the last 14 days of life would “reflect disparities in access to care.” Commenters felt that for palliative care, measuring disparities in its access should be evaluated more directly than through assessing chemotherapy use for terminally ill patients and suggested that terminally ill patients receiving chemotherapy may have greater access to medical care in general.
- Several comments supported the use of these measures in order to reduce inappropriate end-of-life care.

### Developer Response:
- The measures are not intended to imply that any single incidence of these care processes is wrong, but rather to...
0210 Proportion receiving chemotherapy in the last 14 days of life

Identify consistently outlying practice which could raise a ‘red flag’ about either practice style (not having realistic discussions about the end-of-life in a timely fashion) or access to palliative or hospice care (lack of access has been consistently shown to be associated with more acute and aggressive care near the end of life). Lastly, while it is true that prognostication is difficult, if a provider’s practice is an outlier because they are particularly poor at prognostication, which may be a problem as well.

- Identifying the end of life phase prospectively in administrative data is challenging as the definition always creates a biased sub cohort (a particular stage at diagnosis, using particular services, etc.).
- Users may make adjustments to the numerator and denominator definitions as they see fit.
- The access issue is that these measures of potentially aggressive care near the end of life are associated with less availability of hospice.

Steering Committee Response:

- These issues were discussed extensively during the Cancer Steering Committee in-person meeting. In that discussion, the measure developer noted that at times the interventions can and should occur for many patients. The measures are intended to compare similar providers who have similar patient mixes and identify outlying patterns of care. Consequently, relative incidence of the situations should be similar. For example, grouping patients receiving palliative chemotherapies at the end of life with those receiving curative chemotherapies should not result in markedly different performance rates between two facilities with a similar case mix. This reasoning may also be applied to grouping patients who are terminally ill and those who died suddenly.
- Further, the Steering Committee respectfully disagreed with the statement that prognostication of death is limited, and believed that taking this stance would severely limit measures of this type, which are very important quality indicators for patient preference and the availability of resources at the end of life.
- The Steering Committee also noted that though there are a limited number of studies, it has been demonstrated that patients who receive palliative care earlier have lower rates of chemotherapy at the end of life, lending credence to the importance of palliative interventions in reducing overtreatment.

0211 Proportion with more than one emergency room visit in the last days of life

Maintenance Measure

Measure Evaluation and Specifications

Description: Percentage of patients who died from cancer with more than one emergency room visit in the last days of life

Numerator Statement: Patients who died from cancer and had >1 ER visit in the last 30 days of life

Denominator Statement: Patients who died from cancer.

Exclusions: None

Adjustment/Stratification: No risk adjustment or risk stratification

No risk adjustment or risk stratification is necessary because the measure is intended to be used for comparison among similar providers; unless there is a reason to believe that one providers’ patients have significantly different risks than others, it will not affect relative comparisons. Since, however, comorbidity risks could increase the likelihood of experiencing this process of care, stratification or adjustment as described above can be considered.

No risk adjustment is necessary. The Deyo modification of the Charlson score can be applied to claims as this measure may be sensitive to comorbidity, omitting ‘Cancer’ as a comorbid condition in the calculation, and used as an independent variable in a regression model to predict an adjusted rate. No stratification was used in the measure’s development or evaluation, however, it would be reasonable to apply the Deyo modification of the Charlson score (Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619, 1992).
**0211 Proportion with more than one emergency room visit in the last days of life**

claims and stratifying for comorbidities, e.g., scores of 0, 1, or 2+.

**Level of Analysis:** Clinician: Group/Practice, Facility, Health Plan, Integrated Delivery System, Population: County or City, Population: National, Population: Regional, Population: State

**Type of Measure:** Process

**Data Source:** Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Registry, Management Data, Paper Records

**Measure Steward:** American Society of Clinical Oncology

**Steering Committee In-Person March 13-14, 2012**

1. **Importance to Measure and Report: The measure meets the importance criteria.**
   (1a. High Impact; 1b. Performance Gap; 1c. Evidence)
   1a. Impact: H-10; M-4; L-1; I-1; 1b. Performance Gap: H-10; M-3; L-3; I-0; 1c. Evidence: Y-11, N-3, I-2

   **Rationale:**
   - The Steering Committee agreed the measure affects a large number of patients and is high impact.
   - In most cases, overutilization of emergency department services for the actively dying is inappropriate and distressing for patients.
   - The Steering Committee noted that in some cases more than one visit to the ER during the last days of life is appropriate. The measure is useful for detecting variations in performance and identifying outliers when comparing similar practices with similar patient populations.
   - The measure is important because it addresses patient preferences and overtreatment at the end of life.
   - The measure also reflects disparities in access to care and the capacity of a local healthcare system to treat patients appropriately at the end of life.

2. **Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.**
   (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)
   2a. Reliability: H-7; M-3; L-5; I-1; 2b. Validity: H-5; M-5; L-5; I-1

   **Rationale:**
   - Steering Committee members raised concerns about use of the measure given the current systemic issues with access to quality hospice facilities. The Committee believed patients may utilize emergency department services when good hospice care is not available. In areas where performance of the measure is poor, it will call attention to a lack of resources available for patients at the end of life.
   - The measure is well specified.
   - The reliability testing presented for the measure is appropriate and demonstrates the reliability of the measure.
   - Face validity of the measure is demonstrated.

3. **Usability:** H-5; M-4; L-6; I-1
   (Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

   **Rationale:**
   - The measure is usable for public reporting, as it captures the preference of patients to die in a setting other than the emergency department, or to avoid distressing ER visits at the end of life.
   - The measure is useful for QI, particularly when comparing facilities with similar patient populations to see if there are irregularities in achieving the measure.
   - The measure is in use in Cancer Care Ontario’s Cancer System Quality Index.

4. **Feasibility:** H-6; M-7; L-3; I-1
   (4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)
**0211 Proportion with more than one emergency room visit in the last days of life**

**Rationale:**
- The measure is reported using claims data and is feasible to implement.

**Steering Committee Recommendation for Endorsement:** Y-10; N-6

**Rationale:** The Steering Committee found that the measure is important because it addresses patient preferences and overtreatment at the end of life.

### Public & Member Comment

**Comments included:**
- Commenters noted that while overtreatment of terminally ill patients is an important area for study and measurement, there are concerns that the measures imply that patients receiving such treatments as chemotherapy in the last 14 days of life, or patients with more than one ER visit in the last days of life, are receiving poor care.
- The commenters expressed concern that grouping all patient populations together in these measures results in patients who are appropriately receiving said treatments being counted in the numerator against the reporting facility.
- Further, commenters indicated that prognostication of death is limited; in addition to being unable to determine accurately in advance a patient’s expected death, the measures do not distinguish between patients who were terminally ill and those who died suddenly.
- For the measures of chemotherapy, ER and ICU use in the last days before death, eligibility for the denominator is defined as ‘patients who died from cancer.’ All types and stages of cancer are combined, ranging from those that are highly treatable to those that are functionally incurable. At the extremes, the measure makes no distinction between a patient who has a benign skin condition (code 216) and a patient with pancreatic cancer (code 157). If interested in capturing service utilization for terminally ill patients, the measures should focus on pre-specified patient populations with poor prognosis.
- Several comments supported the use of these measures in order to reduce inappropriate end-of-life care and patient-centered care.

### Developer Response:

- The measures are not intended to imply that any single incidence of these care processes is wrong, but rather to identify consistently outlying practice which could raise a ‘red flag’ about either practice style (not having realistic discussions about the end-of-life in a timely fashion) or access to palliative or hospice care (lack of access has been consistently shown to be associated with more acute and aggressive care near the end of life). Lastly, while it is true that prognostication is difficult, if a provider’s practice is an outlier because they are particularly poor at prognostication, which may be a problem as well.
- Identifying the end of life phase prospectively in administrative data is challenging as the definition always creates a biased sub cohort (a particular stage at diagnosis, using particular services, etc.).
- Users may make adjustments to the numerator and denominator definitions as they see fit.
- The access issue is that these measures of potentially aggressive care near the end of life are associated with less availability of hospice.

### Steering Committee Response:

- These issues were discussed extensively during the Cancer Steering Committee in-person meeting. In that discussion, the measure developer noted that at times the interventions can and should occur for many patients. The measures are intended to compare similar providers who have similar patient mixes and identify outlying patterns of care. Consequently, relative incidence of the situations should be similar. For example, grouping patients receiving palliative chemotherapies at the end of life with those receiving curative chemotherapies should not result in markedly
0211 Proportion with more than one emergency room visit in the last days of life

**Description:**

Different performance rates between two facilities with a similar case mix. This reasoning may also be applied to grouping patients who are terminally ill and those who died suddenly.

- Further, the Steering Committee respectfully disagreed with the statement that prognostication of death is limited, and believed that taking this stance would severely limit measures of this type, which are very important quality indicators for patient preference and the availability of resources at the end of life.
- The Steering Committee also noted that though there are a limited number of studies, it has been demonstrated that patients who receive palliative care earlier have lower rates of chemotherapy at the end of life, lending credence to the importance of palliative interventions in reducing overtreatment.

0213 Proportion admitted to the ICU in the last 30 days of life

**Maintenance Measure**

**Measure Evaluation and Specifications**

**Description:** Percentage of patients who died from cancer admitted to the ICU in the last 30 days of life

**Numerator Statement:** Patients who died from cancer and were admitted to the ICU in the last 30 days of life

**Denominator Statement:** Patients who died from cancer.

**Exclusions:** None

**Adjustment/Stratification:** No risk adjustment or risk stratification. No risk adjustment or risk stratification is necessary because the measure is intended to be used for comparison among similar providers; unless there is a reason to believe that one providers’ patients have significantly different risks than others, it will not affect relative comparisons. Since, however, comorbidity risks could increase the likelihood of experiencing this process of care, stratification or adjustment as described above can be considered.

The Deyo modification of the Charlson score can be applied to claims as this measure may be sensitive to comorbidity, omitting ‘Cancer’ as a comorbid condition in the calculation, and used as an independent variable in a regression model to predict an adjusted rate. No stratification was used in the measure’s development or evaluation, however, it would be reasonable to apply the Deyo modification of the Charlson score (Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619, 1992) to claims and stratifying for comorbidities, e.g., scores of 0, 1, or 2+.

**Level of Analysis:** Clinician: Group/Practice, Facility, Health Plan, Integrated Delivery System, Population: County or City, Population: National, Population: Regional, Population: State

**Type of Measure:** Process

**Data Source:** Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Registry, Management Data, Paper Records

**Measure Steward:** American Society of Clinical Oncology

**Steering Committee In-Person March 13-14, 2012**

1. Importance to Measure and Report: The measure meets the importance criteria.
   (1a. High Impact; 1b. Performance Gap; 1c. Evidence)

   **1a. Impact:** H-14; M-2; L-0; I-0
   **1b. Performance Gap:** H-8; M-8; L-0; I-0
   **1c. Evidence:** Y-16, N-0, I-0

   **Rationale:**
   - The Steering Committee agreed the measure affects a large number of patients and will have a high impact.
   - Patients overwhelmingly would prefer to not die in the ICU; it is distressing for the patient and the patient’s family.
   - The Steering Committee noted that in some cases occurrence of this event is appropriate. The measure is useful for detecting variation in performance and identifying outliers when comparing similar practices with similar patient populations.
### 0213 Proportion admitted to the ICU in the last 30 days of life

- The measure is important because it addresses patient preferences and over-treatment at the end of life.
- The measure also reflects disparities in access to care and the capacity of a local healthcare system to treat patients appropriately at the end of life.

#### 2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.

(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)

**2a. Reliability:** H-12; M-4; L-0; I-0;  
**2b. Validity:** H-11; M-5; L-0; I-0

**Rationale:**
- Steering Committee members were concerned about use of the measure given current issues related to access to quality hospice facilities. Patients may utilize ICU at the end of life when quality hospice care is not available. In areas where performance of the measure is poor, it will call attention to the lack of resources available for patients at the end of life.  
- The measure is well specified.  
- The reliability testing presented for the measure is appropriate and demonstrates the reliability of the measure.  
- Face validity of the measure was demonstrated.

#### 3. Usability: H-9; M-7; L-0; I-0

(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

**Rationale:**
- The measure is usable for public reporting, as it captures the preference of patients to die in a setting other than the emergency department, or to avoid distressing ER visits at the end of life.  
- The measure is useful for QI, particularly when comparing facilities with similar patient populations to see if there are irregularities in achieving the measure.  
- The measure is in use in Cancer Care Ontario’s Cancer System Quality Index.

#### 4. Feasibility: H-13; M-3; L-0; I-0

(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

**Rationale:**
- The measure is reported using claims data and is feasible to implement.

**Steering Committee Recommendation for Endorsement:** Y-16; N-0

**Rationale:** The Steering Committee strongly agreed that patients generally do not wish to die in the ICU and believe this intervention should be avoided if at all possible. The measure captures patient preference as well as disparities in access to quality hospice care at the end of life.

**Public & Member Comment**

Comments included:
- Commenters noted that while overtreatment of terminally ill patients is an important area for study and measurement, there are concerns that the measures imply that patients receiving such treatments as chemotherapy in the last 14 days of life, or patients with more than one ER visit in the last days of life, are receiving poor care.  
- The commenters expressed concern that grouping all patient populations together in these measures results in patients who are appropriately receiving said treatments being counted in the numerator against the reporting facility.  
- Further, commenters indicated that prognostication of death is limited; in addition to being unable to determine accurately in advance a patient’s expected death, the measures do not distinguish between patients who were terminally ill and those who died suddenly.  
- For the measures of chemotherapy, ER and ICU use in the last days before death, eligibility for the denominator is...
Proportion admitted to the ICU in the last 30 days of life

- Defined as ‘patients who died from cancer.’ All types and stages of cancer are combined, ranging from those that are highly treatable to those that are functionally incurable. At the extremes, the measure makes no distinction between a patient who has a benign skin condition (code 216) and a patient with pancreatic cancer (code 157). If interested in capturing service utilization for terminally ill patients, the measures should focus on pre-specified patient populations with poor prognosis.
- Several comments supported the use of these measures in order to reduce inappropriate end-of-life care and patient-centered care.

Developer Response:
- The measures are not intended to imply that any single incidence of these care processes is wrong, but rather to identify consistently outlying practice which could raise a ‘red flag’ about either practice style (not having realistic discussions about the end-of-life in a timely fashion) or access to palliative or hospice care (lack of access has been consistently shown to be associated with more acute and aggressive care near the end of life). Lastly, while it is true that prognostication is difficult, if a provider's practice is an outlier because they are particularly poor at prognostication, which may be a problem as well.
- Identifying the end of life phase prospectively in administrative data is challenging as the definition always creates a biased sub cohort (a particular stage at diagnosis, using particular services, etc.).
- Users may make adjustments to the numerator and denominator definitions as they see fit.
- The access issue is that these measures of potentially aggressive care near the end of life are associated with less availability of hospice.

Steering Committee Response:
- These issues were discussed extensively during the Cancer Steering Committee in-person meeting. In that discussion, the measure developer noted that at times the interventions can and should occur for many patients. The measures are intended to compare similar providers who have similar patient mixes and identify outlying patterns of care. Consequently, relative incidence of the situations should be similar. For example, grouping patients receiving palliative chemotherapies at the end of life with those receiving curative chemotherapies should not result in markedly different performance rates between two facilities with a similar case mix. This reasoning may also be applied to grouping patients who are terminally ill and those who died suddenly.
- Further, the Steering Committee respectfully disagreed with the statement that prognostication of death is limited, and believed that taking this stance would severely limit measures of this type, which are very important quality indicators for patient preference and the availability of resources at the end of life.
- The Steering Committee also noted that though there are a limited number of studies, it has been demonstrated that patients who receive palliative care earlier have lower rates of chemotherapy at the end of life, lending credence to the importance of palliative interventions in reducing overtreatment.

Proportion not admitted to hospice

Maintenance Measure

Measure Evaluation and Specifications

Description: Percentage of patients who died from cancer not admitted to hospice

Numerator Statement: Patients who died from cancer without being admitted to hospice

Denominator Statement: Patients who died from cancer.
### Exclusions: None

**Adjustment/Stratification:** No risk adjustment or risk stratification. No risk adjustment or risk stratification is necessary because a) the measure is intended to be used for comparison among similar providers; unless there is a reason to believe that one providers’ patients have significantly different risks than others, it will not affect relative comparisons, and b) comorbidity risks will if anything decrease the likelihood of experiencing this process of care. None

**Level of Analysis:** Clinician: Group/Practice, Facility, Health Plan, Integrated Delivery System, Population: County or City, Population: National, Population: Regional, Population: State

**Type of Measure:** Process

**Data Source:** Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Registry, Management Data, Paper Records

**Measure Steward:** American Society of Clinical Oncology

**Steering Committee In-Person March 13-14, 2012**

#### 1. Importance to Measure and Report: The measure meets the importance criteria.

1a. **Impact:** H-10; M-3; L-2; I-1; 1b. **Performance Gap:** H-9; M-5; L-1; I-2; 1c. **Evidence:** Y-10, N-2, I-5

**Rationale:**
- The Steering Committee agreed the measure affects a large number of patients and has a high impact.
- Many cancer patients die in a hospital receiving futile care until the end. Referring patients to hospice, when appropriate, addresses patient preferences, improves quality of care, and reduces cost of care.
- The Steering Committee noted that poor performance on the measure would indicate that providers may be failing to have direct conversations with patients about the futility of further treatment and the benefits of hospice care.
- The Committee agreed the measure developer provided good evidence to support that hospice referral would mean increased quality of care.

#### 2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.

2a. **Reliability:** H-4; M-9; L-3; I-1; 2b. **Validity:** H-6; M-7; L-3; I-1

**Rationale:**
- The measure is well specified.
- The reliability testing presented for the measure is appropriate and demonstrates the reliability of the measure.
- Face validity of the measure is demonstrated.

#### 3. Usability: H-6; M-5; L-3; I-3

**Rationale:**
- The measure is usable for public reporting, as it captures the use of hospice for appropriate patients.
- The measure is useful for QI, particularly when comparing facilities with similar patient populations to see if there are irregularities in achieving this measure.
- The measure is in use through ASCO’s QOPI program.

#### 4. Feasibility: H-6; M-8; L-2; I-1

**Rationale:**
- The measure is reported using claims data and is feasible to implement.
- Steering Committee members noted that this measure—in conjunction with measure #0216: Proportion admitted to hospice for less than 3 days—would prevent providers from making patient care decisions about sending patients to hospice without considering palliative care.
NATIONAL QUALITY FORUM

0216 Proportion admitted to hospice for less than 3 days

Maintenance Measure

Measure Evaluation and Specifications

Description: Percentage of patients who died from cancer, and admitted to hospice and spent less than 3 days there

Numerator Statement: Patients who died from cancer and spent fewer than three days in hospice.

Denominator Statement: Patients who died from cancer who were admitted to hospice

Exclusions: None

Adjustment/Stratification: No risk adjustment or risk stratification

because a) the measure is intended to be used for comparison among similar providers; unless there is a reason to believe that one providers’ patients have significantly different risks than others, it will not affect relative comparisons, and b) comorbidity risks will if anything decrease the likelihood of experiencing this process of care. None


Type of Measure: Process

Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Registry, Management Data, Paper Records

Measure Steward: American Society of Clinical Oncology

Workgroup Preliminary Evaluations

1. Importance to Measure and Report: The measure meets the Importance criteria.

(1a. High Impact; 1b. Performance Gap; 1c. Evidence)

1a. Impact: H-14; M-3; L-0; I-0. 1b. Performance Gap: H-13; M-3; L-1; I-0; 1c. Evidence: Y-16, N-1, I-0

Rationale:

• It is well documented that short lengths of stay in hospice compromises patients’ quality of care and that there is a substantial portion of hospice patients that are referred within 1-3 days of death.
• The measure affects a large number of patients and is high impact.
• Many cancer patients die in a hospital receiving futile care until the end. Referring patients to hospice, when appropriate, addresses patient preferences, improves quality of care, and reduces health care costs.
• The Steering Committee noted that poor performance on this measure would indicate that providers are failing to have direct conversations with their patients about the futility of further treatment and the benefits of hospice care.
• The committee felt the measure developer provided good evidence to support that the concept that hospice referral would mean increased quality of care.

2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.

NQF VOTING DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER votes are due June 26, 2012 by 6:00 PM ET
0216 Proportion admitted to hospice for less than 3 days

(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)

2a. Reliability: H-14; M-3; L-1; I-0; 2b. Validity: H-13; M-4; L-0; I-0

Rationale:

- Steering Committee members questioned why three days was selected as the numerator. The developer noted that three days is the minimum lowest bar; seven days may be a better indicator of quality of care. Also, data was more easily obtained with the three day threshold than the seven day threshold.
- The measure is well specified.
- The reliability testing for the measure is appropriate and demonstrates the reliability of the measure.
- Face validity of the measure was demonstrated.

3. Usability: H-11; M-6; L-0; I-0

(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

Rationale:

- The measure is usable for public reporting, as it captures the use of hospice for appropriate patients.
- The measure is useful for QI, particularly when comparing facilities with similar patient populations to see if there are irregularities in achieving this measure.
- The measure is in use through ASCO’s QOPI program.

4. Feasibility: H-12; M-5; L-0; I-0

(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/unintended consequences identified 4d. Data collection strategy can be implemented)

Rationale:

- The measure is reported using claims data and is feasible to implement.
- Steering Committee members noted that this measure in conjunction with measure #0215 would prevent providers from not sending patients to hospice because of the fear that the patient would die in the next 3 days and prevents providers from making patient care decisions about sending patients to hospice based on measure performance.

Steering Committee Recommendation for Endorsement: Y-17; N-0

Rationale: The Steering Committee found that the measure affects a large patient population and will help identify when facilities are providing overly aggressive, futile care to patients rather than referring them to hospice.

Public & Member Comment

- Commenters indicated support for the measure.

1822 External Beam Radiotherapy for Bone Metastases

New Measure

Measure Evaluation and Specifications

Description: This measure reports the percentage of patients, regardless of age, with a diagnosis of painful bone metastases and no history of previous radiation who receive external beam radiation therapy (EBRT) with an acceptable fractionation scheme as defined by the guideline.

Numerator Statement: All patients, regardless of age, with painful bone metastases, and no previous radiation to the same anatomic site who receive EBRT with any of the following recommended fractionation schemes: 30Gy/10fxns, 24Gy/6fxns, 20Gy/5fxns, 8Gy/1fxn.

Denominator Statement: All patients with painful bone metastases and no previous radiation to the same anatomic site who receive EBRT

Exclusions: The medical reasons for denominator exclusions are:
External Beam Radiotherapy for Bone Metastases

1) Previous radiation treatment to the same anatomic site;
2) Patients with femoral axis cortical involvement greater than 3 cm in length;
3) Patients who have undergone a surgical stabilization procedure; and
4) Patients with spinal cord compression, cauda equina compression or radicular pain

**Adjustment/Stratification:** No risk adjustment or risk stratification. Not applicable. Stratification of the measure is not required.

**Level of Analysis:** Clinician: Group/Practice, Clinician: Individual, Clinician: Team, Facility, Health Plan

**Type of Measure:** Process

**Data Source:** Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Paper Records

**Measure Steward:** American Society for Radiation Oncology (ASTRO) Other organizations: None

**Steering Committee: In-Person March 13-14, 2012**

<table>
<thead>
<tr>
<th>1. Importance to Measure and Report: The measure meets the importance criteria.</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(1a. High Impact; 1b. Performance Gap; 1c. Evidence)</td>
<td></td>
</tr>
<tr>
<td><strong>1a. Impact:</strong> H-15; M-1; L-0; I-0; 1b. Performance Gap: H-13; M-3; L-0; I-0; 1c. Evidence: Y-16, N-0, I-0</td>
<td></td>
</tr>
<tr>
<td><strong>Rationale:</strong></td>
<td></td>
</tr>
<tr>
<td>• The measure has high impact.</td>
<td></td>
</tr>
<tr>
<td>• There is a high opportunity for improvement, with nearly a 20% performance gap noted.</td>
<td></td>
</tr>
<tr>
<td>• The measure represents quality care.</td>
<td></td>
</tr>
<tr>
<td>• There is a strong supportive evidence base for this intervention.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)</td>
<td></td>
</tr>
<tr>
<td><strong>2a. Reliability:</strong> H-13; M-3; L-0; I-0; 2b. Validity:** H-11; M-5; L-0; I-0</td>
<td></td>
</tr>
<tr>
<td><strong>Rationale:</strong></td>
<td></td>
</tr>
<tr>
<td>• The measure is well specified and exclusions are appropriate, except the patient reason exclusions. The Steering Committee asked the developer to remove those exclusions, and the developer agreed to do so.</td>
<td></td>
</tr>
<tr>
<td>• The reliability testing for the measure is appropriate and demonstrates the reliability of the measure.</td>
<td></td>
</tr>
<tr>
<td>• Face validity of the measure was demonstrated.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. Usability: H-13; M-3; L-0; I-0</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)</td>
<td></td>
</tr>
<tr>
<td><strong>Rationale:</strong></td>
<td></td>
</tr>
<tr>
<td>• The developer has provided a detailed plan for representation of measure results, usability for QI, and public reporting of the measure through PQRS.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. Feasibility: H-14; M-2; L-0; I-0</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)</td>
<td></td>
</tr>
<tr>
<td><strong>Rationale:</strong></td>
<td></td>
</tr>
<tr>
<td>• Data elements are in EHR and generated during the provision of care.</td>
<td></td>
</tr>
</tbody>
</table>

**Steering Committee Recommendation for Endorsement:** Y-16; N-0

**Rationale:** The Steering Committee stated that this measure represents good care with a strong evidence base supporting the focus of the measure. The patients affected by this measure suffer from severe pain and the intervention will help alleviate their discomfort.

**RECOMMENDATIONS:** The Steering Committee asked the developer to remove the patient reason exclusions from the
### 1822 External Beam Radiotherapy for Bone Metastases

measure denominator. The developer agreed to do so, and the Steering Committee reviewed the changes on a follow up call. The Committee agreed with the changes and recommended the measure for endorsement.

#### Public & Member Comment

- While commenters indicated general support for the measure, several issues were raised including the burden of data collection data on whether a case meets exclusion criteria, and patient preference for other types of treatment.

#### Developer Response:

- ASTRO appreciates your comments and support for the measure. The clinical practice guideline has identified specific exclusion criteria for patients that can receive fractionation schedules other than what is recommended and specified in the measure. Considering that the goal of the measure is to assess appropriate use and prevent overuse of treatment, it is important that the specific exclusions are outlined in the measure specifications. The measure, including its exclusions, was tested for feasibility of data collection and the measure was abstracted without difficulty at the testing sites. The following data sources have been identified for the measure exclusions: 1) Previous radiation treatment to the same anatomic site (Medical Record); Patients with femoral axis cortical involvement greater than 3 cm in length(Imaging Studies); Patients who have undergone a surgical stabilization procedure (Operative Report); Patients with spinal cord compression, cauda equina compression or radicular pain (Diagnosis/Problem list).

- We do recognize that this measure is currently not in use in any quality reporting or public reporting programs. However, ASTRO intends to submit the measure for the upcoming CMS’s call for measures for potential inclusion in the proposed set of quality measures in the Physician Quality Reporting System for future rule-making years.

- The measure is specified such that the denominator includes only those patients who have consented to radiation therapy and who are receiving External Beam Radiation Therapy for bone metastases; informed consent includes the risks and benefits of the procedure.

#### Steering Committee Response:

- The Steering Committee agrees with the measure developer’s response. The response is in line with discussions that occurred at the in-person meeting and on related conference calls.

### MEASURES NOT RECOMMENDED

#### Hematology and Melanoma Measures

**0561 Melanoma Coordination of Care**

**Maintenance Measure**

**Measure Evaluation and Specifications**

**Description:** Percentage of patient visits, regardless of age, seen with a new occurrence of melanoma who have a treatment plan documented in the chart that was communicated to the physician(s) providing continuing care within one month of diagnosis.

**Numerator Statement:** Patient visits with a treatment plan documented in the chart that was communicated to the physician(s) providing continuing care within one month of diagnosis.

**Denominator Statement:** All visits for patients, regardless of age, diagnosed with a new occurrence of melanoma.

**Exclusions:** Documentation of patient reason(s) for not communicating treatment plan (eg, patient asks that treatment plan not be communicated physician(s) providing continuing care).

---

**NQF VOTING DRAFT—DO NOT CITE OR QUOTE**

**NQF MEMBER votes are due June 26, 2012 by 6:00 PM ET**
0561 Melanoma Coordination of Care

Documentation of system reason(s) for not communicating treatment plan to the primary care provider(s) (eg, patient does not have a primary care provider or referring physician)

**Adjustment/Stratification:** No risk adjustment or risk stratification. We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

**Level of Analysis:** Clinician: Group/Practice, Clinician: Individual, Clinician: Team

**Type of Measure:** Process

**Data Source:** Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Registry, Paper Records

**Measure Steward:** American Medical Association - Physician Consortium for Performance Improvement Other organizations: American Academy of Dermatology and National Committee for Quality Assurance

**Steering Committee In-Person March 13-14, 2012**

1. **Importance to Measure and Report: The measure does not meet the Importance criteria.**

   1a. Impact: H-4; M-7; L-3; I-3; 1b. Performance Gap: H-1; M-10; L-3; I-3; 1c. Evidence: Y-1, N-4, I-10

   **Rationale:**
   - Measure demonstrates good clinical care; however, there was concern that this was not important for devoting resources for performance measurement.
   - The measure developers presented data that about 12% of the charts did not have evidence regarding the documentation of treatment plans directed to the primary care physicians. However, there is no supporting evidence that this communication would improve the quality of care of a melanoma patient. This is compounded by the fact that patients are already being seen by a “treating” physician which suggests that they are receiving adequate oncology specific care.
   - The Steering Committee agreed communication among providers is important but were not sure that this measure improves quality of care or outcomes, especially based on data provided since primary care provider not likely to be directly involved in the treatment of a patient with melanoma. A better measure would be documentation of follow up by an oncology-specific provider.

2. **Scientific Acceptability of Measure Properties: N/A**

   2a. Reliability: H- ; M- ; L- ; I- ;
   2b. Validity: H- ; M- ; L- ; I-

3. **Usability: N/A**

   (Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

4. **Feasibility: N/A**

   (4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

**Steering Committee Recommendation for Endorsement:** The measure failed the Importance criteria and will not be recommended for endorsement.

**Public & Member Comment**

- No comments were received.
### 0625 History of Prostate Cancer - Cancer Surveillance

#### Maintenance Measure

**Description:** The percentage of men with definitively treated localized prostate cancer who had at least one PSA level in the past 12 months.

**Numerator Statement:** Men who had at least one PSA level in the past 12 months.

**Denominator Statement:** Men with localized prostate cancer who were treated with curative intent.

**Exclusions:**
1. Surgical treatment for prostate cancer in the past year
2. Drug treatment for prostate cancer in the past year
3. Radiation therapy for prostate cancer in the past year
4. Prostate MRI in past year
5. Prostate biopsy in the past year
6. Metastatic prostate cancer
7. Provider or patient feedback stating patient does not have a diagnosis of prostate cancer.
8. General exclusions
   a. Terminal illness
   b. Active treatment of malignancy (chemotherapy or radiation therapy) in the past 6 months.
   c. Patients who were admitted to a skilled nursing facility in the past 3 months.

**Adjustment/Stratification:** No risk adjustment or risk stratification. No risk adjustment is done with our measures, therefore, we do not have a risk model. This specific measure addresses all men with a history of a diagnosis of prostate cancer who were treated with curative intent, across the entire measured population. Using our highly specific rule algorithms, people with a history of a diagnosis of prostate cancer who were treated with curative intent will be included in the denominator. Therefore, no risk adjustment or risk stratification is necessary for this unique measure.

**Level of Analysis:** Clinician: Group/Practice, Clinician: Individual, Facility, Health Plan, Population: County or City, Population: National, Population: State

**Type of Measure:** Process

**Data Source:** Administrative claims, Electronic Clinical Data, Healthcare Provider Survey, Patient Reported Data/Survey

**Measure Steward:** ActiveHealth Management

#### 0625 History of Prostate Cancer - Cancer Surveillance

**Steering Committee In-Person March 13-14, 2012**

**1. Importance to Measure and Report:** The measure does not meet the Importance criteria.


**Rationale:**
- The Steering Committee agreed prostate cancer is a prevalent disease and surveillance care and survivorship care are important areas for measuring quality, however the presented evidence did not demonstrate a link between process and a prostate cancer specific desired outcome.
- There was no evidence presented that management of recurrence is associated with high resource use.
- There was low level evidence that delay in detection of recurrence was associated with adverse outcomes.
- There was no evidence presented that there is variation or suboptimal performance with regard to PSA testing in these patients.
National Quality Forum

0625 History of Prostate Cancer - Cancer Surveillance

- The Steering Committee was concerned with unintended harm, as overtreatment of patients with relapses of prostate cancer is a current problem.

2. Scientific Acceptability of Measure Properties: N/A
   (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)
   2a. Reliability: H- ; M- ; L- ; I-
   2b. Validity: H- ; M- ; L- ; I-

Rationale:
- The Steering Committee was concerned about the lack of results data presented on the reliability and validity of the measure. The Steering Committee felt that the testing database was inappropriate for evaluating reliability and validity for prostate cancer, due in part to the young age of the cohort.
- The Steering Committee was concerned about the open-ended time window.
- The Steering Committee was concerned that the exclusions for the measure eliminated the patients who would require more rigorous follow up after a diagnosis of prostate cancer. Although one exclusion was mis-stated, this concern extended to other exclusions in the measure.
- The Steering Committee stated that patients who are asymptomatic and not eligible for salvage therapies may not need to be followed.

3. Usability: N/A
   (Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)
   - The Steering Committee was concerned that although the developer indicated that 20 percent of patients lack surveillance PSA levels within one year of their treatment, the developer does not document the lower level of care or worse outcomes for that group.

4. Feasibility: N/A
   (4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

Rationale:
- The Steering Committee was concerned about attribution to a provider following the care of the patient. The developer stated they had a database that would pull the most recent test during a 1-year window and using an algorithm, determine the care provider. The Steering Committee was concerned that users of the measure would not be able to do this without the developer’s database.

Steering Committee Recommendation for Endorsement: The measure failed the Importance criteria and will not be recommended for endorsement.

Public & Member Comment
- No comments were received.

Palliative Measures

0212 Proportion with more than one hospitalization in the last 30 days of life

Maintenance Measure

Measure Evaluation and Specifications

Description: Percentage of patients who died from cancer with more than one hospitalization in the last 30 days of life

Numerator Statement: Patients who died from cancer and had >1 hospitalization in the last 30 days of life

NQF Voting Draft—Do not cite or quote
NQF Member votes are due June 26, 2012 by 6:00 PM ET

55
0212 Proportion with more than one hospitalization in the last 30 days of life

Denominator Statement: Patients who died from cancer.

Exclusions: None

Adjustment/Stratification: No risk adjustment or risk stratification

No risk adjustment or risk stratification is necessary because the measure is intended to be used for comparison among similar providers; unless there is a reason to believe that one providers' patients have significantly different risks than others, it will not affect relative comparisons. Since, however, comorbidity risks could increase the likelihood of experiencing this process of care, stratification or adjustment as described above can be considered.

None. No risk adjustment is necessary. The Deyo modification of the Charlson score can be applied to claims as this measure may be sensitive to comorbidity, omitting 'Cancer' as a comorbid condition in the calculation, and used as an independent variable in a regression model to predict an adjusted rate. No stratification was used in the measure’s development or evaluation, however, it would be reasonable to apply the Deyo modification of the Charlson score (Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619, 1992) to claims and stratifying for comorbidities, e.g., scores of 0, 1, or 2+.


Type of Measure: Process

Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Registry, Management Data, Paper Records

Measure Steward: American Society of Clinical Oncology

Steering Committee In-Person March 13-14, 2012

1. Importance to Measure and Report: The measure does not meet the Importance criteria.

(1a. High Impact; 1b. Performance Gap; 1c. Evidence)

1a. Impact: H-4; M-10; L-2; I-0; 1b. Performance Gap: H-4; M-8; L-3; I-1; 1c. Evidence: Y-6, N-6, I-4

Rationale:

- The measure affects a large number of patients and is high impact.
- The Steering Committee noted that repeated hospitalizations for a dying patient are indicative that a trajectory of care to deal with end of life issues has not been established.
- The Steering Committee was concerned that this measure did not take into account the increase in Palliative Care Units in hospitals, which provide appropriate care for dying patients in pain and should be utilized.
- The Steering Committee raised concerns that the evidence base for this measure needs to evolve with the use of palliation in inpatient facilities.
- There was concern that not recommending this measure for endorsement would not allow capture of the full spectrum of hospitalizations for cancer patients at the end of life (emergency department, hospitalization, and ICU).

2. Scientific Acceptability of Measure Properties: N/A

(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)

2a. Reliability: H-; M-; L-; I-; 2b. Validity: H-; M-; L-; I-

3. Usability: N/A

(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

4. Feasibility: N/A

(4a. Clinical data generated during care process; 4b. Electronic data: 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)
### 0212 Proportion with more than one hospitalization in the last 30 days of life

**Steering Committee Recommendation for Endorsement:** The measure failed the Importance criteria and will not be recommended for endorsement.

#### Public and Member Comment

- Commenters urged endorsement of the measure as complementary to measures 0211 and 0213.
- Commenters indicated that given the variation in the use of emergency room (ER) or direct hospital admissions for patients in advanced stages of illness, as well as variation in the intensity of care provided in diverse health care settings, it will not be possible to understand variations in ER and intensive care unit (ICU) use at the end of life without including the hospital admissions piece represented by measure 0212.
- Commenters suggested excluding patients in inpatient hospice and palliative care units to strengthen the measure.

#### Developer Response:

- True hospice, as paid for through the hospice benefit, is not included. If inpatient palliative care units can be identified in administrative claims (currently not possible in Medicare), then they should be excluded.
- The user could certainly use these measures as a package when implementing them.
- Inpatient hospice care is not included. A more difficult problem is hospitalization on an inpatient palliative care unit which currently is not generally identifiable in administrative claims. If it was, it should be treated like inpatient hospice.

#### Steering Committee Response:

- Steering Committee members noted that ER and ICU utilization varies regionally and often by facility, with some facilities utilizing ICUs in circumstances where other facilities would simply admit a patient to the hospital. However, the Committee members stated concerns that without a way to distinguish palliative care units, many patients who were receiving appropriate and necessary care via hospitalization would be counted in this measure.
- The data source for the measure is Medicare claims data, which does not currently distinguish between palliative care units and other hospitalizations. Because of this the Steering Committee agreed the measure would not present a valid depiction of the quality of care provided within a facility.

### 0214 Proportion dying from Cancer in an acute care setting

**Maintenance Measure**

**Measure Evaluation and Specifications**

**Description:** Percentage of patients who died from cancer dying in an acute care setting

**Numerator Statement:** Patients who died from cancer in an acute care hospital

**Denominator Statement:** Patients who died from cancer.

**Exclusions:** None

**Adjustment/Stratification:** No risk adjustment or risk stratification. No risk adjustment or risk stratification is necessary because the measure is intended to be used for comparison among similar providers; unless there is a reason to believe that one providers' patients have significantly different risks than others, it will not affect relative comparisons. Since, however, comorbidity risks could increase the likelihood of experiencing this process of care, stratification or adjustment as described above can be considered. is necessary because the measure is intended to be used for comparison among similar providers; unless there is a reason to believe that one providers' patients have significantly different risks than others, it will not affect relative comparisons. Since, however, comorbidity risks could increase the likelihood of experiencing this process of care,
WITHDRAWN FROM CONSIDERATION

Changing practice prompted the AMA-PCPI to withdraw from consideration measure #0388 Prostate Cancer: Three Dimensional Radiotherapy. The measure focused on patients, regardless of age, with a diagnosis of clinically localized prostate cancer receiving external beam radiotherapy as primary therapy to the prostate with or without nodal irradiation (no metastases; no salvage therapy) who receive three-dimensional conformal radiotherapy (3D-CRT) or intensity modulated radiation therapy (IMRT). The developer explained that high clinician performance and a change in the standard of care meant the measure no longer represented an opportunity for quality improvement. The Steering Committee noted that most patients prefer to die at home, not in an acute care setting. The Steering Committee was concerned that this measure did not take into account the increase in Palliative Care Units in hospitals, which provide appropriate care for dying patients in pain and should be utilized. The Steering Committee stated that this measure does not take into account that the majority of patients want to die comfortably, and in many circumstances an acute care setting may be the most appropriate place for that to occur.
Committee agreed with this assessment, noting that two-dimensional radiotherapy is now uncommon and removal of endorsement is recommended.

NOTES


## APPENDIX A: MEASURE SPECIFICATIONS

<table>
<thead>
<tr>
<th>Measure Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0210</td>
<td>Proportion receiving chemotherapy in the last 14 days of life</td>
</tr>
<tr>
<td>0211</td>
<td>Proportion with more than one emergency room visit in the last days of life</td>
</tr>
<tr>
<td>0213</td>
<td>Proportion admitted to the ICU in the last 30 days of life</td>
</tr>
<tr>
<td>0215</td>
<td>Proportion not admitted to hospice</td>
</tr>
<tr>
<td>0216</td>
<td>Proportion admitted to hospice for less than 3 days</td>
</tr>
<tr>
<td>0377</td>
<td>Myelodysplastic Syndrome (MDS) and Acute Leukemias – Baseline Cytogenetic</td>
</tr>
<tr>
<td>0378</td>
<td>MDS: Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy</td>
</tr>
<tr>
<td>0379</td>
<td>Chronic Lymphocytic Leukemia (CLL) – Baseline Flow Cytometry</td>
</tr>
<tr>
<td>0370</td>
<td>Multiple Myeloma – Treatment with Bisphosphonates</td>
</tr>
<tr>
<td>0381</td>
<td>Oncology: Treatment Summary Communication – Radiation Oncology</td>
</tr>
<tr>
<td>0382</td>
<td>Oncology: Radiation Dose Limits to Normal Tissues</td>
</tr>
<tr>
<td>0383</td>
<td>Oncology: Plan of Care for Pain – Medical Oncology and Radiation Oncology (paired with 0384)</td>
</tr>
<tr>
<td>0384</td>
<td>Oncology: Pain Intensity Quantified – Medical Oncology and Radiation Oncology (paired with 0383)</td>
</tr>
<tr>
<td>0386</td>
<td>Oncology: Cancer Stage Documented</td>
</tr>
<tr>
<td>0389</td>
<td>Prostate Cancer: Avoidance of Overuse Measure – Bone Scan for Staging Low-Risk Patients</td>
</tr>
<tr>
<td>0390</td>
<td>Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Patients</td>
</tr>
<tr>
<td>0562</td>
<td>Overutilization of Imaging Studies in Melanoma</td>
</tr>
<tr>
<td>0650</td>
<td>Melanoma Continuity of Care – Recall System</td>
</tr>
<tr>
<td>1790</td>
<td>Risk-Adjusted Morbidity and Mortality for Lung Resection for Lung Cancer</td>
</tr>
<tr>
<td>1822</td>
<td>External Beam Radiotherapy for Bone Metastases</td>
</tr>
<tr>
<td>1853</td>
<td>Radical Prostatectomy Pathology Reporting</td>
</tr>
<tr>
<td>1854</td>
<td>Barrett’s Esophagus</td>
</tr>
<tr>
<td>0210 Proportion receiving chemotherapy in the last 14 days of life</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Status</strong></td>
<td>Maintenance, Original Endorsement: Aug 10, 2009, Most Recent Endorsement: Aug 10, 2009</td>
</tr>
<tr>
<td><strong>Steward</strong></td>
<td>American Society of Clinical Oncology</td>
</tr>
<tr>
<td><strong>Description</strong></td>
<td>Percentage of patients who died from cancer receiving chemotherapy in the last 14 days of life</td>
</tr>
<tr>
<td><strong>Type</strong></td>
<td>Process</td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
<td>Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Pharmacy, Electronic Clinical Data: Registry, Management Data, Paper Records Medicare claims and denominator file</td>
</tr>
<tr>
<td><strong>Level</strong></td>
<td>Clinician: Group/Practice, Facility, Health Plan, Integrated Delivery System, Population: County or City, Population: National, Population: Regional, Population: State</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Ambulatory Care: Clinician Office, Hospital/Acute Care Facility</td>
</tr>
<tr>
<td><strong>Numerator Statement</strong></td>
<td>Patients who died from cancer and received chemotherapy in the last 14 days of life</td>
</tr>
<tr>
<td><strong>Numerator Details</strong></td>
<td>Time Window: 14 days prior to death</td>
</tr>
<tr>
<td></td>
<td>ICD-9: 140 – 239</td>
</tr>
<tr>
<td></td>
<td>Chemotherapy administration codes:</td>
</tr>
<tr>
<td></td>
<td>ICD-9 diagnosis codes: V58.1</td>
</tr>
<tr>
<td></td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td>ICD-9 procedure codes: 99.25</td>
</tr>
<tr>
<td></td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td>CPT codes: 964xx, 965xx</td>
</tr>
<tr>
<td></td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td>HCPCS codes: J7150, J85xx, J86xx, J87xx, J8999, J9xxx, Q0083, Q0084, Q0085</td>
</tr>
<tr>
<td></td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td>DRG codes: 410</td>
</tr>
<tr>
<td></td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td>Revenue center codes: 0331, 0332, 0335</td>
</tr>
<tr>
<td></td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td>BETOS codes: O1D</td>
</tr>
<tr>
<td></td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td>NDC Brand descriptions: Alkeran, Cytoxan, Methotrexate Sodium, Temodar, VePesid, Xeloda</td>
</tr>
<tr>
<td><strong>Denominator Statement</strong></td>
<td>Patients who died from cancer.</td>
</tr>
<tr>
<td><strong>Denominator Details</strong></td>
<td>Time Window: None</td>
</tr>
<tr>
<td></td>
<td>Medicare patients in the death registry with cancer as their cause of death. In the cited analyses by the measure submitter, this is a field in the cancer registry or denominator file not requiring specific codes. This may be different in other administrative data sets.</td>
</tr>
<tr>
<td><strong>Exclusions</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Exclusion Details</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Risk Adjustment</strong></td>
<td>No risk adjustment or risk stratification</td>
</tr>
<tr>
<td></td>
<td>No risk adjustment or risk stratification is necessary because a) the measure is intended to be used for comparison among similar providers; unless there is a reason to believe that one providers’ patients have significantly different risks than others, i</td>
</tr>
<tr>
<td><strong>Stratification</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Type Score</strong></td>
<td>Rate/proportion better quality = lower score</td>
</tr>
</tbody>
</table>

<p>| 0211 Proportion with more than one emergency room visit in the last days of life |</p>
<table>
<thead>
<tr>
<th>Measure</th>
<th>Proportion with more than one emergency room visit in the last days of life</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status</strong></td>
<td>Maintenance, Original Endorsement: Aug 10, 2009, Most Recent Endorsement: Aug 10, 2009</td>
</tr>
<tr>
<td><strong>Steward</strong></td>
<td>American Society of Clinical Oncology</td>
</tr>
<tr>
<td><strong>Description</strong></td>
<td>Percentage of patients who died from cancer with more than one emergency room visit in the last days of life</td>
</tr>
<tr>
<td><strong>Type</strong></td>
<td>Process</td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
<td>Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Registry, Management Data, Paper Records Medicare claims and denominator file</td>
</tr>
<tr>
<td><strong>Level</strong></td>
<td>Clinician : Group/Practice, Facility, Health Plan, Integrated Delivery System, Population : County or City, Population : National, Population : Regional, Population : State</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Hospital/Acute Care Facility</td>
</tr>
<tr>
<td><strong>Numerator Statement</strong></td>
<td>Patients who died from cancer and had &gt;1 ER visit in the last 30 days of life</td>
</tr>
<tr>
<td><strong>Numerator Details</strong></td>
<td>Time Window: 30 days prior to death</td>
</tr>
<tr>
<td><strong>Denominator Statement</strong></td>
<td>Patients who died from cancer.</td>
</tr>
<tr>
<td><strong>Denominator Details</strong></td>
<td>Time Window: None</td>
</tr>
<tr>
<td><strong>Exclusions</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Risk Adjustment</strong></td>
<td>No risk adjustment or risk stratification</td>
</tr>
<tr>
<td><strong>Stratification</strong></td>
<td>No stratification was used in the measure’s development or evaluation, however, it would be reasonable to apply the Deyo modification of the Charlson score (Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administ</td>
</tr>
<tr>
<td><strong>Type Score</strong></td>
<td>Rate/proportion better quality = lower score</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Measure</th>
<th>Proportion admitted to the ICU in the last 30 days of life</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status</strong></td>
<td>Maintenance, Original Endorsement: Aug 10, 2009, Most Recent Endorsement: Aug 10, 2009</td>
</tr>
<tr>
<td><strong>Steward</strong></td>
<td>American Society of Clinical Oncology</td>
</tr>
<tr>
<td><strong>Description</strong></td>
<td>Percentage of patients who died from cancer admitted to the ICU in the last 30 days of life</td>
</tr>
<tr>
<td><strong>Type</strong></td>
<td>Process</td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
<td>Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Registry, Management Data, Paper Records Medicare claims and denominator file</td>
</tr>
<tr>
<td><strong>Level</strong></td>
<td>Clinician : Group/Practice, Facility, Health Plan, Integrated Delivery System, Population : County or City, Population : National, Population : Regional, Population : State</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Hospital/Acute Care Facility</td>
</tr>
<tr>
<td><strong>Numerator Statement</strong></td>
<td>Patients who died from cancer and were admitted to the ICU in the last 30 days of life</td>
</tr>
<tr>
<td><strong>Numerator Details</strong></td>
<td>Time Window: 30 days before death</td>
</tr>
</tbody>
</table>
### Proportion admitted to the ICU in the last 30 days of life

<table>
<thead>
<tr>
<th>Denominator Statement</th>
<th>Patients who died from cancer.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Details</td>
<td>Medicare patients in the death registry with cancer as their cause of death. In the cited analyses by the measure submitter, this is a field in the cancer registry or denominator file not requiring specific codes. This may be different in other administrative data sets.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exclusions</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>Details</td>
<td>N/A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Risk Adjustment</th>
<th>No risk adjustment or risk stratification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Details</td>
<td>No risk adjustment or risk stratification is necessary because the measure is intended to be used for comparison among similar providers; unless there is a reason to believe that one providers’ patients have significantly different risks than others, it is not necessary.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stratification</th>
<th>No stratification was used in the measure’s development or evaluation, however, it would be reasonable to apply the Deyo modification of the Charlson score (Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administ)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Type Score</th>
<th>Rate/proportion better quality = lower score</th>
</tr>
</thead>
</table>

### Proportion not admitted to hospice

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Steward</td>
<td>American Society of Clinical Oncology</td>
</tr>
<tr>
<td>Description</td>
<td>Percentage of patients who died from cancer not admitted to hospice</td>
</tr>
<tr>
<td>Type</td>
<td>Process</td>
</tr>
<tr>
<td>Data Source</td>
<td>Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Registry, Management Data, Paper Records Medicare claims and denominator file</td>
</tr>
<tr>
<td>Setting</td>
<td>Hospice</td>
</tr>
<tr>
<td>Numerator Statement</td>
<td>Patients who died from cancer without being admitted to hospice</td>
</tr>
<tr>
<td>Numerator Details</td>
<td>Time Window: None</td>
</tr>
<tr>
<td></td>
<td>Those without claims in Medicare HOSPICE file. No codes used.</td>
</tr>
<tr>
<td>Denominator Statement</td>
<td>Patients who died from cancer.</td>
</tr>
<tr>
<td>Denominator Details</td>
<td>Time Window: None</td>
</tr>
<tr>
<td></td>
<td>Medicare patients in the death registry with cancer as their cause of death. In the cited analyses by the measure submitter, this is a field in the cancer registry or denominator file not requiring specific codes. This may be different in other administrative data sets.</td>
</tr>
<tr>
<td>Exclusions</td>
<td>None</td>
</tr>
</tbody>
</table>
### 0215 Proportion not admitted to hospice

<table>
<thead>
<tr>
<th>Exclusion Details</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk Adjustment</td>
<td>No risk adjustment or risk stratification. No risk adjustment or risk stratification is necessary because a) the measure is intended to be used for comparison among similar providers; unless there is a reason to believe that one provider's patients have significantly different risks than others, i</td>
</tr>
<tr>
<td>Stratification</td>
<td>None</td>
</tr>
<tr>
<td>Type Score</td>
<td>Rate/proportion better quality = lower score</td>
</tr>
</tbody>
</table>

### 0216 Proportion admitted to hospice for less than 3 days

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Data Source</td>
<td>Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Registry, Management Data, Paper Records Medicare claims and denominator file</td>
</tr>
<tr>
<td>Setting</td>
<td>Hospice</td>
</tr>
<tr>
<td>Numerator Statement</td>
<td>Patients who died from cancer and spent fewer than three days in hospice.</td>
</tr>
<tr>
<td>Numerator Details</td>
<td>Time Window: 3 days</td>
</tr>
<tr>
<td>Denominator Statement</td>
<td>Time Window: None</td>
</tr>
<tr>
<td>Denominator Details</td>
<td>Patients in the death registry with cancer as their cause of death who also appear in the Medicare hospice file. In the cited analyses by the measure submitter, this is a field in the cancer registry or denominator file not requiring specific codes. This may be different in other administrative data sets.</td>
</tr>
<tr>
<td>Exclusions</td>
<td>None</td>
</tr>
<tr>
<td>Exclusion Details</td>
<td>No risk adjustment or risk stratification. No risk adjustment or risk stratification is necessary because a) the measure is intended to be used for comparison among similar providers; unless there is a reason to believe that one provider's patients have significantly different risks than others, i</td>
</tr>
<tr>
<td>Stratification</td>
<td>None</td>
</tr>
<tr>
<td>Type Score</td>
<td>Rate/proportion better quality = lower score</td>
</tr>
</tbody>
</table>

### 0377 Myelodysplastic Syndrome (MDS) and Acute Leukemias – Baseline Cytogenetic Testing Performed on Bone Marrow

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Steward</td>
<td>American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI) Other organizations: The American Society of Hematology</td>
</tr>
<tr>
<td>Description</td>
<td>Percentage of patients aged 18 years and older with a diagnosis of MDS or an acute leukemia who had baseline cytogenetic testing performed on bone marrow.</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Type</td>
<td>Process</td>
</tr>
<tr>
<td>Data Source</td>
<td>Administrative claims, Electronic Clinical Data : Laboratory Not Applicable Attachment 0377 Cytogenetic Testing Data Elements_FINAL.pdf</td>
</tr>
<tr>
<td>Level</td>
<td>Clinician : Group/Practice, Clinician : Individual, Clinician : Team</td>
</tr>
<tr>
<td>Setting</td>
<td>Ambulatory Care : Clinic/Urgent Care, Ambulatory Care : Clinician Office, Laboratory</td>
</tr>
</tbody>
</table>
| Numerator Statement | Patients who had baseline cytogenetic testing performed on bone marrow  
Definition: *Baseline Cytogenetic Testing- Testing that is performed at time of diagnosis or prior to initiating treatment (transfusion, growth factors, or antineoplastic therapy) for that diagnosis. |
| Numerator Details | Time Window: At least once during measurement period  
Definition: *Baseline Cytogenetic Testing- Testing that is performed at time of diagnosis or prior to initiating treatment (transfusion, growth factors, or antineoplastic therapy) for that diagnosis.  
For EHR: specification currently under development. Data elements (using Quality Data Model) required for the measure attached.  
Administrative claims.  
Report the CPT Category II code: 3155F – Cytogenetic testing performed on bone marrow at time of diagnosis or prior to initiating treatment |
| Denominator Statement | All patients aged 18 years and older with a diagnosis of MDS or an acute leukemia |
| Denominator Details | Time Window: 12 consecutive months  
For EHR: specification currently under development. Data elements (using Quality Data Model) required for the measure attached.  
Administrative claims data  
AGE: >= 18 years and older  
AND  
Diagnosis: Myelodysplastic Syndrome (MDS) and Acute Leukemias  
ICD-9-CM diagnosis codes: 204.00, 204.02, 205.00, 205.02, 206.00, 206.02, 207.00, 207.02, 207.20, 207.22, 208.00, 208.02, 238.72, 238.73, 238.74, 238.75  
ICD-10-CM diagnosis codes: C91.00, C91.02, C91.04, C92.00, C92.02, C92.40, C92.42, C92.50, C92.52, C92.60, C92.62, C92.a0, C92.a2, C93.00, C93.02, C94.00, C94.02, C94.20, C94.22, C95.00, C95.02, D46.0, D46.1, D46.20, D46.21, D46.22, D46.4, D46.9, D46.a, D46.b, D46.c, D46.d  
AND  
CPT codes: 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99241, 99242, 99243, 99244, 99245 |
| Exclusions | Documentation of medical reason(s) for not performing baseline cytogenetic testing  
Documentation of patient reason(s) for not performing baseline cytogenetic testing  
Denominator Exclusions: Documentation of system reason(s) for not performing baseline cytogenetic testing |
<p>| Exclusion Details | The PCPI methodology uses three categories of reasons for which a patient may be excluded from the denominator of an individual measure. These measure exception categories are not uniformly relevant across all measures; for each measure, there must be a clear rationale to permit an exception for a medical, patient, or system reason. Examples are provided in the measure exception language of instances that may constitute an exception and are intended to serve as a guide to clinicians. For this measure, exceptions may include medical reason, patient or system reason for not performing baseline cytogenetic testing. Where examples of exceptions are included in the measure language, these examples are coded and included in the eSpecifications. Although this methodology does not require the external reporting of more detailed exception data, the PCPI recommends that physicians document the specific reasons for exception in patients' medical records for purposes of optimal patient management and audit-readiness. The PCPI also advocates the systematic review and analysis of each physician's exceptions data to identify practice patterns and opportunities for quality improvement. For example, |</p>
<table>
<thead>
<tr>
<th>0377 Myelodysplastic Syndrome (MDS) and Acute Leukemias – Baseline Cytogenetic Testing Performed on Bone Marrow</th>
</tr>
</thead>
<tbody>
<tr>
<td>it is possible for implementers to calculate the percentage of patients that physicians have identified as meeting the criteria for exception. Additional details by data source are as follows:</td>
</tr>
<tr>
<td>For EHR: specification currently under development. Data elements (using Quality Data Model) required for the measure attached.</td>
</tr>
<tr>
<td>Administrative claims:</td>
</tr>
<tr>
<td>Denominator Exceptions:</td>
</tr>
<tr>
<td>Documentation of medical reason(s) for not performing baseline cytogenetic testing on bone marrow (e.g., no liquid bone marrow or fibrotic marrow) Appendix modifier to CPT Category II code: 3155F-1P</td>
</tr>
<tr>
<td>Documentation of patient reason(s) for not performing baseline cytogenetic testing on bone marrow (e.g., at time of diagnosis receiving palliative care or not receiving treatment as defined above) Appendix modifier to CPT Category II code: 3155F-2P</td>
</tr>
<tr>
<td>Documentation of system reason(s) for not performing baseline cytogenetic testing on bone marrow (e.g., patient previously treated by another physician at the time of cytogenetic testing performed) Appendix modifier to CPT Category II code: 3155F-3P</td>
</tr>
<tr>
<td>Risk Adjustment</td>
</tr>
<tr>
<td>No risk adjustment or risk stratification</td>
</tr>
<tr>
<td>No risk adjustment or risk stratification.</td>
</tr>
<tr>
<td>Stratification</td>
</tr>
<tr>
<td>We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.</td>
</tr>
<tr>
<td>Type Score</td>
</tr>
<tr>
<td>Rate/proportion better quality = higher score</td>
</tr>
<tr>
<td>Algorithm</td>
</tr>
<tr>
<td>To calculate performance rates:</td>
</tr>
<tr>
<td>1) Find the patients who meet the initial patient population (ie, the general group of patients that the performance measure is designed to address).</td>
</tr>
<tr>
<td>2) From the patients within the initial patient population criteria, find the patients who qualify for the denominator (ie, the specific group of patients for inclusion in a specific performance measure based on defined criteria). Note: in some cases the initial patient population and denominator are identical.</td>
</tr>
<tr>
<td>3) From the patients within the denominator, find the patients who qualify for the Numerator (ie, the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator</td>
</tr>
<tr>
<td>4) From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator exception when exceptions have been specified [e.g., medical, system or patient reason for not performing baseline cytogenetic testing]. If the patient meets any exception criteria, they should be removed from the denominator for performance calculation. --Although the exception cases are removed from the denominator population for the performance calculation, the number of patients with valid exceptions should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI.</td>
</tr>
<tr>
<td>If the patient does not meet the numerator and a valid exception is not present, this case represents a quality failure. Calculation algorithm is included in data dictionary/code table attachment 2a1.30. Attachment Generic Measure Logic.pdf</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>0378 MDS: Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Status</td>
</tr>
<tr>
<td>Steward</td>
</tr>
<tr>
<td>American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI) Other organizations: American Society of Hematology</td>
</tr>
<tr>
<td>Description</td>
</tr>
<tr>
<td>Percentage of patients aged 18 years and older with a diagnosis of MDS who are receiving erythropoietin therapy with documentation of iron stores prior to initiating erythropoietin therapy</td>
</tr>
<tr>
<td>Type</td>
</tr>
<tr>
<td>Process</td>
</tr>
<tr>
<td>Data Source</td>
</tr>
<tr>
<td>Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Laboratory Not Applicable</td>
</tr>
<tr>
<td>Numerator Statement</td>
</tr>
<tr>
<td>---------------------</td>
</tr>
<tr>
<td>*Definition: documentation of iron stores which includes either: 1) bone marrow examination including iron stain OR 2) serum iron measurement including ferritin, serum iron and TIBC.</td>
</tr>
<tr>
<td>Definition: Erythropoietin Therapy: Includes the following medications: epoetin and darbepoetin for the purpose of this measure.</td>
</tr>
<tr>
<td>For EHR: especificación currently under development. Data elements (using Quality Data Model) required for the measure attached.</td>
</tr>
<tr>
<td>Administrative claims:</td>
</tr>
<tr>
<td>CPT Category II code: 3160F: Documentation of iron stores prior to initiating erythropoietin therapy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Denominator Statement</th>
<th>Time Window: 12 consecutive months</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients aged 18 years and older with a diagnosis of MDS who are receiving erythropoietin therapy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exclusions</th>
<th>Documentation of system reason(s) for not documenting iron stores prior to initiating erythropoietin therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Details</td>
<td>The PCPI methodology uses three categories of reasons for which a patient may be excluded from the denominator of an individual measure. These measure exception categories are not uniformly relevant across all measures; for each measure, there must be a clear rationale to permit an exception for a medical, patient, or system reason. Examples are provided in the measure exception language of instances that may constitute an exception and are intended to serve as a guide to clinicians. For this measure, exceptions may include system reasons, e.g. for not documenting iron stores prior to initiating erythropoietin therapy. Where examples of exceptions are included in the measure language, these examples are coded and included in the eSpecifications. Although this methodology does not require the external reporting of more detailed exception data, the PCPI recommends that physicians document the specific reasons for exception in patients' medical records for purposes of optimal patient management and audit-readiness. The PCPI also advocates the systematic review and analysis of each physician's exceptions data to identify practice patterns and opportunities for quality improvement. For example, it is possible for implementers to calculate the percentage of patients that physicians have identified as meeting the criteria for exception. Additional details by data source are as follows:</td>
</tr>
<tr>
<td>For EHR: especificación currently under development. Data elements (using Quality Data Model) required for the measure attached.</td>
<td></td>
</tr>
<tr>
<td>Administrative claims:</td>
<td></td>
</tr>
<tr>
<td>Denominator Exceptions:</td>
<td></td>
</tr>
<tr>
<td>Documentation of system reason(s) for not documenting iron stores prior to initiating erythropoietin therapy</td>
<td></td>
</tr>
<tr>
<td>Append modifier to CPT Category II code: 3160F-3P</td>
<td></td>
</tr>
</tbody>
</table>
0378 MDS: Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy

### Risk Adjustment

| No risk adjustment or risk stratification |

### Stratification

We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

### Type Score

Rate/proportion. Better quality = higher score

### Algorithm

To calculate performance rates:

1. Find the patients who meet the initial patient population (i.e., the general group of patients that the performance measure is designed to address).
2. From the patients within the initial patient population criteria, find the patients who qualify for the denominator (i.e., the specific group of patients for inclusion in a specific performance measure based on defined criteria). Note: in some cases the initial patient population and denominator are identical.
3. From the patients within the denominator, find the patients who qualify for the Numerator (i.e., the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator.
4. From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator exception when exceptions have been specified [for this measure: or system reason(s) (e.g., for not documenting iron stores prior to initiating erythropoietin therapy)]. If the patient meets any exception criteria, they should be removed from the denominator for performance calculation. Although the exception cases are removed from the denominator population for the performance calculation, the number of patients with valid exceptions should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI.

If the patient does not meet the numerator and a valid exception is not present, this case represents a quality failure.


0379: Chronic Lymphocytic Leukemia (CLL) – Baseline Flow Cytometry

### Description

Percentage of patients aged 18 years and older with a diagnosis of CLL who had baseline flow cytometry studies performed

### Numerator

Patients who had baseline flow cytometry studies performed and documented in the chart

Definition: *Baseline flow cytometry studies: Refer to testing that is performed at time of diagnosis or prior to initiating treatment for that diagnosis. Treatment may include antineoplastic therapy.*

### Numerator Details

Definition: *Baseline flow cytometry studies: Refer to testing that is performed at time of diagnosis or prior to initiating treatment for that diagnosis. Treatment may include antineoplastic therapy.*

For EHR: specification currently under development. Data elements (using Quality Data Model) required for the measure attached.

Administrative claims:

CPT Category II code: 3170F – Baseline flow cytometry studies performed

### Denominator

All patients aged 18 years and older seen within a 12 month reporting period, with a diagnosis of chronic lymphocytic leukemia (CLL) made at any time during or prior to the reporting period

### Denominator Details

For EHR: specification currently under development. Data elements (using Quality Data Model) required for the measure attached.

AGE: >= 18 years and older

AND

Diagnosis: Chronic Lymphocytic Leukemia
<table>
<thead>
<tr>
<th>0379: Chronic Lymphocytic Leukemia (CLL) – Baseline Flow Cytometry</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICD-9-CM diagnosis codes: 204.10, 204.12</td>
</tr>
<tr>
<td>ICD-10-CM diagnosis codes: C91.10, C91.12</td>
</tr>
<tr>
<td>AND</td>
</tr>
<tr>
<td>CPT codes: 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99241, 99242, 99243, 99244, 99245</td>
</tr>
</tbody>
</table>

**Exclusions**
- Documentation of medical reason(s) for not performing baseline flow cytometry
- Documentation of patient reason(s) for not performing baseline flow cytometry
- Documentation of system reason(s) for not performing baseline flow cytometry

**Exclusion details**
The PCPI methodology uses three categories of reasons for which a patient may be excluded from the denominator of an individual measure. These measure exception categories are not uniformly relevant across all measures; for each measure, there must be a clear rationale to permit an exception for a medical, patient, or system reason. Examples are provided in the measure exception language of instances that may constitute an exception and are intended to serve as a guide to clinicians. For this measure, exceptions may include medical reason, e.g. for not performing baseline flow cytometry; patient reason, e.g. for not performing baseline flow cytometry (for example, receiving palliative care or not receiving treatment as defined above) or system reason, e.g. for not performing baseline flow cytometry (for example, patient previously treated by another physician at the time baseline flow cytometry studies were performed). Where examples of exceptions are included in the measure language, these examples are coded and included in the eSpecifications. Although this methodology does not require the external reporting of more detailed exception data, the PCPI recommends that physicians document the specific reasons for exception in patients’ medical records for purposes of optimal patient management and audit-readiness. The PCPI also advocates the systematic review and analysis of each physician’s exceptions data to identify practice patterns and opportunities for quality improvement. For example, it is possible for implementers to calculate the percentage of patients that physicians have identified as meeting the criteria for exception. Additional details by data source are as follows:

**For EHR:** Specification currently under development. Data elements (using Quality Data Model) required for the measure attached.

**Administrative claims**

**Denominator Exceptions:**
- Documentation of medical reason(s) for not performing baseline flow cytometry studies
  - Append modifier to CPT Category II code: 3170F-1P
- Documentation of patient reason(s) for not performing baseline flow cytometry studies (e.g., receiving palliative care or not receiving treatment as defined above)
  - Append modifier to CPT Category II code: 3170F-2P
- Documentation of system reason(s) for not performing baseline flow cytometry studies (e.g., patient previously treated by another physician at the time baseline flow cytometry studies were performed)
  - Append modifier to CPT Category II code: 3170F-3P

**Risk Adjustment**
- No risk adjustment or risk stratification

**Stratification**
- We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

**Numerator Time window**
- At least once during the measurement period

**Type**
- Process

**Type of Score**
- Rate/proportion

**Data Source**
- Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Laboratory

**Level**
- Clinician: Group/Practice, Clinician: Individual, Clinician: Team

**NQF VOTING DRAFT—DO NOT CITE OR QUOTE**

NQF MEMBER votes are due June 26, 2012 by 6:00 PM ET
| **0379: Chronic Lymphocytic Leukemia (CLL) – Baseline Flow Cytometry** |
| Setting | Ambulatory Care : Ambulatory Surgery Center (ASC), Laboratory |

| **0380 Multiple Myeloma – Treatment with Bisphosphonates** |
| Steward | American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI) Other organizations: American Society of Hematology |
| Description | Percentage of patients aged 18 years and older with a diagnosis of multiple myeloma, not in remission, who were prescribed or received intravenous bisphosphonates within the 12 month reporting period |
| Type | Process |
| Data Source | Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Paper Records Attachment 0380_multiple myeloma DE.pdf |
| Level | Clinician : Group/Practice, Clinician : Individual, Clinician : Team |
| Setting | Ambulatory Care : Clinic/Urgent Care, Ambulatory Care : Clinician Office |
| Numerator Statement | Patients who were prescribed or received intravenous bisphosphonate therapy* within the 12 month reporting period. Definition: *Bisphosphonate Therapy: Includes the following medications: pamidronate and zoledronate |
| Numerator Details | Time Window: At least once during the measurement period Definition: *Bisphosphonate Therapy: Includes the following medications: pamidronate and zoledronate Definition: Prescribed: Includes patients who are currently receiving medication(s) that follow the treatment plan recommended at an encounter during the reporting period, even if the prescription for that medication was ordered prior to the encounter For EHR: specification currently under development. Data elements (using Quality Data Model) required for the measure attached. Administrative claims: CPT Category II code: 4100F – Intravenous bisphosphonate therapy prescribed or received |
| Denominator Statement | All patients aged 18 years and older with a diagnosis of multiple myeloma, not in remission |
| Denominator Details | Time Window: 12 consecutive months For EHR: specification currently under development. Data elements (using Quality Data Model) required for the measure attached. AGE: >=18 years and older AND Diagnosis: Multiple Myeloma ICD-9-CM diagnosis codes: 203.00, 203.02 ICD-10-CM diagnosis codes: C90.00, C90.02 AND CPT codes: 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99241, 99242, 99243, 99244, 99245 |
| Exclusions | Documentation of medical reason(s) for not prescribing bisphosphonates (eg, patients who do not have bone disease, patients with dental disease, patients with renal insufficiency) Documentation of patient reason(s) for not prescribing bisphosphonates |
| Exclusion Details | The PCPI methodology uses three categories of reasons for which a patient may be excluded from the denominator of an individual measure. These measure exception categories are not uniformly relevant across all measures; for each measure, there must be a clear rationale to permit an exception for a medical, patient, or system reason. Examples are provided in the measure exception language of instances that may constitute an exception and are intended to serve as a guide to clinicians. For this measure, exceptions may include medical reason(s), e.g. for not prescribing bisphosphonates (patients who do not have bone disease, patients with dental disease, patients with renal insufficiency) or patient reason(s), e.g. for not prescribing bisphosphonates. Where examples of exceptions are included in the measure language, these examples are coded and included in the
0380 Multiple Myeloma – Treatment with Bisphosphonates

ESpecifications. Although this methodology does not require the external reporting of more detailed exception data, the PCPI recommends that physicians document the specific reasons for exception in patients’ medical records for purposes of optimal patient management and audit-readiness. The PCPI also advocates the systematic review and analysis of each physician’s exceptions data to identify practice patterns and opportunities for quality improvement. For example, it is possible for implementers to calculate the percentage of patients that physicians have identified as meeting the criteria for exception. Additional details by data source are as follows:

For EHR: Especification currently under development. Data elements (using Quality Data Model) required for the measure attached.

Administrative claims:

Denominator Exceptions:
- Documentation of medical reason(s) for not prescribing bisphosphonates (e.g., patients who do not have bone disease, patients with dental disease, patients with renal insufficiency)
  - Append modifier to CPT Category II code: 4100F-1P
- Documentation of patient reason(s) for not prescribing bisphosphonates
  - Append modifier to CPT Category II code: 4100F-2P

Risk Adjustment: No risk adjustment or risk stratification

Stratification: We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

Type Score: Rate/proportion. Better quality = higher score

Algorithm:

To calculate performance rates:
1) Find the patients who meet the initial patient population (i.e., the general group of patients that the performance measure is designed to address).
2) From the patients within the initial patient population criteria, find the patients who qualify for the denominator (i.e., the specific group of patients for inclusion in a specific performance measure based on defined criteria). Note: in some cases the initial patient population and denominator are identical.
3) From the patients within the denominator, find the patients who qualify for the Numerator (i.e., the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator.
4) From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator exception when exceptions have been specified [for this measure: exceptions may include medical reason(s), e.g., for not prescribing bisphosphonates (patients who do not have bone disease, patients with dental disease, patients with renal insufficiency) or patient reason(s), e.g., for not prescribing bisphosphonates]. If the patient meets any exception criteria, they should be removed from the denominator for performance calculation. Although the exception cases are removed from the denominator population for the performance calculation, the number of patients with valid exceptions should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI. If the patient does not meet the numerator and a valid exception is not present, this case represents a quality failure.

Calculation algorithm is included in data dictionary/code table attachment 2a1.30. Attachment Generic Measure Logic-634620584294869354.pdf

0381 Oncology: Treatment Summary Communication – Radiation Oncology


Steward: American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI) Other organizations: The measure set was developed in collaboration with the American Society of Clinical Oncology and the American Society for Radiation Oncology.

Description: Percentage of patients, regardless of age, with a diagnosis of cancer who have undergone brachytherapy or external beam radiation therapy who have a treatment summary report in the chart that was communicated to the physician(s) providing continuing care and to the patient within one month of completing treatment.

Type: Process
<table>
<thead>
<tr>
<th><strong>Data Source</strong></th>
<th>Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Registry, Paper Records Not Applicable Attachment AMA-PCPI_0381_DataElements_AppendixA.pdf</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Level</strong></td>
<td>Clinician : Group/Practice, Clinician : Individual, Clinician : Team</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Ambulatory Care : Clinician Office, Other Radiation Oncology Dept/Clinic</td>
</tr>
<tr>
<td><strong>Numerator Statement</strong></td>
<td>Patients who have a treatment summary* report in the chart that was communicated to the physician(s) providing continuing care and to the patient within one month of completing treatment</td>
</tr>
<tr>
<td><strong>Definition:</strong></td>
<td>*Treatment Summary: a report that includes mention of all of the following components: 1) dose delivered; 2) relevant assessment of tolerance to and progress towards the treatment goals; and 3) subsequent care plans</td>
</tr>
<tr>
<td><strong>Numerator Instructions:</strong></td>
<td>This measure should be reported once per course of radiation treatment – less than or equal to 30 days from the end of treatment.</td>
</tr>
<tr>
<td><strong>Numerator Details</strong></td>
<td>Time Window: &lt;= one month after completion of therapy during measurement period</td>
</tr>
<tr>
<td><strong>For EHR:</strong></td>
<td>eSpecification currently under development. Data elements (using Quality Data Model) required for the measure are attached.</td>
</tr>
<tr>
<td><strong>For Claims/Administrative:</strong></td>
<td>Report CPT Category II code: 5020F - Treatment summary report communicated to physician(s) managing continuing care and to the patient within one month of completing treatment</td>
</tr>
<tr>
<td><strong>Denominator Statement</strong></td>
<td>All patients, regardless of age, with a diagnosis of cancer who have undergone brachytherapy or external beam radiation therapy</td>
</tr>
<tr>
<td><strong>Denominator Details</strong></td>
<td>Time Window: Each course of brachytherapy or external beam radiation therapy within 12 consecutive months</td>
</tr>
<tr>
<td><strong>For EHR:</strong></td>
<td>eSpecification currently under development. Data elements (using Quality Data Model) required for the measure are attached.</td>
</tr>
<tr>
<td><strong>For Claims/Administrative:</strong></td>
<td>CPT® codes for external beam radiation therapy, weekly management or brachytherapy: 77427, 77431, 77432, 77435, 77470, 77761, 77762, 77763, 77776, 77777, 77778, 77785, 77786, 77787 AND ICD-9-CM diagnosis codes: See Attached Code List (Appendix A in attachment) ICD-10-CM diagnosis codes: See Attached Code List (Appendix A in attachment)</td>
</tr>
<tr>
<td><strong>Exclusions</strong></td>
<td>Documentation of a patient reason(s) for not communicating the treatment summary report to the physician(s) providing continuing care (eg, patient requests that report not be sent) and to the patient within one month of completing treatment</td>
</tr>
</tbody>
</table>
| **Exclusion Details** | The PCPI methodology uses three categories of reasons for which a patient may be excluded from the denominator of an individual measure. These measure exception categories are not uniformly relevant across all measures; for each measure, there must be a clear rationale to permit an exception for a medical, patient, or system reason. Examples are provided in the measure exception language of instances that may constitute an exception and are intended to serve as a guide to clinicians. For this measure, exceptions may include patient (eg, patient requests that report not be sent) or system reason(s)(eg, patient does not have any physician responsible for providing continuing care) for not communicating the treatment summary report to the physician(s) providing continuing care and to the patient within one month of completing treatment. Where examples of exceptions are included in the measure language, these examples are coded and included in the eSpecifications. Although this methodology does not require the external reporting of more detailed exception data, the PCPI recommends that physicians document the specific reasons for exception in patients’ medical records for purposes of optimal patient management and audit-readiness. The PCPI also advocates the
**0381 Oncology: Treatment Summary Communication – Radiation Oncology**

<table>
<thead>
<tr>
<th>Risk Adjustment</th>
<th>No risk adjustment or risk stratification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stratification</td>
<td>We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.</td>
</tr>
<tr>
<td>Type Score</td>
<td>Rate/proportion  better quality = higher score</td>
</tr>
</tbody>
</table>

**Algorithm**

To calculate performance rates:

1. Find the patients who meet the initial patient population (ie, the general group of patients that the performance measure is designed to address).
2. From the patients within the initial patient population criteria, find the patients who qualify for the denominator (ie, the specific group of patients for inclusion in a specific performance measure based on defined criteria). Note: in some cases the initial patient population and denominator are identical.
3. From the patients within the denominator, find the patients who qualify for the Numerator (ie, the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator.
4. From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator exception when exceptions have been specified [for this measure: patient reason(s) (eg, patient requests that report not be sent) or system reason(s) (eg, patient does not have any physician responsible for providing continuing care)]. If the patient meets any exception criteria, they should be removed from the denominator for performance calculation.

Although the exception cases are removed from the denominator population for the performance calculation, the number of patients with valid exceptions should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI.


**Copyright/Disclaimer**

Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance ImprovementTM (the Consortium), are intended to facilitate quality improvement activities by physicians. These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures. Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or
### 0381 Oncology: Treatment Summary Communication – Radiation Oncology

Distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

**THE MEASURES ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND**

© 2007 American Medical Association. All Rights Reserved

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

**THE SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.**

See copyright statement above.

### 0382 Oncology: Radiation Dose Limits to Normal Tissues

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Steward</td>
<td>American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI) Other organizations: This measure set was developed in collaboration with the American Society of Clinical Oncology and the American Society for Radiation Oncology.</td>
</tr>
<tr>
<td>Description</td>
<td>Percentage of patients, regardless of age, with a diagnosis of pancreatic or lung cancer who receive 3D conformal radiation therapy with documentation in medical record that radiation dose limits to normal tissues were established prior to the initiation of a course of 3D conformal radiation for a minimum of two tissues</td>
</tr>
<tr>
<td>Type</td>
<td>Process</td>
</tr>
<tr>
<td>Data Source</td>
<td>Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Registry, Paper Records Not Applicable Attachment NQF#0382_DataElements-634820692307678721.xls</td>
</tr>
<tr>
<td>Level</td>
<td>Clinician : Group/Practice, Clinician : Individual, Clinician : Team</td>
</tr>
<tr>
<td>Setting</td>
<td>Ambulatory Care : Clinician Office, Other Radiation Oncology Dept/Clinic</td>
</tr>
<tr>
<td>Numerator Statement</td>
<td>Patients who had documentation in medical record that radiation dose limits to normal tissues were established prior to the initiation of a course of 3D conformal radiation for a minimum of two tissues</td>
</tr>
<tr>
<td>Numerator Details</td>
<td>Time Window: Once, prior to start of 3D conformal radiation therapy</td>
</tr>
<tr>
<td>Denominator Statement</td>
<td>All patients, regardless of age, with a diagnosis of pancreatic or lung cancer who receive 3D conformal radiation therapy</td>
</tr>
<tr>
<td>Denominator Details</td>
<td>Time Window: Each course of 3D conformal radiation therapy within 12 consecutive months</td>
</tr>
</tbody>
</table>

For EHR:
- eSpecification and eMeasure are currently under development (expected completion: end of Q1 2012). Data elements (using Quality Data Model) required for the measure attached.
- For Claims/Administrative Data:
  - To submit the numerator option for patients who had documentation in the medical record that radiation dose limits to normal tissues were established prior to the initiation of a course of 3D conformal radiation for a minimum of two tissues, report the following CPT Category II code: 0520F – Radiation dose limits to normal tissues established prior to the initiation of a course of 3D conformal radiation for a minimum of two tissues or organs

ICD-9-CM diagnosis codes: 157.0, 157.1, 157.2, 157.3, 157.4, 157.8, 157.9, 162.0, 162.2, 162.3, 162.4, 162.5, 162.8,
0382 Oncology: Radiation Dose Limits to Normal Tissues

162.9
ICD-10-CM diagnosis codes: C25.0, C25.1, C25.2, C25.3, C25.4, C25.7, C25.8, C25.9, C33, C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, C34.92
AND
• CPT code for radiation therapy 3D simulation: 77295

Exclusions
None

Exclusion Details
There are no exceptions for this measure.

Risk Adjustment
No risk adjustment or risk stratification

Stratification
We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

Type Score
Rate/proportion better quality = higher score

Algorithm
To calculate performance rates:
1) Find the patients who meet the initial patient population (ie, the general group of patients that the performance measure is designed to address).
2) From the patients within the initial patient population criteria, find the patients who qualify for the denominator (ie, the specific group of patients for inclusion in a specific performance measure based on defined criteria). Note: in some cases the initial patient population and denominator are identical.
3) From the patients within the denominator, find the patients who qualify for the Numerator (ie, the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator.
4) If the measure does not have exceptions, STOP. If the measure does have exceptions, proceed with the following steps. From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator exception, when exceptions have been specified. If the patient meets any exception criteria, they should be removed from the denominator for performance calculation. Although the exception cases are removed from the denominator population for the performance calculation, the number of patients with valid exceptions should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI. If the patient does not meet the numerator and a valid exception is not present, this case represents a quality failure.


Copyright/Disclaimer
Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance ImprovementTM (the Consortium), are intended to facilitate quality improvement activities by physicians. These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures. Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures. THE MEASURES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND © 2007 American Medical Association. All Rights Reserved

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary
### 0382 Oncology: Radiation Dose Limits to Normal Tissues

- Code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

THE SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND. See copyright statement above.

### 0383 Oncology: Plan of Care for Pain – Medical Oncology and Radiation Oncology (paired with 0384)

**Status**

**Steward**
- American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI) Other organizations: This measure set was developed in collaboration with the American Society of Clinical Oncology and the American Society for Radiation Oncology.

**Description**
- Percentage of visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy who report having pain with a documented plan of care to address pain

**Type**
- Process

**Data Source**
- Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Registry, Other, Paper Records
  - Attachment NQF_0383_DataElements_AppendixA.pdf

**Level**
- Clinician: Group/Practice, Clinician: Individual, Clinician: Team

**Setting**
- Ambulatory Care: Clinician Office, Other Oncology/Outpatient Clinic; Radiation Oncology Dept/Clinic

**Numerator Statement**
- Patient visits that included a documented plan of care* to address pain
  - Numerator Instructions: *A documented plan of care may include: use of opioids, nonopioid analgesics, psychological support, patient and/or family education, referral to a pain clinic, or reassessment of pain at an appropriate time interval.

**Numerator Details**
- Time Window: At each visit within the measurement period
  - For EHR: eSpecification and eMeasure are currently under development (expected completion: end of Q1 2012). Data elements (using Quality Data Model) required for the measure attached (please refer to Appendix A).
  - For Claims/Administrative Data: To submit the numerator option for patient visits that included a documented plan of care to address pain, report the following CPT Category II code: 0521F – Plan of care to address pain documented

**Denominator Statement**
- All visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy who report having pain

**Denominator Details**
- Time Window: 12 consecutive months
  - For EHR: eSpecification and eMeasure are currently under development (expected completion: end of Q1 2012). Data elements (using Quality Data Model) required for the measure attached (please refer to Appendix A).
  - For Claims/Administrative Data: All visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy who report having pain
  - Eligible patients for this measure are identified by:
    - ICD-9-CM diagnosis codes:
      - PLEASE REFER TO ATTACHED EXCEL FILE TITLED, APPENDIX A, FOR THE APPLICABLE ICD-9-CM CODES
    - ICD-10-CM diagnosis codes:
      - PLEASE REFER TO ATTACHED EXCEL FILE TITLED, APPENDIX A, FOR THE APPLICABLE ICD-10-CM CODES AND
  - Report CPT Category II code: 1125F: Pain severity quantified; pain present
### Oncology: Plan of Care for Pain – Medical Oncology and Radiation Oncology (paired with 0384)

**Exclusions** None

**Exclusion Details** There are no exceptions for this measure.

**Risk Adjustment** No risk adjustment or risk stratification

**Stratification** We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

**Type Score** Rate/proportion  better quality = higher score

**Algorithm** To calculate performance rates:

1. Find the patients who meet the initial patient population (ie, the general group of patients that the performance measure is designed to address).
2. From the patients within the initial patient population criteria, find the patients who qualify for the denominator (ie, the specific group of patients for inclusion in a specific performance measure based on defined criteria).
   - Note: in some cases the initial patient population and denominator are identical.
3. From the patients within the denominator, find the patients who qualify for the Numerator (ie, the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator.
4. If the measure does not have exceptions, STOP. If the measure does have exceptions, proceed with the following steps. From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator exception, when exceptions have been specified. If the patient meets any exception criteria, they should be removed from the denominator for performance calculation. Although the exception cases are removed from the denominator population for the performance calculation, the number of patients with valid exceptions should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI. If the patient does not meet the numerator and a valid exception is not present, this case represents a quality failure.


**Copyright/Disclaimer**

Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance ImprovementTM (the Consortium), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.

Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or
**0383 Oncology: Plan of Care for Pain – Medical Oncology and Radiation Oncology (paired with 0384)**

Distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

THE MEASURES ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND © 2007 American Medical Association. All Rights Reserved

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

THE SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.

See copyright statement above.

<table>
<thead>
<tr>
<th>0384 Oncology: Pain Intensity Quantified – Medical Oncology and Radiation Oncology (paired with 0383)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status</strong></td>
</tr>
<tr>
<td><strong>Steward</strong></td>
</tr>
<tr>
<td><strong>Description</strong></td>
</tr>
<tr>
<td><strong>Type</strong></td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
</tr>
<tr>
<td><strong>Level</strong></td>
</tr>
<tr>
<td><strong>Setting</strong></td>
</tr>
</tbody>
</table>
| **Numerator Statement** | Patient visits in which pain intensity is quantified*  
* Pain intensity should be quantified using a standard instrument, such as a 0-10 numerical rating scale, a categorical scale, or the pictorial scale |
| **Numerator Details** | Time Window: At each visit within the measurement period  
For EHR:  
eSpecification and eMeasure are currently under development (expected completion: end of Q1 2012). Data elements (using Quality Data Model) required for the measure attached (please refer to Appendix A).  
For Claims/Administrative Data:  
To submit the numerator option for number of patient visits in which pain intensity was quantified, report one of the following CPT Category II codes:  
1125F – Pain severity quantified; pain present  
OR  
1126F – Pain severity quantified; no pain present |
| **Denominator Statement** | All visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy |
| **Denominator Details** | Time Window: 12 consecutive months  
For EHR:  
eSpecification and eMeasure are currently under development (expected completion: end of Q1 2012). Data elements (using Quality Data Model) required for the measure attached (please refer to Appendix A).  
For Claims/Administrative Data:  
All visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy |

NQF VOTING DRAFT—DO NOT CITE OR QUOTE
NQF MEMBER votes are due June 26, 2012 by 6:00 PM ET

A-19
## 0384 Oncology: Pain Intensity Quantified – Medical Oncology and Radiation Oncology (paired with 0383)

**therapy**

Eligible patients for this measure are identified by:

**ICD-9-CM diagnosis codes:**

PLEASE REFER TO ATTACHED EXCEL FILE TITLED, APPENDIX A, FOR THE APPLICABLE ICD-9-CM CODES

**ICD-10-CM diagnosis codes:**

PLEASE REFER TO ATTACHED EXCEL FILE TITLED, APPENDIX A, FOR THE APPLICABLE ICD-10-CM CODES

AND either option 1 or 2

1. Chemotherapy
   - CPT codes:
     - 99201, 99202, 99203, 99204, 99205,
     - 99212, 99213, 99214, 99215
     AND
     - CPT procedure codes: 51720, 96401, 96402, 96405, 96409, 96411, 96413, 96415, 96416, 96417, 96420, 96422, 96423, 96425, 96440, 96445, 96450, 96521, 96522, 96523, 96542, 96549 (chemotherapy administration)
   OR

2. Radiation therapy
   - CPT codes for radiation treatment weekly management: 77427, 77431, 77432, 77435, 77470

**Exclusions**

None

**Exclusion Details**

There are no exceptions for this measure.

**Risk Adjustment**

No risk adjustment or risk stratification

**Stratification**

We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

**Type Score**

Rate/proportion  better quality = higher score

**Algorithm**

To calculate performance rates:

1) Find the patients who meet the initial patient population (ie, the general group of patients that the performance measure is designed to address).

2) From the patients within the initial patient population criteria, find the patients who qualify for the denominator (ie, the specific group of patients for inclusion in a specific performance measure based on defined criteria).

   Note: in some cases the initial patient population and denominator are identical.

3) From the patients within the denominator, find the patients who qualify for the Numerator (ie, the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator

4) If the measure does not have exceptions, STOP. If the measure does have exceptions, proceed with the following steps. From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator exception, when exceptions have been specified. If the patient meets any exception criteria, they should be removed from the denominator for performance calculation. Although the exception cases are removed from the denominator population for the performance calculation, the number of patients with valid exceptions should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI.

   If the patient does not meet the numerator and a valid exception is not present, this case represents a quality failure.


**Copyright/Disclaimer**

Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance ImprovementTM (the Consortium), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not
0384 Oncology: Pain Intensity Quantified – Medical Oncology and Radiation Oncology (paired with 0383)

tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures. Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

THE MEASURES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND

© 2007 American Medical Association. All Rights Reserved

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

THE SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.

See copyright statement above.

0386 Oncology: Cancer Stage Documented


Steward American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI) Other organizations: This measure is jointly copyrighted by the AMA-PCPI and American Society of Clinical Oncology. The measure set was also developed in collaboration with the American Society for Radiation Oncology.

Description Percentage of patients, regardless of age, with a diagnosis of breast, colon, or rectal cancer who are seen in the ambulatory setting who have a baseline AJCC cancer stage or documentation that the cancer is metastatic in the medical record at least once during the 12 month reporting period

Type Process

Data Source Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Pharmacy, Paper Records Not Applicable

Attachment Data_Elements_0386.xls

Level Clinician : Group/Practice, Clinician : Individual, Clinician : Team

Setting Ambulatory Care : Clinician Office, Other Oncology/Outpatient Clinic;

Numerator Statement Patients who have a baseline AJCC cancer stage* or documentation that the cancer is metastatic in the medical record at least once during the 12 month reporting period

Numerator Instructions: *Cancer stage refers to stage at diagnosis

Numerator Details Time Window: At least once during the measurement period

For EHR:
eSpecification currently under development. Data elements (using the Quality Data Model) required for the measure attached.

For Claims/Administrative Data:
To submit the numerator option for patients who have a baseline AJCC cancer stage or documentation that the cancer is metastatic in the medical record at least once during the 12 month reporting period, report one of the following CPT Category II codes:
3300F – American Joint Committee on Cancer (AJCC) stage documented and reviewed
OR
3301F – Cancer stage documented in medical record as metastatic and reviewed

Denominator Statement All patients, regardless of age, with a diagnosis of breast, colon, or rectal cancer who are seen in the ambulatory setting
### 0386 Oncology: Cancer Stage Documented

#### Denominator Details
- **Time Window:** 12 consecutive months
- For EHR:
  - eSpecification currently under development. Data elements (using the Quality Data Model) required for the measure attached.
- For Claims/Administrative Data:
  - All patients, regardless of age, with a diagnosis of breast, colon, or rectal cancer who are seen in the ambulatory setting
  - AND
- AND either option 1 or 2
  1. Chemotherapy
     - CPT codes:
       - 99201, 99202, 99203, 99204, 99205,
       - 99212, 99213, 99214, 99215,
       - 99241, 99242, 99243, 99244, 99245,
       - 99024
  2. Radiation therapy
     - CPT codes for radiation treatment planning: 77261, 77262, 77263

#### Exclusions
- None
- Exclusion Details: There are no exceptions for this measure.

#### Risk Adjustment
- No risk adjustment or risk stratification
- None

#### Stratification
- We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

#### Type Score
- Rate/proportion: better quality = higher score

#### Algorithm
- To calculate performance rates:
  1) Find the patients who meet the initial patient population (ie, the general group of patients that the performance measure is designed to address).
  2) From the patients within the initial patient population criteria, find the patients who qualify for the denominator (ie, the specific group of patients for inclusion in a specific performance measure based on defined criteria).
  - Note: in some cases the initial patient population and denominator are identical.
  3) From the patients within the denominator, find the patients who qualify for the Numerator (ie, the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator.
  4) If the measure does not have exceptions, STOP. If the measure does have exceptions, proceed with the following steps. From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator exception, when exceptions have been specified. If the patient meets any exception criteria, they should be removed from the denominator for performance calculation. Although the exception cases are removed from the denominator population for the performance calculation, the number of patients with valid exceptions should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI.
  - If the patient does not meet the numerator and a valid exception is not present, this case represents a quality failure.
<table>
<thead>
<tr>
<th>0386 Oncology: Cancer Stage Documented</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Copyright/Disclaimer</strong></td>
</tr>
<tr>
<td>Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement® (the Consortium), are intended to facilitate quality improvement activities by physicians. These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures. Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures. THE MEASURES ARE PROVIDED &quot;AS IS&quot; WITHOUT WARRANTY OF ANY KIND. © 2007 American Medical Association and American Society of Clinical Oncology. All Rights Reserved. CPT® Copyright 2006 American Medical Association. Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications. THE SPECIFICATIONS ARE PROVIDED &quot;AS IS&quot; WITHOUT WARRANTY OF ANY KIND. CPT® contained in the Measures specifications is copyright 2006 American Medical Association. See copyright statement above.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>0389 Prostate Cancer: Avoidance of Overuse Measure – Bone Scan for Staging Low-Risk Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status</strong></td>
</tr>
<tr>
<td><strong>Steward</strong></td>
</tr>
<tr>
<td>American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI) Other organizations: American Urological Association and American Society for Therapeutic Radiology &amp; Oncology</td>
</tr>
<tr>
<td><strong>Description</strong></td>
</tr>
<tr>
<td>Percentage of patients, regardless of age, with a diagnosis of prostate cancer, at low risk of recurrence, receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer</td>
</tr>
<tr>
<td><strong>Type</strong></td>
</tr>
<tr>
<td>Process</td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
</tr>
<tr>
<td>Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Registry, Paper Records Not applicable.</td>
</tr>
<tr>
<td><strong>Level</strong></td>
</tr>
<tr>
<td>Clinician : Group/Practice, Clinician : Individual, Clinician : Team</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
</tr>
<tr>
<td>Ambulatory Care : Ambulatory Surgery Center (ASC), Ambulatory Care : Clinician Office, Other Radiation Oncology Clinic/Department</td>
</tr>
<tr>
<td><strong>Numerator Statement</strong></td>
</tr>
<tr>
<td>Patients who did not have a bone scan performed at any time since diagnosis of prostate cancer</td>
</tr>
<tr>
<td><strong>Numerator Details</strong></td>
</tr>
<tr>
<td>Time Window: Once for each procedure for treatment of prostate cancer (i.e., interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy) For EHR: See attached eMeasure For Claims/Administrative Data: To submit the numerator option for patients who did not have a bone scan performed at any time since diagnosis</td>
</tr>
<tr>
<td>0389 Prostate Cancer: Avoidance of Overuse Measure – Bone Scan for Staging Low-Risk Patients</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>of prostate cancer, report the following CPT Category II code: 3270F – Bone scan not performed prior to initiation of treatment nor at any time since diagnosis of prostate cancer</td>
</tr>
</tbody>
</table>

| Denominator Statement | All patients, regardless of age, with a diagnosis of prostate cancer, at low risk* of recurrence, receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy |

| Denominator Details | Time Window: Each procedure for treatment of prostate cancer (i.e., interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy) |

<table>
<thead>
<tr>
<th>Risk strata definitions:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Low Risk: PSA =10 mg/dL; AND Gleason score 6 or less; AND clinical stage T1c or T2a</td>
</tr>
<tr>
<td>• Intermediate Risk: PSA &gt;10 to 20 mg/dL; OR Gleason score 7; OR clinical stage T2b, and not qualifying for high risk2</td>
</tr>
<tr>
<td>• High Risk: PSA &gt; 20 mg/dL; OR Gleason score 8 to 10; OR clinical stage T2c or greater; and not qualifying for very high risk2</td>
</tr>
</tbody>
</table>

Note: Only patients with prostate cancer with low risk of recurrence will be counted in the denominator of this measure.

For EHR:
See attached eMeasure.

For Claims/Administrative Data:
All patients with a diagnosis of prostate cancer, at low risk of recurrence, receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy
ICD-9-CM diagnosis code: 185
ICD-10-CM diagnosis code: C61
AND
CPT codes: 55810, 55812, 55815 (perineal prostatectomies); 55840, 55842, 55845 (retropubic prostatectomies); 55866 (laparoscopic prostatectomy); 55873 (cryotherapy); 77427 (radiation treatment management); 77776, 77777, 77778, 77787 (brachytherapy)
AND
Report the following CPT Category II Code to identify the risk of recurrence:
• 3271F – Low risk of recurrence, prostate cancer

Exclusions Documentation of medical reason(s) for having a bone scan performed (including documented pain, salvage therapy, other medical reasons)
Document the system reason(s) for having a bone scan performed (including bone scan ordered by someone other than reporting physician)

Exclusion Details The PCPI methodology uses three categories of reasons for which a patient may be excluded from the denominator of an individual measure. These measure exception categories are not uniformly relevant across all measures; for each measure, there must be a clear rationale to permit an exception for a medical, patient, or system reason. Examples are provided in the measure exception language of instances that may constitute an exception and are intended to serve as a guide to clinicians. For this measure, exceptions may include medical reason(s) for having a bone scan performed (e.g., documented pain, salvage therapy, other medical reasons) or system reason(s) for having a bone scan performed (e.g., bone scan ordered by someone other than reporting physician). Where examples of exceptions are included in the measure language, these examples are coded and included in the eSpecifications. Although this methodology does not require the external reporting of more detailed exception data, the PCPI recommends that physicians document the specific reasons for exception in patients’ medical records for purposes of optimal patient management and audit-readiness. The PCPI also advocates the systematic review and analysis of each physician’s exceptions data to identify practice patterns and opportunities for quality improvement. For example, it is possible for implementers to calculate the percentage of patients that physicians have identified as meeting the criteria for exception. Additional details by data source are as follows:
For EHR:
See attached eMeasure.
**0389 Prostate Cancer: Avoidance of Overuse Measure – Bone Scan for Staging Low-Risk Patients**

<table>
<thead>
<tr>
<th>For Claims/Administrative Data:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Documentation of medical reason(s) for having a bone scan performed (including documented pain, salvage therapy, other medical reasons)</td>
<td>Append modifier to CPT Category II code: 3269F-1P – Bone scan performed prior to initiation of treatment or at any time since diagnosis of prostate cancer (including documented pain, salvage therapy, other medical reasons)</td>
</tr>
<tr>
<td>Documentation of system reason(s) for having a bone scan performed (including bone scan ordered by someone other than reporting physician)</td>
<td>Append modifier to CPT Category II code: 3269F-3P – Bone scan performed prior to initiation of treatment or at any time since diagnosis of prostate cancer (including bone scan ordered by someone other than reporting physician)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Risk Adjustment</th>
<th>No risk adjustment or risk stratification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stratification</td>
<td>We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Type Score</th>
<th>Rate/proportion better quality = higher score</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Algorithm</th>
<th>For measures with exceptions:</th>
</tr>
</thead>
<tbody>
<tr>
<td>To calculate performance rates:</td>
<td></td>
</tr>
<tr>
<td>1) Find the patients who meet the initial patient population (ie, the general group of patients that the performance measure is designed to address).</td>
<td></td>
</tr>
<tr>
<td>2) From the patients within the initial patient population criteria, find the patients who qualify for the denominator (ie, the specific group of patients for inclusion in a specific performance measure based on defined criteria). Note: in some cases the initial patient population and denominator are identical.</td>
<td></td>
</tr>
<tr>
<td>3) From the patients within the denominator, find the patients who qualify for the Numerator (ie, the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator</td>
<td></td>
</tr>
<tr>
<td>4) From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator exception when exceptions have been specified [for this measure: medical reason(s) (eg, documented pain, salvage therapy, other medical reasons) or system reason(s) (eg, bone scan ordered by someone other than reporting physician)]. If the patient meets any exception criteria, they should be removed from the denominator for performance calculation. --Although the exception cases are removed from the denominator population for the performance calculation, the number of patients with valid exceptions should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI.</td>
<td></td>
</tr>
<tr>
<td>If the patient does not meet the numerator and a valid exception is not present, this case represents a quality failure. Attachment Measure Calculation_0389.pdf</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Copyright/Disclaimer</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance ImprovementTM (the Consortium), are intended to facilitate quality improvement activities by physicians. These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures. Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures. THE MEASURES ARE PROVIDED &quot;AS IS&quot; WITHOUT WARRANTY OF ANY KIND</td>
<td></td>
</tr>
</tbody>
</table>

**NATIONAL QUALITY FORUM**

**NQF VOTING DRAFT—DO NOT CITE OR QUOTE**

**NQF MEMBER votes are due June 26, 2012 by 6:00 PM ET**

A-25
### 0389 Prostate Cancer: Avoidance of Overuse Measure – Bone Scan for Staging Low-Risk Patients

| © 2007 American Medical Association. All Rights Reserved |
| Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications. |
| THE SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND. |

### 0390 Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Patients

| Steward | American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI) Other organizations: American Urological Association and American Society for Therapeutic Radiology & Oncology |
| Description | Percentage of patients, regardless of age, with a diagnosis of prostate cancer, at high risk of recurrence, receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH agonist or antagonist) |
| Type | Process |
| Data Source | Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Registry, Paper Records Not applicable |
| Attachment | NQF_0390_DataElements.xls |
| Level | Clinician : Group/Practice, Clinician : Individual, Clinician : Team |
| Setting | Ambulatory Care : Ambulatory Surgery Center (ASC), Ambulatory Care : Clinician Office, Other Radiation Oncology Clinic/Department |
| Numerator Statement | Patients who were prescribed adjuvant hormonal therapy (GnRH [gonadotropin-releasing hormone] agonist or antagonist) |
| Numerator Details | Time Window: Once for each procedure for treatment of prostate cancer (i.e., external beam radiotherapy to the prostate) |
| For EHR: | eSpecification currently under development. Data elements (using the Quality Data Model) required for the measure attached. |
| For Claims/Administrative Data: | To submit the numerator option for patients who were prescribed adjuvant hormonal therapy (GnRH agonist or antagonist), report the following CPT Category II code: 4164F – Adjuvant (ie, in combination with external beam radiotherapy to the prostate for prostate cancer) hormonal therapy (GnRH [gonadotropin-releasing hormone] agonist or antagonist) prescribed/administered |
| Denominator Statement | All patients, regardless of age, with a diagnosis of prostate cancer, at high risk of recurrence, receiving external beam radiotherapy to the prostate |
| Denominator Details | Time Window: Each procedure for treatment of prostate cancer (i.e., external beam radiotherapy to the prostate) |
| Risk strata definition: | High Risk: PSA > 20 mg/dL; OR Gleason score 8 to 10; OR clinically localized stage T3a1 |
| For EHR: | eSpecification currently under development. Data elements (using the Quality Data Model) required for the measure attached. |
| For Claims/Administrative Data: | All patients with a diagnosis of prostate cancer, at high risk of recurrence receiving external beam radiotherapy to the prostate |
| ICD-9-CM diagnosis code: | 185 |
| ICD-10-CM diagnosis code: | C61 AND |
Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Patients

CPT code: 77427 (radiation treatment management)
AND
Report the following CPT Category II code to identify the risk of recurrence:
• 3273F – High risk of recurrence, prostate cancer

Exclusions
Documentation of medical reason(s) for not prescribing adjuvant hormonal therapy (eg, salvage therapy)
Documentation of patient reason(s) for not prescribing adjuvant hormonal therapy

Exclusion Details
The PCPI methodology uses three categories of reasons for which a patient may be excluded from the denominator of an individual measure. These measure exception categories are not uniformly relevant across all measures; for each measure, there must be a clear rationale to permit an exception for a medical, patient, or system reason. Examples are provided in the measure exception language of instances that may constitute an exception and are intended to serve as a guide to clinicians. For this measure, exceptions may include medical reason(s) for not prescribing adjuvant hormonal therapy (eg, salvage therapy) or patient reason(s). Where examples of exceptions are included in the measure language, these examples are coded and included in the eSpecifications. Although this methodology does not require the external reporting of more detailed exception data, the PCPI recommends that physicians document the specific reasons for exception in patients' medical records for purposes of optimal patient management and audit-readiness. The PCPI also advocates the systematic review and analysis of each physician's exceptions data to identify practice patterns and opportunities for quality improvement. For example, it is possible for implementers to calculate the percentage of patients that physicians have identified as meeting the criteria for exception. Additional details by data source are as follows:

For EHR:
eSpecification currently under development. Data elements (using the Quality Data Model) required for the measure attached.
For Claims/Administrative Data:
Documentation of medical reason(s) for not prescribing adjuvant hormonal therapy (eg, salvage therapy)
Append modifier to CPT Category II code: 4164F-1P
Documentation of patient reason(s) for not prescribing adjuvant hormonal therapy
Append modifier to CPT Category II code: 4164F-2P

Risk Adjustment
No risk adjustment or risk stratification
Not applicable

Stratification
We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

Type Score
Rate/proportion better quality = higher score

Algorithm
To calculate performance rates:
1) Find the patients who meet the initial patient population (ie, the general group of patients that the performance measure is designed to address).
2) From the patients within the initial patient population criteria, find the patients who qualify for the denominator (ie, the specific group of patients for inclusion in a specific performance measure based on defined criteria). Note: in some cases the initial patient population and denominator are identical.
3) From the patients within the denominator, find the patients who qualify for the Numerator (ie, the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator.
4) From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator exception when exceptions have been specified (for this measure: medical reason(s) for not prescribing adjuvant hormonal therapy (eg, salvage therapy) or patient reason(s)). If the patient meets any exception criteria, they should be removed from the denominator for performance calculation. --Although the exception cases are removed from the denominator population for the performance calculation, the number of patients with valid exceptions should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI.
If the patient does not meet the numerator and a valid exception is not present, this case represents a quality failure. Attachment Measure Calculation_0390.pdf

Copyright/Physician Performance Measures (Measures) and related data specifications, developed by the Physician Performance Improvement Program (PCPI)
### 0930 Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Patients

**Disclaimer**

Consortium for Performance Improvement™ (the Consortium), are intended to facilitate quality improvement activities by physicians. These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.

Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

THE MEASURES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND

© 2007 American Medical Association. All Rights Reserved

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

THE SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.

### 0562 Overutilization of Imaging Studies in Melanoma

**Status**

Time-limited

**Steward**

American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)  
Other organizations: American Academy of Dermatology and National Committee for Quality Assurance

**Description**

Percentage of patients, regardless of age, with a current diagnosis of stage 0 through IIC melanoma or a history of melanoma of any stage, without signs or symptoms suggesting systemic spread, seen for an office visit during the one-year measurement period

**Type**

Process

**Data Source**

Not Applicable

Attachment AMA-PCPI_0562_MEL.OveruseImaging_DATAELEMENTS 562.pdf

**Level**

Clinician: Group/Practice, Clinician: Individual, Clinician: Team

**Setting**

Ambulatory Care: Clinician Office

**Numerator Statement**

Patients for whom no diagnostic imaging studies* were ordered

**Numerator Details**

Time Window: Once during measurement period

**Numerator Definition:**

*Diagnostic imaging studies include CXR, CT, Ultrasound, MRI, PET, and nuclear medicine scans. Ordering any of these imaging studies during the one year measurement period is considered a failure of the measure, unless a justified reason is documented through use of a medical or system reason for exception.

For EHR:
<table>
<thead>
<tr>
<th>0562 Overutilization of Imaging Studies in Melanoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>eSpecification and eMeasure are currently under development (expected completion end of Q1 2012). Data Elements (using Quality Data Model) required for the measure are attached.</td>
</tr>
<tr>
<td>For Claims/Administrative: Report CPT Category II Code: 3320F - None of the following diagnostic imaging studies ordered: chest x-ray, CT, ultrasound, MRI, PET, and nuclear medicine scans</td>
</tr>
<tr>
<td>Denominator Statement</td>
</tr>
<tr>
<td>Denominator Details</td>
</tr>
<tr>
<td>Denominator Definitions:</td>
</tr>
<tr>
<td>Denominator Definitions:</td>
</tr>
<tr>
<td>Denominator Definitions:</td>
</tr>
<tr>
<td>Denominator Definitions:</td>
</tr>
<tr>
<td>Exclusions</td>
</tr>
</tbody>
</table>
| **Exclusion Details** | The PCPI methodology uses three categories of reasons for which a patient may be excluded from the denominator of an individual measure. These measure exception categories are not uniformly relevant across all measures; for each measure, there must be a clear rationale to permit an exception for a medical, patient, or system reason. Examples are provided in the measure exception language of instances that may constitute an exception and are intended to serve as a guide to clinicians. For this measure, exceptions may include medical reason(s) (e.g., patient has comorbid condition that warrants imaging, other medical reasons) or system reason(s) for ordering diagnostic imaging studies (e.g., requirement for clinical trial enrollment, ordered by another provider, other system reasons). Where examples of exceptions are included in the measure language, these examples are coded and included in the eSpecifications. Although this methodology does not require the external reporting of more detailed exception data, the PCPI recommends that physicians document the specific reasons for exception in patients' medical records for purposes of optimal patient management and audit-readiness. The PCPI also advocates the systematic review and analysis of each physician’s exceptions data to identify practice patterns and opportunities for quality improvement. For example, it is possible for implementers to calculate the percentage of patients that physicians have identified as meeting the criteria for exception. Additional details by data source are as follows: 

**For EHR:**

- eSpecification and eMeasure are currently under development (expected completion end of Q1 2012).
- Data Elements (using Quality Data Model) required for the measure are attached.

**For Claims/Administrative:**

- The CPT Category II Code below is reported when diagnostic imaging study(ies) are performed (failure of measure).
- 3319F - 1 of the following diagnostic imaging studies ordered; chest x-ray, CT, ultrasound, MRI, PET, or nuclear medicine scans
- When there is a valid medical reason documented for ordering diagnostic imaging studies
  - Append modifier to CPT Category II code: 3319F-1P
- When there is a valid system reason documented for ordering diagnostic imaging studies
  - Append modifier to CPT Category II code: 3319F-3P

---

<table>
<thead>
<tr>
<th><strong>Risk Adjustment</strong></th>
<th>No risk adjustment or risk stratification</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No risk adjustment or risk stratification.</td>
</tr>
</tbody>
</table>

| **Stratification** | We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected. |

| **Type Score** | Rate/proportion  
better quality = higher score |

| **Algorithm** | To calculate performance rates:

1) Find the patients who meet the initial patient population (i.e., the general group of patients that the performance measure is designed to address).

2) From the patients within the initial patient population criteria, find the patients who qualify for the denominator (i.e., the specific group of patients for inclusion in a specific performance measure based on defined criteria). Note: in some cases the initial patient population and denominator are identical.

3) From the patients within the denominator, find the patients who qualify for the Numerator (i.e., the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator.
### 0562 Overutilization of Imaging Studies in Melanoma

<table>
<thead>
<tr>
<th>Step</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>4)</td>
<td>From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator exception when exceptions have been specified [for this measure: medical reason(s) (eg, patient has comorbid condition that warrants imaging, other medical reasons), or system reason(s) (eg, requirement for clinical trial enrollment, ordered by another provider, other system reasons)]. If the patient meets any exception criteria, they should be removed from the denominator for performance calculation. Although the exception cases are removed from the denominator population for the performance calculation, the number of patients with valid exceptions should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI. If the patient does not meet the numerator and a valid exception is not present, this case represents a quality failure. Attachment AMA-PCPI_Measure Calculation-Standard Measures 562.pdf</td>
</tr>
</tbody>
</table>

### 0650 Melanoma Continuity of Care – Recall System

<table>
<thead>
<tr>
<th>Field</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Status</td>
<td>Maintenance, Original Endorsement: May 05, 2010, Most Recent Endorsement: May 05, 2010</td>
</tr>
<tr>
<td>Steward</td>
<td>American Medical Association - Physician Consortium for Performance Improvement® (PCPI™) Other organizations: American Academy of Dermatology and National Committee for Quality Assurance</td>
</tr>
<tr>
<td>Description</td>
<td>Percentage of patients, regardless of age, with a current diagnosis of melanoma or a history of melanoma whose information was entered, at least once within a 12 month reporting period into a recall system that includes: A target date for the next complete physical skin exam, AND A process to follow up with patients who either did not make an appointment within the specified timeframe or who missed a scheduled appointment</td>
</tr>
<tr>
<td>Type</td>
<td>Structure</td>
</tr>
<tr>
<td>Data Source</td>
<td>Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Registry, Other, Paper Records Not Applicable</td>
</tr>
<tr>
<td>Level</td>
<td>Clinician : Group/Practice, Clinician : Individual, Clinician : Team</td>
</tr>
<tr>
<td>Setting</td>
<td>Ambulatory Care : Clinician Office</td>
</tr>
<tr>
<td>Numerator Statement</td>
<td>Patients whose information is entered, at least once within a 12 month period, into a recall system that includes: A target date for the next complete physical skin exam, AND A process to follow up with patients who either did not make an appointment within the specified timeframe or who missed a scheduled appointment</td>
</tr>
<tr>
<td>Numerator Details</td>
<td>Time Window: At least once during measurement period</td>
</tr>
<tr>
<td>Numerator Instructions:</td>
<td></td>
</tr>
<tr>
<td>To satisfy this measure, the recall system must be linked to a process to notify patients when their next physical exam is due and to follow up with patients who either did not make an appointment within the specified timeframe or who missed a scheduled appointment and must include the following elements at a minimum; patient identifier, patient contact information, cancer diagnosis(es), date(s) of initial cancer diagnosis (if known), and the target date for the next complete physical exam. For Claims/Administrative: Report CPT Category II code: 7010F -- Patient information entered into a recall system with the target date for the next complete physical skin exam specified For EHR:</td>
<td></td>
</tr>
<tr>
<td>0650 Melanoma Continuity of Care – Recall System</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Denominator Statement</strong></td>
<td></td>
</tr>
<tr>
<td>All patients, regardless of age, with a current diagnosis of melanoma or a history of melanoma.</td>
<td></td>
</tr>
<tr>
<td><strong>Denominator Details</strong></td>
<td></td>
</tr>
<tr>
<td>Time Window: 12 consecutive months</td>
<td></td>
</tr>
<tr>
<td><strong>Exclusions</strong></td>
<td></td>
</tr>
<tr>
<td>Documentation of system reason(s) for not entering patients into a recall system (eg, melanoma being monitored by another physician provider)</td>
<td></td>
</tr>
<tr>
<td><strong>Exclusion Details</strong></td>
<td></td>
</tr>
<tr>
<td>The PCPI methodology uses three categories of reasons for which a patient may be excluded from the denominator of an individual measure. These measure exception categories are not uniformly relevant across all measures; for each measure, there must be a clear rationale to permit an exception for a medical, patient, or system reason. Examples are provided in the measure exception language of instances that may constitute an exception and are intended to serve as a guide to clinicians. For this measure, exceptions may include system reason(s) for not entering patients into a recall system (eg, melanoma being monitored by another physician provider). Where examples of exceptions are included in the measure language, these examples are coded and included in the eSpecifications. Although this methodology does not require the external reporting of more detailed exception data, the PCPI recommends that physicians document the specific reasons for exception in patients’ medical records for purposes of optimal patient management and audit-readiness. The PCPI also advocates the systematic review and analysis of each physician’s exceptions data to identify practice patterns and opportunities for quality improvement. For example, it is possible for implementers to calculate the percentage of patients that physicians have identified as meeting the criteria for exception. Additional details by data source are as follows:</td>
<td></td>
</tr>
<tr>
<td>For EHR:</td>
<td></td>
</tr>
<tr>
<td>This measure does not lend itself to a “traditional specification” for EHR reporting. This is a structural measure; each facility may have a different process or software system for tracking and transmitting recalls as well as different appointment tracking systems.</td>
<td></td>
</tr>
<tr>
<td>For Claims/Administrative:</td>
<td></td>
</tr>
<tr>
<td>Documentation of system reason exception</td>
<td></td>
</tr>
<tr>
<td>• Append modifier to CPT Category II code: 7010F-3P</td>
<td></td>
</tr>
<tr>
<td><strong>Risk Adjustment</strong></td>
<td></td>
</tr>
<tr>
<td>No risk adjustment or risk stratification</td>
<td></td>
</tr>
<tr>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td><strong>Stratification</strong></td>
<td></td>
</tr>
<tr>
<td>We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.</td>
<td></td>
</tr>
<tr>
<td><strong>Type Score</strong></td>
<td></td>
</tr>
<tr>
<td>Rate/proportion better quality = higher score</td>
<td></td>
</tr>
<tr>
<td><strong>Algorithm</strong></td>
<td></td>
</tr>
<tr>
<td>To calculate performance rates:</td>
<td></td>
</tr>
<tr>
<td>1) Find the patients who meet the initial patient population (ie, the general group of patients that the performance measure is designed to address).</td>
<td></td>
</tr>
<tr>
<td>2) From the patients within the initial patient population criteria, find the patients who qualify for the</td>
<td></td>
</tr>
</tbody>
</table>
denominator (ie, the specific group of patients for inclusion in a specific performance measure based on defined criteria). Note: in some cases the initial patient population and denominator are identical.

3) From the patients within the denominator, find the patients who qualify for the Numerator (ie, the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator

4) From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator exception when exceptions have been specified (for this measure: system reason(s) (eg, melanoma being monitored by another physician provider)). If the patient meets any exception criteria, they should be removed from the denominator for performance calculation. Although the exception cases are removed from the denominator population for the performance calculation, the number of patients with valid exceptions should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI.

If the patient does not meet the numerator and a valid exception is not present, this case represents a quality failure.

Attachment AMA-PCPI_Measure Calculation-Standard Measures650.pdf

Copyright/Disclaimer

Physician Performance Measures (Measures) and related data specifications, developed by the American Medical Association (AMA) in collaboration with the Physician Consortium for Performance Improvement (the Consortium) and the National Committee for Quality Assurance (NCQA) pursuant to government sponsorship under subcontract 6205-05-054 with Mathematica Policy Research, Inc. under contract 500-00-0033 with Centers for Medicare & Medicaid Services. These performance Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and the AMA, (on behalf of the Consortium) or NCQA. Neither the AMA, NCQA, Consortium nor its members shall be responsible for any use of the Measures.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND. © 2004-6 American Medical Association and National Committee for Quality Assurance. All Rights Reserved. Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, NCQA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications. CPT® contained in the Measures specifications is copyright 2005 American Medical Association.

1790 Risk-Adjusted Morbidity and Mortality for Lung Resection for Lung Cancer

Status New Submission

Steward Society of Thoracic Surgeons

Description Percentage of patients > 18 years of age undergoing elective lung resection (Open or VATS wedge resection, segmentectomy, lobectomy, bilobectomy, sleeve lobectomy, pneumonectomy) for lung cancer who developed any of the following postoperative complications: reintubation, need for tracheostomy, initial ventilator support > 48 hours, ARDS, pneumonia, pulmonary embolus, bronchopleural fistula, bleeding requiring reoperation,
<table>
<thead>
<tr>
<th><strong>1790 Risk-Adjusted Morbidity and Mortality for Lung Resection for Lung Cancer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>myocardial infarction or operative mortality.</strong></td>
</tr>
</tbody>
</table>

**Type**  
Outcome

**Data Source**  

**Level**  
Clinician : Group/Practice, Clinician : Team, Facility

**Setting**  
Hospital/Acute Care Facility

| **Numerator Statement** | Number of patients > 18 years of age undergoing elective lung resection for lung cancer who developed any of the following postoperative complications: reintubation, need for tracheostomy, initial ventilator support > 48 hours, ARDS, pneumonia, pulmonary embolus, bronchopleural fistula, bleeding requiring reoperation, myocardial infarction or operative mortality. |
|---|
| **Numerator Details** | Time Window: During hospitalization regardless of length of stay or within 30 days of surgery if discharged from the hospital. Number of patients undergoing elective lung resection for lung cancer for whom:  
1. Postoperative events (POEvents - STS GTS Database, v 2.2, sequence number 1710) is marked “Yes” and one of the following items is marked:  
a. Reintubation (Reintube - STS GTS Database, v 2.2, sequence number 1850)  
b. Need for tracheostomy (Trach - STS GTS Database, v 2.2, sequence number 1860)  
c. Initial ventilator support > 48 hours (Vent - STS GTS Database, v 2.2, sequence number 1840)  
d. Adult Respiratory Distress Syndrome (ARDS - STS GTS Database, v 2.2, sequence number 1790)  
e. Pneumonia (Pneumonia - STS GTS Database, v 2.2, sequence number 1780)  
f. Pulmonary Embolus (PE - STS GTS Database, v 2.2, sequence number 1820)  
g. Bronchopleural Fistula (Bronchopleural - STS GTS Database, v 2.2, sequence number 1810)  
h. Myocardial infarction (MI - STS GTS Database, v 2.2, sequence number 1900)  
Or  
2. Unexpected return to the operating room (ReturnOR - STS GTS Database, Version 2.2, sequence number 1720) is marked “yes” and primary reason for return to OR (ReturnORRsn – STS GTS Database, Version 2.2, sequence number 1730) is marked “bleeding”  
Or  
3. One of the following fields is marked “dead”  
a. Discharge status (MtDCStat - STS GTS Database, Version 2.2, sequence number 2200);  
b. Status at 30 days after surgery (Mt30Stat - STS GTS Database, Version 2.2, sequence number 2240) |

| **Denominator Statement** | Number of patients > 18 years of age undergoing elective lung resection for lung cancer. |
|---|
| **Denominator Details** | Time Window: 36 months  
1. Lung cancer (LungCancer - STS GTS Database, v 2.2, sequence number 830) is marked “yes” and Category of Disease – Primary (CategoryPrim - STS GTS Database, v 2.2, sequence number 1300) is marked as one of the following: (ICD-9, ICD-10)  
Lung cancer, main bronchus, carina (162.2, C34.00)  
Lung cancer, upper lobe (162.3, C34.10)  
Lung cancer, middle lobe (162.4, C34.2)  
Lung cancer, lower lobe (162.5, C34.30)  
Lung cancer, location unspecified (162.9, C34.90)  
2. Patient has lung cancer (as defined in #1 above) and primary procedure is one of the following CPT |
1790 Risk-Adjusted Morbidity and Mortality for Lung Resection for Lung Cancer

codes:
Thoracoscopy, surgical; with lobectomy (32663)
Thoracoscopy with therapeutic wedge resection (eg mass or nodule) initial, unilateral (3266X)
Thoracoscopy with therapeutic wedge resection (eg mass or nodule) each additional resection, ipsilateral (3266X1)
Thoracoscopy with diagnostic wedge resection followed by anatomic lung resection (3266X2)
Thoracoscopy with removal of a single lung segment (segmentectomy) (3268X4)
Thoracoscopy with removal of two lobes (bilobectomy) (3266X3)
Thoracoscopy with removal of lung, pneumonectomy (3266X5)
Thoracotomy with therapeutic wedge resection (eg mass nodule) initial (3250X)
Thoracotomy with therapeutic wedge resection (eg mass nodule) each additional resection, ipsilateral (+3250X1)
Thoracotomy with diagnostic wedge resection followed by anatomic lung resection (+3250X2)
Removal of lung, total pneumonectomy; (32440)
Removal of lung, sleeve (carinal) pneumonectomy (32442)
Removal of lung, total pneumonectomy; extrapleural (32445)
Removal of lung, single lobe (lobectomy) (32480)
Removal of lung, two lobes (bilobectomy) (32482)
Removal of lung, single segment (segmentectomy) (32484)
Removal of lung, sleeve lobectomy (32486)
Removal of lung, completion pneumonectomy (32488)
Resection of apical lung tumor (e.g., Pancoast tumor), including chest wall resection, without chest wall reconstruction(s) (32503)
Resection of apical lung tumor (e.g., Pancoast tumor), including chest wall resection, with chest wall reconstruction (32504)

3. Status of Operation (Status - STS General Thoracic Surgery Database, Version 2.2, sequence number 1420) is marked as “Elective”

4. Only analyze the first operation of the hospitalization meeting criteria 1-3

Exclusions
Emergency procedures

Risk Adjustment
Statistical risk model
Bayesian hierarchical modeling was used to assess the statistical reliability of hospital-specific standardized incidence ratio (SIR) estimates derived from the January 1, 2008 – December 31, 2010 STS data. All hospitals regardless of sample size were included.
Attachment Kozower et al.pdf

Stratification
n/a

Type Score
Rate/proportion better quality = lower score

Algorithm
Target population is patients 18 years of age or older undergoing elective lung resection for lung cancer. Emergency procedures were excluded. Outcome is occurrence of postoperative complications: reintubation, need for trachostomy, initial ventilator support > 48 hours, ARDS, pneumonia, pulmonary embolus, bronchopleural fistula, bleeding requiring reoperation, myocardial infarction or operative mortality. Analysis considered 22,677 patients with procedures between 01/01/2008 and 12/31/2010 (36 months). Risk adjustment was achieved with a Bayesian hierarchical model with composite of the above postoperative complications as the outcome. The measure score was estimated with this model. For additional information review risk model in attachment.

1822 External Beam Radiotherapy for Bone Metastases

Status New Submission Time-limited

Steward American Society for Radiation Oncology (ASTRO) Other organizations: None

Description This measure reports the percentage of patients, regardless of age, with a diagnosis of painful bone metastases and no history of previous radiation who receive external beam radiation therapy (EBRT) with an acceptable...
<table>
<thead>
<tr>
<th>Type</th>
<th>Process</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data Source</td>
<td>Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Paper Records The data sources for this measure include: Radiation oncologist consultation note, physician office progress note, radiation flow sheet, radiology report Attachment bone metastases DATA COLLECTION INSTRUMENT.docx Attachment DATA ELEMENTS.docx</td>
</tr>
<tr>
<td>Level</td>
<td>Clinician : Group/Practice, Clinician : Individual, Clinician : Team, Facility, Health Plan</td>
</tr>
<tr>
<td>Setting</td>
<td>Ambulatory Care : Clinician Office, Hospital/Acute Care Facility</td>
</tr>
<tr>
<td>Numerator Statement</td>
<td>All patients, regardless of age, with painful bone metastases, and no previous radiation to the same anatomic site who receive EBRT with any of the following recommended fractionation schemes: 30Gy/10fxns, 24Gy/6fxns, 20Gy/5fxns, 8Gy/1fxn.</td>
</tr>
<tr>
<td>Numerator Details</td>
<td>Time Window: Once per reporting period Bone metastases diagnosis (198.5- Secondary malignant neoplasm of bone and bone marrow) Use of EBRT (Therapeutic radiology treatment planning: CPT 77261; simple, CPT 77262; Intermediate, CPT 77263; complex)</td>
</tr>
<tr>
<td>Denominator Statement</td>
<td>All patients with painful bone metastases and no previous radiation to the same anatomic site who receive EBRT</td>
</tr>
<tr>
<td>Denominator Details</td>
<td>Time Window: Once per reporting period Bone metastases diagnosis (198.5- Secondary malignant neoplasm of bone and bone marrow) Use of EBRT (Therapeutic radiology treatment planning: CPT 77261; simple, CPT 77262; Intermediate, CPT 77263; complex)</td>
</tr>
<tr>
<td>Exclusions</td>
<td>The medical reasons for denominator exclusions are: 1) Previous radiation treatment to the same anatomic site; 2) Patients with femoral axis cortical involvement greater than 3 cm in length; 3) Patients who have undergone a surgical stabilization procedure; and 4) Patients with spinal cord compression, cauda equina compression or radicular pain</td>
</tr>
<tr>
<td>Exclusion Details</td>
<td>A. Medical Reasons (Data Source) 1) Previous radiation treatment to the same anatomic site (Medical Record) 2) Patients with femoral axis cortical involvement greater than 3 cm in length(Imaging Studies) 3) Patients who have undergone a surgical stabilization procedure (Operative Report) 4) Patients with spinal cord compression, cauda equina compression or radicular pain (Diagnosis/Problem list)</td>
</tr>
<tr>
<td>Risk Adjustment</td>
<td>No risk adjustment or risk stratification Not applicable</td>
</tr>
<tr>
<td>Stratification</td>
<td>Stratification of the measure is not required.</td>
</tr>
<tr>
<td>Type Score</td>
<td>Rate/proportion better quality = higher score</td>
</tr>
<tr>
<td>Algorithm</td>
<td>Denominator Calculation Step 1: Identify patients with: (a) diagnosis of bone metastases and (b) a prescription for EBRT Step 2: Identify patients with no history of previous radiation therapy to the same anatomic site Step 3: Identify patients with specified exceptions and exclude from denominator calculation Numerator Calculation: Step 1: Identify patients with: (a) diagnosis of bone metastases and (b) a prescription for EBRT Step 2: Identify patients prescribed with one of the recommended fractionation schemes: 30Gy/10fxns or 24Gy/6fxns or 20Gy/5fxns or 8Gy/1fxn</td>
</tr>
<tr>
<td>Measure ID</td>
<td>Measure Title</td>
</tr>
<tr>
<td>1853</td>
<td>Radical Prostatectomy Pathology Reporting</td>
</tr>
<tr>
<td>1854</td>
<td>Barrett’s Esophagus</td>
</tr>
<tr>
<td><strong>Type</strong></td>
<td>Process</td>
</tr>
<tr>
<td>----------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
<td>Administrative claims, Other, Paper Records Medical records/pathology report/Claims forms</td>
</tr>
<tr>
<td><strong>Level</strong></td>
<td>Clinician : Group/Practice, Clinician : Individual</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Laboratory</td>
</tr>
<tr>
<td><strong>Numerator Statement</strong></td>
<td>Numerator: Esophageal biopsy reports with the histologic finding of Barrett's mucosa that contain a statement about dysplasia (present, absent, or indefinite; and if present, contains appropriate grading.) 3125F Esophageal biopsy report with a statement about dysplasia (present, absent, or indefinite)</td>
</tr>
<tr>
<td><strong>Numerator Details</strong></td>
<td>Time Window: Report once per patient per date of service</td>
</tr>
<tr>
<td></td>
<td>Numerator: Esophageal biopsy reports with the histologic finding of Barrett's mucosa that contain a statement about dysplasia (present, absent, or indefinite; and if present, contains appropriate grading.) 3125F Esophageal biopsy report with a statement about dysplasia (present, absent, or indefinite)</td>
</tr>
<tr>
<td><strong>Denominator Statement</strong></td>
<td>Denominator (Eligible Population): All esophageal biopsy reports that document the presence of Barrett's mucosa. CPT codes: • 88305 Level IV – Surgical pathology, gross and microscopic examination AND ICD-9 codes: • 530.85 Barrett's esophagus</td>
</tr>
<tr>
<td><strong>Denominator Details</strong></td>
<td>Time Window: Once per patient per date of service; time period not specified in the measure and can be determined by the program (typically one year.)</td>
</tr>
<tr>
<td></td>
<td>The pathology report is needed as well as access to correct coding of claims to identify patients: CPT codes: • 88305 Level IV – Surgical pathology, gross and microscopic examination AND ICD-9 codes: • 530.85 Barrett's esophagus</td>
</tr>
<tr>
<td><strong>Exclusions</strong></td>
<td>Documentation of medical reason for not reporting the histologic finding of Barrett's mucosa (eg, malignant neoplasm or absence of intestinal metaplasia).</td>
</tr>
<tr>
<td><strong>Exclusion Details</strong></td>
<td>Documentation of medical reason for not reporting the histologic finding of Barrett's mucosa (eg, malignant neoplasm or absence of intestinal metaplasia). [For patient with appropriate exclusion criteria, report 3125F with modifier 1P]</td>
</tr>
<tr>
<td><strong>Risk Adjustment</strong></td>
<td>No risk adjustment or risk stratification</td>
</tr>
<tr>
<td><strong>Stratification</strong></td>
<td>Not applicable</td>
</tr>
<tr>
<td><strong>Type Score</strong></td>
<td>Rate/proportion better quality = higher score</td>
</tr>
<tr>
<td><strong>Algorithm</strong></td>
<td>Performance Measure: 3125F/CPT codes 88305 and ICD-9 codes 530.85</td>
</tr>
</tbody>
</table>
| **Copyright/Disclaimer** | © 2007 College of American Pathologists. All Rights Reserved Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The College of American Pathologists disclaims all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.
APPENDIX B: STEERING COMMITTEE and NQF STAFF

STEERING COMMITTEE

Stephen Lutz, MD (Chair)
Blanchard Valley Regional Cancer Center, Findlay, OH

Joseph Alvarnas, MD
City of Hope, Duarte, CA

Eduardo Bruera, MD, FAAHPM
The University of Texas MD Anderson Cancer Center, Houston, TX

Elaine Chottiner, MD
University of Michigan Medical Center, Ann Arbor, MI

William Dale, MD, PhD
The University of Chicago Medical Center, Chicago, IL

Heidi Donovan, PhD, RN
University of Pittsburgh School of Nursing, Pittsburgh, PA

Karen Fields, MD
Moffitt Cancer Center, Tampa, FL

John Gore, MD, MS
University of Washington School of Medicine, Seattle, WA

Elizabeth Hammond, MD
Intermountain Healthcare, Salt Lake City, UT

Joseph Laver, MD, MHA
St. Jude Children’s Research Hospital, Memphis, TN

Jerod Loeb, PhD
The Joint Commission, Oakbrook Terrace, IL

Bryan Loy, MD, MBA
Humana Inc., Louisville, KY

Jennifer Malin, MD, PhD
WellPoint, Santa Monica, CA

Lawrence Marks, MD, FASTRO
University of North Carolina, School of Medicine, Chapel Hill, NC

Robert Miller, MD, FACP
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Lutherville, MD

NQF VOTING DRAFT—DO NOT CITE OR QUOTE
NQF MEMBER votes are due June 26, 2012 by 6:00 PM ET
Naomi Naierman, MPA
American Hospice Foundation, Washington, DC

David Pfister, MD
Memorial Sloan-Kettering Cancer Center, New York, NY

Rocco Ricciardi, MD, MPH
Lahey Clinic Medical Center, Burlington, MA

Patrick Ross, M.D., Phd
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital, Columbus, OH

Nicole Tapay, JD
National Coalition for Cancer Survivorship, Silver Spring, MD

Wendy Tenzyk
Colorado PERA, Denver, CO

NATIONAL QUALITY FORUM STAFF

Helen Burstin, MD, MPH
Senior Vice President, Performance Measures

Heidi Bossley, MSN, MBA
Vice President, Performance Measures

Angela Franklin, JD
Senior Director, Performance Measures

Lindsey Tighe, MS
Project Manager, Performance Measures

Adeela Khan, MPH
Project Analyst, Performance Measures

Eugene Cunningham, MS
Project Manager, Performance Measures
### Appendix C – RELATED MEASURE COMPARISON TABLE

<table>
<thead>
<tr>
<th>Steward</th>
<th>Description</th>
<th>Type</th>
<th>Data Source</th>
<th>Level</th>
<th>Setting</th>
<th>Numerator Statement</th>
<th>Numerator Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>RAND Corporation</td>
<td>Adult patients with advanced cancer who are screened for pain with a standardized quantitative tool at each outpatient visit</td>
<td>Process</td>
<td>Electronic Clinical Data, Electronic Clinical Data : Registry, Paper Records Patients were identified via the testing organizations’ cancer registries. At one institution, outpatient pain vital sign scores were extracted electronically from the patient EHR. At other institutions, quantitative pain scores were collected via medical record abstraction.</td>
<td>Facility, Health Plan, Integrated Delivery System</td>
<td>Ambulatory Care : Clinician Office</td>
<td>Outpatient visits from the denominator in which the patient was screened for pain (and if present, severity noted) with a quantitative standardized tool</td>
<td>Pain screening with a standardized quantitative tool during the primary care or cancer-related/specialty outpatient visit(s). Screening may be completed using verbal, numeric, visual analog, rating scales designed for use with nonverbal patients, or other standardized tools.</td>
</tr>
<tr>
<td>University of North Carolina-Chapel Hill</td>
<td>Percentage of hospice or palliative care patients who were screened for pain during the hospice admission evaluation / palliative care initial encounter.</td>
<td>Process</td>
<td>Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record Structured medical record abstraction tool with separate collection of numerator and denominator data values. URL PEACE Project Data Dictionary <a href="http://www.thecarolinascancer.org/default.aspx?pageid=46">http://www.thecarolinascancer.org/default.aspx?pageid=46</a> URL PEACE Project Data Dictionary <a href="http://www.thecarolinascancer.org/default.aspx?pageid=46">http://www.thecarolinascancer.org/default.aspx?pageid=46</a></td>
<td>Clinician : Group/Practice, Facility</td>
<td>Hospice, Hospital/Acute Care Facility</td>
<td>Patients who are screened for the presence or absence of pain (and if present, rating of its severity) using a standardized quantitative tool during the admission evaluation for hospice / initial encounter for palliative care.</td>
<td>Pain screening with a standardized quantitative tool during the primary care or cancer-related/specialty outpatient visit(s). Screening may be completed using verbal, numeric, visual analog, rating scales designed for use with nonverbal patients, or other standardized tools.</td>
</tr>
<tr>
<td>American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)</td>
<td>Percentage of visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified</td>
<td>Process</td>
<td>Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Registry, Other, Paper Records Not Applicable</td>
<td>Clinician : Group/Practice, Clinician : Individual, Clinician : Team</td>
<td>Ambulatory Care : Clinician Office, Other Oncology/Outpatient Clinic; Radiation Oncology Dept/Clinic</td>
<td>Patient visits in which pain intensity is quantified*</td>
<td>Pain intensity should be quantified using a standard instrument, such as a 0-10 numerical rating scale, a categorical scale, or the pictorial scale</td>
</tr>
</tbody>
</table>

#### Numerator Details
- **Time Window:** At the time of outpatient visit(s)
  - Pain screening with a standardized quantitative tool during the primary care or cancer-related/specialty outpatient visit(s). Screening may be completed using verbal, numeric, visual analog, rating scales designed for use with nonverbal patients, or other standardized tools.

- **Time Window:** Hospice admission evaluation / initial clinical encounter for palliative care
  - Patients who are screened for the presence or absence of pain (and if present, rating of its severity) using a standardized tool during the admission evaluation for hospice / initial encounter for hospital-based palliative care. Screening may be completed using verbal, numeric, visual analog, rating scales designed for use the non-verbal patients, or other standardized tools.

- **Time Window:** At each visit within the measurement period
  - For EHR:
    - eSpecification and eMeasure are currently under development (expected completion: end of Q1 2012). Data elements (using Quality Data Model) required for the measure attached (please refer to Appendix A).
    - For Claims/Administrative Data:
      - To submit the numerator option for number of patient visits in which pain intensity was quantified, report one of the following CPT Category II codes:
### NATIONAL QUALITY FORUM

<table>
<thead>
<tr>
<th>1628 Patients with Advanced Cancer Screened for Pain at Outpatient Visits</th>
<th>1634 Hospice and Palliative Care -- Pain Screening</th>
<th>0384 Oncology: Pain Intensity Quantified – Medical Oncology and Radiation Oncology (paired with 0383)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denominator Statement</td>
<td>Adult patients with advanced cancer who have at least 1 primary care or cancer-related/specialty outpatient visit</td>
<td>Patients enrolled in hospice for 7 or more days OR patients receiving hospital-based palliative care for 1 or more days.</td>
</tr>
<tr>
<td>Denominator Details</td>
<td>Time Window: At the time of outpatient visit(s) Adult patients with Stage IV cancer who are alive 30 days or more after diagnosis and who have had at least 1 primary care visit or cancer-related/specialty outpatient visit. Cancer-related visit = any oncology (medical, surgical, radiation) visit, chemotherapy infusion</td>
<td>Time Window: Hospice admission evaluation / palliative care initial encounter The Pain Screening quality measure is intended for patients with serious illness who are enrolled in hospice care OR receive palliative care in an acute hospital setting. Conditions may include, but are not limited to: cancer, heart disease, pulmonary disease, dementia and other progressive neurodegenerative diseases, stroke, HIV/AIDS, and advanced renal or hepatic failure. [NOTE: This quality measure should be paired with the Pain Assessment quality measure to ensure that all patients who report pain are clinically assessed.]</td>
</tr>
<tr>
<td>Exclusions</td>
<td>Exclusion Details</td>
<td>Risk Adjustment</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>--------------------------------------------------------</td>
<td>------------------------------------------------------</td>
</tr>
</tbody>
</table>
| None (other than those patients noted in 2a1.7. who did not survive at least 30 days after cancer diagnosis) | Calculation of length of stay; discharge date - date of initial encounter. | No risk adjustment or risk stratification           | N/A                                                | Rate/proportion better quality = higher score                                                                 | 1. Identify patients at least 18 years of age with Stage IV cancer  
2. Identify patients who have had at least 1 primary care or cancer-related visit. Exclude patients who are not alive 30 or more days after diagnosis.  
3. For each applicable visit, determine if a screening for pain was performed using a quantitative standardized tool.  
4. Performance score = number of visits with standardized quantitative screening for pain/total number of outpatient visits  
Screened for pain : a. Step 1- Identify all patients with serious, life-limiting illness who received either specialty palliative care in an acute hospital setting or hospice care  
b. Step 2- Identify admission / initial encounter dates; exclude palliative care patients if length of stay is less than one day. Exclude hospice patients if length of stay is less than 7 days  
c. Step 3- Identify patients who were screened for pain during the admission evaluation (hospice) OR initial encounter (palliative care) using a standardized tool.  
Quality Measure = Numerator: Patients screened for pain in Step 3 / Denominator: Patients in Step 1-Patients excluded in Step 2  
To calculate performance rates:  
1) Find the patients who meet the initial patient population (ie, the general group of patients that the performance measure is designed to address).  
2) From the patients within the initial patient population criteria, find the patients who qualify for the denominator (ie, the specific group of patients for inclusion in a specific performance measure based on defined criteria). Note: in some cases the initial patient population and denominator are identical.  
3) From the patients within the denominator, find the patients who qualify for the Numerator (ie, the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator  
4) If the measure does not have exceptions, STOP. If the measure does have exceptions, proceed with the following steps. From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator exception, when exceptions have been specified. If the patient meets any exception criteria, they should be removed from the denominator for performance calculation. Although the exception cases are removed from the denominator population for the performance calculation, the number of |
<table>
<thead>
<tr>
<th>Submission items</th>
<th>1628 Patients with Advanced Cancer Screened for Pain at Outpatient Visits</th>
<th>1634 Hospice and Palliative Care -- Pain Screening</th>
<th>0384 Oncology: Pain Intensity Quantified – Medical Oncology and Radiation Oncology (paired with 0383)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.1 Identified measures:</td>
<td></td>
<td></td>
<td>patients with valid exceptions should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI. If the patient does not meet the numerator and a valid exception is not present, this case represents a quality failure. See calculation algorithm in attachment 2a1.21. Attachment AMA-PCPI_Measure Calculation-Standard Measures-634620671516608159.pdf</td>
</tr>
<tr>
<td>5a.1 Are specs completely harmonized?</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>5a.2 If not completely harmonized, identify difference, rationale, impact:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5b.1 If competing, why superior or rationale for additive value:</td>
<td>This measure is part of the NPCRC Key Palliative Measures Bundle. Refer to the NPCRC cover letter and table of bundled measures for description of the selection and harmonization of the Key Palliative Measures Bundle. Measures 0677, 0675, 0523, and 0524 apply to nursing home and home health care settings and are, therefore, not competing with the proposed measure. It is unclear exactly what is the scope of measure 0420 is, however it appears to be directed at ancillary, non-physician professionals. It is unclear what “initiation of therapy” is referring to. The measure’s endorsement is time limited (endorsed July 31, 2008)</td>
<td>This measure has been harmonized with ACOVE / ASSIST Measure 1628: Patients with advanced cancer screened for pain at outpatient visits. The two measures have the same focus, populations are different (although both include patients with advanced cancer), apply in different settings with different timing.</td>
<td>No competing measure.</td>
</tr>
<tr>
<td>5b.2 If not completely harmonized, identify difference, rationale, impact:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5b.1 If competing, why superior or rationale for additive value:</td>
<td>This measure is part of the NPCRC Key Palliative Care Measures Bundle. Refer to the NPCRC cover letter and table of bundle measures for description of the selection and harmonization of the Key Palliative Care Measures Bundle. This measure targets only patients who are currently receiving chemotherapy or radiation therapy, and by definition, excludes some patients with advanced cancer who are not receiving this type of treatment. The proposed measure targets patients with Stage IV cancer and includes more venues of care than the existing measure</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NATIONAL QUALITY FORUM**

**NQF MEMBER votes are due June 26, 2012 by 6:00 PM ET**
### NATIONAL QUALITY FORUM

<table>
<thead>
<tr>
<th>Measure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1628</td>
<td>Patients with Advanced Cancer Screened for Pain at Outpatient Visits</td>
</tr>
<tr>
<td>1634</td>
<td>Hospice and Palliative Care -- Pain Screening</td>
</tr>
<tr>
<td>0384</td>
<td>Oncology: Pain Intensity Quantified – Medical Oncology and Radiation Oncology (paired with 0383)</td>
</tr>
</tbody>
</table>

- **1628 Patients with Advanced Cancer Screened for Pain at Outpatient Visits**
  - Where it would be applied (primary care and all cancer-related outpatient visits). This is in keeping with the reality that pain and pain control becomes a central focus for patients with late-stage cancer, and regular pain assessment should occur in multiple outpatient care settings. The developers propose that measure 0383 be limited to patients with Stage I-III cancer and endorse the proposed measure which targets Stage IV cancer patients.
  - Proposed measure 1634: Hospice and Palliative Care - Pain Screening: Proposed measure 1634 targets patients with serious conditions who are entering hospice or hospital-based palliative care. The measure proposed here targets a sub-population (advanced cancer). However, the setting and timing of 1634 is hospice/palliative care admission and is a one-time screen. 1628 focuses on pain screening at all outpatient visits. Although the 2 measures focus on different venues of care (and 1 is a time measure and the other every visit), they are completely harmonized in content.

<table>
<thead>
<tr>
<th>SC Evaluation</th>
<th></th>
</tr>
</thead>
</table>